{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132209, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132188, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132199, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132211, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132159, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132169, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132197, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132189, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132202, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132193, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132130, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132115, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132112, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 131980, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132061, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132080, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132037, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132087, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132160, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 355355, "length(tokens)": 132136, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132190, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132199, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132159, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132170, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132198, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132189, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132203, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132193, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132130, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132115, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132113, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 131980, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132061, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132080, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132037, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132088, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132161, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 355355, "length(tokens)": 132137, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132190, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132199, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132159, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132170, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132198, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132189, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132203, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132193, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132130, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132115, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132113, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 131980, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132061, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132080, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132037, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132088, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132161, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 355355, "length(tokens)": 132137, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132190, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132199, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132212, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132159, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132171, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132198, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132189, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132203, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132193, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132130, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132115, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132113, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 131980, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132061, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132080, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132037, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132088, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132161, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 355355, "length(tokens)": 132137, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132209, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132188, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132199, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132211, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132159, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132169, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132197, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132189, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132202, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132193, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132130, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132115, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132112, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 131980, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132061, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132080, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132037, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132087, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132160, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 355355, "length(tokens)": 132136, "length(origin)": 128000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194255, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194250, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194260, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194228, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194203, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194217, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194199, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194115, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194162, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194220, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194193, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194246, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 0, "length(string)": 555355, "length(tokens)": 194237, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194255, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194260, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194229, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194242, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194204, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194218, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194200, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194116, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194163, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194220, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194194, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 25, "length(string)": 555355, "length(tokens)": 194238, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194255, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194260, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194229, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194242, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194204, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194218, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194200, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194116, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194163, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194220, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194194, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 50, "length(string)": 555355, "length(tokens)": 194238, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194255, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194260, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194229, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194240, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194242, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194204, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194218, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194200, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194116, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194163, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194220, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194194, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 75, "length(string)": 555355, "length(tokens)": 194238, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194255, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194250, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194260, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194228, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194247, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194239, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194251, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194203, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194217, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194199, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194115, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194162, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194220, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194193, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194246, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194241, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": "", "pred_origin": "", "position(%)": 100, "length(string)": 555355, "length(tokens)": 194237, "length(origin)": 200000, "model": "Yarn-Mistral-7b-128k", "note": "too long"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: What is the best management of any patient with cancer?\nAnswer: 2. The best management of any patient with cancer is in a clinical trial.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 3. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 4. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 5. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 6. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 7. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 8. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 9. qPCR is the most sensitive assay available for the measurement of BCR::ABL1 mRNA.\n\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 10. qPCR is the most sensitive assay", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3882, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "10 Stonehearts", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Raiden\n6. Bosenmori Mei\n7. Mei\n8. Raiden Bosenmori\n9. Mei\n10. Raiden Bosenmori Mei\n11. Mei\n12. Raiden Bosenmori Mei\n13. Mei\n14. Raiden Bosenmori Mei\n15. Mei\n16. Raiden Bosenmori Mei\n17. Mei\n18. Raiden Bosenmori Mei\n19. Mei\n20. Raiden Bosenmori Mei\n21. Mei\n22. Raiden Bosenmori Mei\n23. Mei\n24. Raiden Bosenmori Mei\n25. Mei\n26. Raiden Bosenmori Mei\n27. Mei\n28. Raiden Bosenmori Mei\n29. Mei\n30. Raiden Bosenmori Mei\n31. Mei\n32. Raiden Bosenmori Mei\n33. Mei\n34. Raiden Bosenmori Mei\n35. Mei\n36. Raiden Bosenmori Mei\n37. Mei\n38. Raiden Bosenmori Mei\n39. Mei\n40. Raiden Bosenmori Mei\n41. Mei\n42. Raiden Bosenmori Mei\n43. Mei\n44. Raiden Bosenmori Mei\n45. Mei\n46. Raiden Bosenmori Mei\n47. Mei\n48. Raiden Bosenmori Mei\n49. Mei\n50. Raiden Bosenmori Mei\n51. Mei\n52. Raiden Bosenmori Mei\n53. Mei\n54. Raiden Bosenmori Mei\n5", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Mara-Struck Soldier", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3887, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity.\n2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger.\n3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3875, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons\n2. The Flintstones\n3. The Jetsons\n4. The Smurfs\n5. The Family Guy\n\nExplanation: The correct answer is 1. The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of a middle-class American lifestyle epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie. The show is set in the fictional town of Springfield and parodies American culture, society, television, and the human condition.\n\nVisit our website for more information: https://www.brainytest.com/", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. Wacq Island\n2. Thestang\n3. Planet Vonwacq\n4. Thestang is located on Wacq Island\n5. Thestang is located on Planet Vonwacq\n6. Wacq Island is located on Planet Vonwacq\n7. Thestang is located on Wacq Island\n8. Thestang is located on Planet Vonwacq\n9. Thestang is located on Wacq Island\n10. Thestang is located on Wacq Island\n11. Thestang is located on Wacq Island\n12. Thestang is located on Planet Vonwacq\n13. Thestang is located on Wacq Island\n14. Thestang is located on Wacq Island\n15. Thestang is located on Wacq Island\n16. Thestang is located on Wacq Island\n17. Thestang is located on Wacq Island\n18. Thestang is located on Wacq Island\n19. Thestang is located on Wacq Island\n20. Thestang is located on Wacq Island\n21. Thestang is located on Wacq Island\n22. Thestang is located on Wacq Island\n23. Thestang is located on Wacq Island\n24. Thestang is located on Wacq Island\n25. Thestang is located on Wacq Island\n26. Thestang is located on Wacq Island\n27. Thestang is located on Wacq Island\n28. Thestang is located on Wacq Island\n29. Thestang is located on Wacq Island\n30. Thestang is located on Wacq Island\n31. Thestang is located on Wacq Island\n32. Thestang is located on Wacq Island\n33. Thestang is located on Wacq Island\n34. Thestang is located on Wacq Island\n35. Thestang is located on Wacq Island\n36. Thestang is located on Wacq Island\n37. Thestang is located on Wacq Island", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3882, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n2. The New England Journal of Medicine\n3. The Journal of the American Medical Association\n4. The Journal of Clinical Oncology\n5. The Journal of the National Comprehensive Cancer Network\n6. The Journal of the American Society of Clinical Oncology\n7. The Journal of the National Cancer Institute\n8. The Journal of the American Medical Association\n9. The Journal of the National Comprehensive Cancer Network\n10. The Journal of the American Medical Association\n11. The Journal of the American Medical Association\n12. The Journal of the National Comprehensive Cancer Network\n13. The Journal of the American Medical Association\n14. The Journal of the National Comprehensive Cancer Network\n15. The Journal of the American Medical Association\n16. The Journal of the National Comprehensive Cancer Network\n17. The Journal of the American Medical Association\n18. The Journal of the National Comprehensive Cancer Network\n19. The Journal of the American Medical Association\n20. The Journal of the National Comprehensive Cancer Network\n21. The Journal of the American Medical Association\n22. The Journal of the National Comprehensive Cancer Network\n23. The Journal of the American Medical Association\n24. The Journal of the National Comprehensive Cancer Network\n25. The Journal of the National Comprehensive Cancer Network\n26. The Journal of the National Comprehensive Cancer Network\n27. The Journal of the National Comprehensive Cancer Network\n28. The Journal of the National Comprehensive Cancer Network\n29. The Journal of the National Comprehensive Cancer Network\n30. The Journal of the National Comprehensive Cancer Network\n31. The Journal of the National Comprehensive Cancer Network\n32. The Journal of the National Comprehensive Cancer Network\n33. The Journal of the National Comprehensive Cancer Network\n34. The Journal of the National Comprehensive Cancer Network\n35. The Journal of the National Comprehensive Cancer Network\n36. The Journal of the National Comprehensive Cancer Network\n37. The Journal of the National Comprehensive Cancer Network\n38. The Journal of the National Comprehensive Cancer", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3838, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\n\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from what number annually in 2020 to what number annually in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from what number", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3849, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": "xxx", "pred_origin": "15 years\n\nQuestion: What is the format requirement for the answer?\nAnswer: {\"answer\": \"xxx\"}\n\nQuestion: What is the context?\nAnswer: The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What is the question type?\nAnswer: MCQ\n\nQuestion: What is the question?\nAnswer: The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What is the answer type?\nAnswer: MCQ\n\nQuestion: What is the answer?\nAnswer: 15 years\n\nQuestion: What is the question stem?\nAnswer: The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What is the question type?\nAnswer: MCQ\n\nQuestion: What is the answer type?\nAnswer: MCQ\n\nQuestion: What is the answer?\nAnswer: 15 years\n\nQuestion: What is the question stem?\nAnswer: The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not under", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3840, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": ""}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nExplanation:\n\nThe Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.\n\nQuestion: In the NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, Version 2.2024, which of the following is true?\n\nOptions:\n\n1. The NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, Version 2.2024, are based on high-level evidence and there is uniform consensus that the intervention is appropriate.\n\n2. The NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, Version 2.2024, are based on lower-level evidence and there is uniform consensus that the intervention is appropriate.\n\n3. The NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, Version 2.2024, are based on lower-level evidence and there is major NCCN disagreement that the intervention is appropriate.\n\n4. The NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, Version 2.2024, are based on any level of evidence and there is major NCCN disagreement that the intervention is appropriate.", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3774, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' depression symptoms are related to their academic achievement goals.\n2. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3793, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 2. Insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 3. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 4. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 5. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 6. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 7. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 8. Frequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient'", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3881, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "Question: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3842, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n2. Blood count with differential\n3. Chemistry profile\n4. Bone marrow aspirate and biopsy\n5. Quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n6. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n7. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n8. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n9. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n10. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n11. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n12. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n13. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n14. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n15. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n16. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymer", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96, still breastfeeding, what can I eat postpartum that is good?", "position(%)": 0, "length(string)": 10911, "length(tokens)": 3873, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 2. Quantitative RT-PCR\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 3. International Scale\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 4. 1%–5%\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 5. Quantitative RT-PCR\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 6. International Scale\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 7. 1%–5%\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 8. Quantitative RT-PCR\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 9. International Scale\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 10. 1%–5%\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 11. Quantitative RT-PCR\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 12. International Scale\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 13. 1%–5%\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 14. Quantitative RT-PCR\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 15. International Scale\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 16. 1%–5%\nQuestion: What is the most sensitive", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3884, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "10. City of Hope National Medical Center", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3871, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Apollo\n4. Apollo 11\n5. Apollo 13\n6. Apollo 14\n7. Apollo 15\n8. Apollo 16\n9. Apollo 17\n10. Apollo 18\n11. Apollo 19\n12. Apollo 20\n13. Apollo 21\n14. Apollo 22\n15. Apollo 23\n16. Apollo 24\n17. Apollo 25\n18. Apollo 26\n19. Apollo 27\n20. Apollo 28\n21. Apollo 29\n22. Apollo 30\n23. Apollo 31\n24. Apollo 32\n25. Apollo 33\n26. Apollo 34\n27. Apollo 35\n28. Apollo 36\n29. Apollo 37\n30. Apollo 38\n31. Apollo 39\n32. Apollo 40\n33. Apollo 41\n34. Apollo 42\n35. Apollo 43\n36. Apollo 44\n37. Apollo 45\n38. Apollo 46\n39. Apollo 47\n40. Apollo 48\n41. Apollo 49\n42. Apollo 50\n43. Apollo 51\n44. Apollo 52\n45. Apollo 53\n46. Apollo 54\n47. Apollo 55\n48. Apollo 56\n49. Apollo 57\n50. Apollo 58\n51. Apollo 59\n52", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The first monster is a Mara-Struck Warden. 2. The second monster is a Mara-Struck Soldier.", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3887, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3876, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons\n2. The Flintstones\n3. The Jetsons\n4. The Smurfs\n5. The Powerpuff Girls", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n2. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n3. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n4. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n5. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n6. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n7. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n8. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n9. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n10. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n11. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n12. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n13. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n14. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.\n15. The War", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. Wacq Island\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 2. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 3. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 4. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 5. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 6. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 7. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 8. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 9. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 10. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 11. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 12. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 13. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 14. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 15. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 16. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer: 17. Thestang\nQuestion: What is the name of the tree that is located on Wacq Island?\nAnswer", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 2. Quantitative reverse transcription polymerase chain reaction (qRT-PCR)\nQuestion: What is the gold standard for expressing qPCR values?\nAnswer: 3. International Scale (IS)\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 4. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 5. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 6. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 7. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 8. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 9. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 10. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 11. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 12. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 13. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 14. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 15. Trisomy 8\nQuestion: What is the most common cytogenetic abnormality in CML?\nAnswer: 16. Trisomy 8\nQuestion: What is the most common", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3883, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n2. The New England Journal of Medicine\n3. The Journal of the American Medical Association\n4. The Journal of Clinical Oncology\n5. The Journal of the National Comprehensive Cancer Network\n\n6. The Journal of the American Medical Association\n\n7. The Journal of Clinical Oncology\n\n8. The Journal of the National Comprehensive Cancer Network\n\n9. The Journal of the American Medical Association\n\n10. The Journal of the American Medical Association\n\n11. The Journal of the National Comprehensive Cancer Network\n\n12. The Journal of the American Medical Association\n\n13. The Journal of the National Comprehensive Cancer Network\n\n14. The Journal of the National Comprehensive Cancer Network\n\n15. The Journal of the National Comprehensive Cancer Network\n\n16. The Journal of the National Comprehensive Cancer Network\n\n17. The Journal of the National Comprehensive Cancer Network\n\n18. The Journal of the National Comprehensive Cancer Network\n\n19. The Journal of the National Comprehensive Cancer Network\n\n20. The Journal of the National Comprehensive Cancer Network\n\n21. The Journal of the National Comprehensive Cancer Network\n\n22. The Journal of the National Comprehensive Cancer Network\n\n23. The Journal of the National Comprehensive Cancer Network\n\n24. The Journal of the National Comprehensive Cancer Network\n\n25. The Journal of the National Comprehensive Cancer Network\n\n26. The Journal of the National Comprehensive Cancer Network\n\n27. The Journal of the National Comprehensive Cancer Network\n\n28. The Journal of the National Comprehensive Cancer Network\n\n29. The Journal of the National Comprehensive Cancer Network\n\n30. The Journal of the National Comprehensive Cancer Network\n\n31. The Journal of the National Comprehensive Cancer Network\n\n32. The Journal of the National Comprehensive Cancer Network\n\n33. The Journal of the National Comprehensive Cancer Network\n\n34. The Journal of the National Comprehensive Cancer Network\n\n35. The Journal of the National", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3839, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common chromosomal abnormality in CML?\nAnswer: t9;22\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is the most common BCR::ABL1 transcript in CML?\nAnswer: e13a2\nQuestion: What is", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3850, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n2. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n3. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n4. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n5. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n6. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n7. The study found that the proportion of different BCR::ABL1 transcripts and the impact of BCR::ABL1 transcript type on response to tyrosine kinase inhibitor (TKI) therapy were not significantly different between patients with e13a2 and e14a2 transcripts.\n8. The study found that the proportion of different BCR::ABL1 transcripts and the impact", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3840, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies\n4. Neither therapy\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the overnight time in target range.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\n\nAnswer: 1. Advanced hybrid closed-loop therapy\n\n2. Standard insulin therapy\n\n3. Both therapies\n\n4. Neither therapy\n\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the time below target range.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy increased treatment satisfaction?\n\nAnswer: 1. Advanced hybrid closed-loop therapy\n\n2. Standard insulin therapy\n\n3. Both therapies\n\n4. Neither therapy\n\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy increased treatment satisfaction.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy did not improve the overall time in target range?\n\nAnswer: 1. Advanced hybrid closed-loop therapy\n\n2. Standard insulin therapy\n\n3. Both therapies\n\n4. Neither therapy\n\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy did not improve the overall time in target range.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy was associated with a false-positive rate of 1%–5% depending on the specific probe used in the assay?\n\nAnswer: 1. Advanced hybrid closed-loop therapy\n\n2. Standard insulin therapy\n\n3. Both therapies\n\n4. Neither therapy\n\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy was associated with a false-positive rate of 1%–5% depending on the specific probe used", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3774, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Academic achievement goals\n2. BCR::ABL1 transcripts\n3. BCR::ABL1 fusion gene\n4. Bone marrow aspirate and biopsy\n5. Bone marrow cytogenetics\n6. Bone marrow cytogenetics with a minimum of 20 metaphases\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells, also known as Question: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. Academic achievement goals\n2. BCR::ABL1 transcripts\n3. BCR::ABL1 fusion gene\n4. Bone marrow aspirate and biopsy\n5. Bone marrow cytogenetics\n6. Bone marrow cytogenetics with a minimum of 20 metaphases\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells, also known as", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3793, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antibiotics\n2. Antiviral medication\n3. Antihistamine medication\n4. Antifungal medication\n5. Antiparasitic medication\n6. Antiprotozoal medication\n7. Antiprotozoal medication\n8. Antiprotozoal medication\n9. Antiprotozoal medication\n10. Antiprotozoal medication\n11. Antiprotozoal medication\n12. Antiprotozoal medication\n13. Antiprotozoal medication\n14. Antiprotozoal medication\n15. Antiprotozoal medication\n16. Antiprotozoal medication\n17. Antiprotozoal medication\n18. Antiprotozoal medication\n19. Antiprotozoal medication\n20. Antiprotozoal medication\n21. Antiprotozoal medication\n22. Antiprotozoal medication\n23. Antiprotozoal medication\n24. Antiprotozoal medication\n25. Antiprotozoal medication\n26. Antiprotozoal medication\n27. Antiprotozoal medication\n28. Antiprotozoal medication\n29. Antiprotozoal medication\n30. Antiprotozoal medication\n31. Antiprotozoal medication\n32. Antiprotozoal medication\n33. Antiprotozoal medication\n34. Antiprotozoal medication\n35. Antiprotozoal medication\n36. Antiprotozoal medication\n37. Antiprotozoal medication\n38. Antiprotozoal medication\n39. Antiprotozoal medication\n40. Antiprotozoal medication\n41. Antiprotozoal medication\n42. Antiprotozoal medication\n43. Antiprotozoal medication\n44. Antiprotozoal medication\n45. Antiprotozoal medication\n46. Antiprotozoal medication\n47. Antiprotozoal medication\n48", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3881, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML) 2. Chronic lymphocytic leukemia (CLL) 3. Acute myeloid leukemia (AML) 4. Acute lymphocytic leukemia (ALL) 5. Chronic myelomonocytic leukemia (CMML) 6. Chronic eosinophilic leukemia (CEL) 7. Chronic neutrophilic leukemia (CNL) 8. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 9. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 10. Chronic myelomonocytic leukemia/myelodysplastic syndrome (CMML/MDS) 11. Chronic myelomonocytic leukemia/myelodysplastic/myeloproliferative neoplasm (CMML/MDS/MPN) 12. Chronic myelomonocytic leukemia/myelodysplastic syndrome/myeloproliferative neoplasm (CMML/MDS/MPN) 13. Chronic myelomonocytic leukemia/myelodysplastic syndrome/myeloproliferative neoplasm/lymphoma (CMML/MDS/MPN/L) 14. Chronic myelomonocytic leukemia/myelodysplastic syndrome/myeloproliferative neoplasm/lymphoma/myeloma (CMML/MDS/MPN/L/M) 15. Chronic myelomonocytic leukemia/myelodysplastic syndrome/myeloproliferative neoplasm/lymphoma/myeloma/plasma cell neoplasm (CMML/MDS/MPN/L/M/PCN) 16. Chronic myelomonocytic leukemia/", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3842, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "Question: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3889, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96, still breastfeeding, what can I eat postpartum that is good?", "position(%)": 25, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 2. Quantitative RT-PCR (qPCR)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 3. International Scale (IS)\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 4. 1%–5%\nQuestion: What is the most sensitive assay available for the measurement of BCR::ABL1 mRNA?\nAnswer: 5. Quantitative RT-PCR (qPCR)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 6. International Scale (IS)\nQuestion: What is the false-positive rate of double-fusion FISH?\nAnswer: 7. 1%–5%\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 8. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 9. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 10. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 11. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 12. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 13. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 14. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 15. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer: 16. International Scale (IS)\nQuestion: What is the gold standard of expressing qPCR values?\nAnswer", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3884, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3871, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Acheron Bosenmori Mei\n4. Raiden Bosenmori Mei Mei\n5. Acheron Bosenmori Mei\n6. Acheron Bosenmori Mei\n7. Acheron Bosenmori Mei\n8. Acheron Bosenmori Mei\n9. Acheron Bosenmori Mei\n10. Acheron Bosenmori Mei\n11. Acheron Bosenmori Mei\n12. Acheron Bosenmori Mei\n13. Acheron Bosenmori Mei\n14. Acheron Bosenmori Mei\n15. Acheron Bosenmori Mei\n16. Acheron Bosenmori Mei\n17. Acheron Bosenmori Mei\n18. Acheron Bosenmori Mei\n19. Acheron Bosenmori Mei\n20. Acheron Bosenmori Mei\n21. Acheron Bosenmori Mei\n22. Acheron Bosenmori Mei\n23. Acheron Bosenmori Mei\n24. Acheron Bosenmori Mei\n25. Acheron Bosenmori Mei\n26. Acheron Bosenmori Mei\n27. Acheron Bosenmori Mei\n28. Acheron Bosenmori Mei\n29. Acheron Bosenmori Mei\n30. Acheron Bosenmori Mei\n31. Acheron Bosenmori Mei\n32. Acheron Bosenmori Mei\n33. Acheron Bosenmori Mei\n34. Acheron Bosenmori Mei\n35. Acheron Bosenmori Mei\n36. Acheron Bosenmori Mei\n37. Acheron Bosenmori Mei\n38. Acheron Bosenmori Mei\n39. Acheron Bosenmori Mei\n40. Acheron", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The first monster is a Mara-Struck Warden. 2. The second monster is a Mara-Struck Soldier.", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3887, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3876, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is a character in the animated series \"South Park\".\n2. Clockboy is a character in the animated series \"The Simpsons\".\n3. Clockboy is a character in the animated series \"Family Guy\".\n4. Clockboy is a character in the animated series \"The Flintstones\".\n5. Clockboy is a character in the animated series \"The Jetsons\".\n6. Clockboy is a character in the animated series \"The Smurfs\".\n7. Clockboy is a character in the animated series \"The Powerpuff Girls\".\n8. Clockboy is a character in the animated series \"The Fairly OddParents\".\n9. Clockboy is a character in the animated series \"The Adventures of Tintin\".\n10. Clockboy is a character in the animated series \"The Amazing World of Gumball\".\n11. Clockboy is a character in the animated series \"The Loud House\".\n12. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly Odder\".\n13. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n14. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby Now\".\n15. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby Now!\".\n16. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n17. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n18. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n19. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n20. Clockboy is a character in the animated series \"The Fairly OddParents: Fairly OddBaby\".\n21. Clockboy is a character in", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n2. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n3. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n4. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n5. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n6. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n7. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n8. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n9. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 2. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 3. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 4. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 5. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 6. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 7. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 8. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 9. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 10. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 11. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 12. The tree named 'Sisten' is located on the island of 'Sisten'.\nQuestion: On which island is the tree named 'Sisten' located?\nAnswer: 13. The tree named 'Sisten' is located on the island of '", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha\nQuestion: Who is the Aeon in charge of the Path of Strength?\nAnswer: 3. Aha\nQuestion: Who is the Aeon in charge of the Path of Serenity?\nAnswer: 4. Aha\nQuestion: Who is the Aeon in charge of the Path of Knowledge?\nAnswer: 5. Aha\nQuestion: Who is the Aeon in charge of the Path of Beauty?\nAnswer: 6. Aha\nQuestion: Who is the Aeon in charge of the Path of Power?\nAnswer: 7. Aha\nQuestion: Who is the Aeon in charge of the Path of Truth?\nAnswer: 8. Aha\nQuestion: Who is the Aeon in charge of the Path of Order?\nAnswer: 9. Aha\nQuestion: Who is the Aeon in charge of the Path of Harmony?\nAnswer: 10. Aha\nQuestion: Who is the Aeon in charge of the Path of Devotion?\nAnswer: 11. Aha\nQuestion: Who is the Aeon in charge of the Path of Creativity?\nAnswer: 12. Aha\nQuestion: Who is the Aeon in charge of the Path of Duty?\nAnswer: 13. Aha\nQuestion: Who is the Aeon in charge of the Path of Understanding?\nAnswer: 14. Aha\nQuestion: Who is the Aeon in charge of the Path of Courage?\nAnswer: 15. Aha\nQuestion: Who is the Aeon in charge of the Path of Conviction?\nAnswer: 16. Aha\nQuestion: Who is the Aeon in charge of the Path of Love?\nAnswer: 17. Aha\nQuestion: Who is the Aeon in charge of the Path of Justice?\nAnswer: 18. Aha\nQuestion: Who is the Aeon in charge of the Path of Wisdom?\nAnswer: 19. Aha\nQuestion: Who", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3883, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n2. The New England Journal of Medicine\n3. The Journal of the American Medical Association\n4. The Journal of Clinical Oncology\n5. The Journal of the National Comprehensive Cancer Network\n6. The Journal of the American Society of Clinical Oncology\n7. The Journal of the National Cancer Institute\n8. The Journal of the American Medical Association\n9. The Journal of the National Comprehensive Cancer Network\n10. The Journal of the American Society of Clinical Oncology\n11. The Journal of the American Medical Association\n12. The Journal of the National Cancer Institute\n13. The Journal of the American Medical Association\n14. The Journal of the National Comprehensive Cancer Network\n15. The Journal of the American Society of Clinical Oncology\n16. The Journal of the American Medical Association\n17. The Journal of the National Comprehensive Cancer Network\n18. The Journal of the American Medical Association\n19. The Journal of the National Comprehensive Cancer Network\n20. The Journal of the American Society of Clinical Oncology\n21. The Journal of the National Cancer Institute\n22. The Journal of the National Comprehensive Cancer Network\n23. The Journal of the American Medical Association\n24. The Journal of the National Comprehensive Cancer Network\n25. The Journal of the American Society of Clinical Oncology\n26. The Journal of the National Comprehensive Cancer Network\n27. The Journal of the National Comprehensive Cancer Network\n28. The Journal of the National Comprehensive Cancer Network\n29. The Journal of the National Comprehensive Cancer Network\n30. The Journal of the National Comprehensive Cancer Network\n31. The Journal of the National Comprehensive Cancer Network\n32. The Journal of the National Comprehensive Cancer Network\n33. The Journal of the National Comprehensive Cancer Network\n34. The Journal of the National Comprehensive Cancer Network\n35. The Journal of the National Comprehensive Cancer Network\n36. The Journal of the National Comprehensive Cancer Network\n37. The Journal of the National Comprehensive Cancer Network\n38. The Journal", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3839, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\n\nQuestion: What is the most common chromosomal abnormality in CML? (Answer in Arabic numerals)\nAnswer: 9\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common BCR::ABL1 transcript in CML? (Answer in Arabic numerals)", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3850, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3840, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nThe International Scale (IS) is a standardized method for reporting\nqPCR results.16 The IS is based on the ratio of BCR::ABL1 transcript\nnumber to the number of control gene transcripts. The IS is calculated\nusing the following formula:\nIS = 100 × (log10 (BCR::ABL1 transcript number) – log10 (control\ngene transcript number))\nThe IS is a logarithmic scale, with a value of 0 indicating the absence\nof BCR::ABL1 transcripts. A value of 1 indicates a 10-fold increase in\nBCR::ABL1 transcripts compared to the control gene transcripts.\nThe IS is used to monitor the response to TKI therapy in patients\nwith CML. A value of 0 indicates a complete molecular response\n(CMR), while a value of 1 indicates a 10-fold increase in BCR::ABL1\ntranscripts compared to the control gene transcripts.\nIn the study from The Lancet, advanced hybrid closed-loop therapy\nimproved the overnight time in target range compared to standard\ninsulin therapy. This is because the advanced hybrid closed-loop therapy\nwas able to more accurately detect and respond to changes in blood\nglucose levels during the night, when blood glucose levels are typically\nlower. Standard insulin therapy, on the other hand, was not able to\nrespond as effectively to these changes, leading to a decrease in the overnight\ntime in target range.\nThe study also found that advanced hybrid closed-loop therapy\nincreased treatment satisfaction compared to standard insulin\ntherapy. This is likely due to the fact that the advanced hybrid closed-loop\ntherapy was able to provide more consistent and stable blood glucose\nlevels throughout the day, reducing the need for frequent blood glucose\nmonitoring and adjustments to insulin doses.\nIn summary, the study from The Lancet found that advanced hybrid\nclosed-loop therapy improved the overnight time in target range and\nincreased treatment satisfaction", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3774, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Academic achievement goals\n2. BCR::ABL1 transcripts\n3. BCR::ABL1 fusion gene\n4. Bone marrow aspirate and biopsy\n5. Bone marrow cytogenetics\n6. Bone marrow cytogenetics with a minimum of 20 metaphases\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells, also known as Question: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. Academic achievement goals\n2. BCR::ABL1 transcripts\n3. BCR::ABL1 fusion gene\n4. Bone marrow aspirate and biopsy\n5. Bone marrow cytogenetics\n6. Bone marrow cytogenetics with a minimum of 20 metaphases\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities in Ph-positive cells, also known as", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3793, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Acetaminophen\n2. Ibuprofen\n3. Naproxen\n4. Aspirin\n5. Dextromethorphan\n6. Pseudoephedrine\n7. Cetirizine\n8. Loratadine\n9. Fexofenadine\n10. Levocetirizine\n11. Montelukast\n12. Cromolyn\n13. Guaifenesin\n14. Diphenhydramine\n15. Phenylephrine\n16. Phenylpropanolamine\n17. Pseudoephedrine\n18. Phenylephrine\n19. Phenylpropanolamine\n20. Dextromethorphan\n21. Cetirizine\n22. Levocetirizine\n23. Montelukast\n24. Cromolyn\n25. Guaifenesin\n26. Diphenhydramine\n27. Fexofenadine\n28. Loratadine\n29. Phenylephrine\n30. Phenylpropanolamine\n31. Pseudoephedrine\n32. Phenylephrine\n33. Phenylpropanolamine\n34. Dextromethorphan\n35. Cetirizine\n36. Levocetirizine\n37. Montelukast\n38. Cromolyn\n39. Guaifenesin\n40. Diphenhydramine\n41. Fexofenadine\n42. Loratadine\n43. Phenylephrine\n44. Phenylpropanolamine\n45. Pseudoephedrine\n46. Phenylephrine\n47. Phenylpropanolamine\n48. Dextromethorphan\n49. Cetirizine\n50. Levocetirizine\n51. Montelukast\n52. Cromolyn\n53. Guaifenesin\n54. Diphen", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3881, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3842, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "Question: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the May 2019 doctor-patient chat record, what is", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3889, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: What is the patient’s gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: What is the patient’s race? (Please answer in the format white, black, asian, or other)\nAnswer: white\n\nQuestion: What is the patient’s ethnicity? (Please answer in the format hispanic or latino, not hispanic or latino, or other)\nAnswer: not hispanic or latino\n\nQuestion: What is the patient’s marital status? (Please answer in the format married, single, divorced, or widowed)\nAnswer: single\n\nQuestion: What is the patient’s occupation? (Please answer in the format retired, student, unemployed, or other)\nAnswer: unemployed\n\nQuestion: What is the patient’s education level? (Please answer in the format high school graduate, some college, college graduate, or other)\nAnswer: college graduate\n\nQuestion: What is the patient’s income level? (Please answer in the format low, medium, or high)\nAnswer: medium\n\nQuestion: What is the patient’s insurance status? (Please answer in the format private, public, or other)\nAnswer: private\n\nQuestion: What is the patient’s smoking status? (Please answer in the format never smoked, former smoker, or current smoker)\nAnswer: never smoked\n\nQuestion: What is the patient’s alcohol consumption status? (Please answer in the format never drank, former drinker, or current drinker)\nAnswer: never drank\n\nQuestion: What is the patient’s body mass index (BMI)? (Please answer in the format underweight, normal weight, overweight, or obese)\nAnswer: normal weight\n\nQuestion: What is the patient’s height? (Please answer in the format under 5 feet, 5 feet to 5 feet 6 inches, 5 feet 6 inches to 5 feet 11 inches, or over 5 feet 11 inches)\nAnswer: 5 feet to 5 feet 6 inches\n\nQuestion: What is the patient’s weight? (Please answer in the format under 100 pounds, 100", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion:", "position(%)": 50, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n2. Shuweng\n3. Shuweng\n4. Shuweng\n5. Shuweng\n6. Shuweng\n7. Shuweng\n8. Shuweng\n9. Shuweng\n10. Shuweng\n11. Shuweng\n12. Shuweng\n13. Shuweng\n14. Shuweng\n15. Shuweng\n16. Shuweng\n17. Shuweng\n18. Shuweng\n19. Shuweng\n20. Shuweng\n21. Shuweng\n22. Shuweng\n23. Shuweng\n24. Shuweng\n25. Shuweng\n26. Shuweng\n27. Shuweng\n28. Shuweng\n29. Shuweng\n30. Shuweng\n31. Shuweng\n32. Shuweng\n33. Shuweng\n34. Shuweng\n35. Shuweng\n36. Shuweng\n37. Shuweng\n38. Shuweng\n39. Shuweng\n40. Shuweng\n41. Shuweng\n42. Shuweng\n43. Shuweng\n44. Shuweng\n45. Shuweng\n46. Shuweng\n47. Shuweng\n48. Shuweng\n49. Shuweng\n50. Shuweng\n51. Shuweng\n52. Shuweng\n53. Shuweng\n54. Shuweng\n55. Shuweng\n56. Shuweng\n57. Shuweng\n58. Shuweng\n59. Shuweng\n60. Shuweng\n61. Shuweng\n62. Shuweng\n63. Shuweng\n64. Shuweng\n65. Shuweng\n66. Shuweng\n67. Shuweng\n68. Shuweng\n69. Shuweng\n70. Shuweng\n71. Shuweng\n72. Shuweng\n73. Shuw", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3884, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "10", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3871, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Raiden\n6. Bosenmori Mei\n7. Mei\n8. Raiden Bosenmori Mei\n9. Raiden Bosenmori\n10. Mei\n11. Raiden Bosenmori Mei\n12. Raiden Bosenmori Mei\n13. Raiden Bosenmori Mei\n14. Raiden Bosenmori Mei\n15. Raiden Bosenmori Mei\n16. Raiden Bosenmori Mei\n17. Raiden Bosenmori Mei\n18. Raiden Bosenmori Mei\n19. Raiden Bosenmori Mei\n20. Raiden Bosenmori Mei", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Mara-Struck Soldier", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3887, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3876, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n2. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.\n3. The NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines) for CML discuss the clinical management of CML in all 3 phases (chronic, accelerated, or blast phase).\n4. Initial evaluations should consist of a history and physical examination, including palpation of the spleen, complete blood count with differential, chemistry profile, and hepatitis B panel.\n5. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (qRT-PCR) to confirm the diagnosis of CML (Seepage CML-1).\n6. If bone marrow evaluation is not feasible, fluorescence in situ hybridization (FISH) on the bone marrow or peripheral blood for at least 20 metaphases is useful to detect additional chromosomal abnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (discussed in next section).\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (discussed in next section).\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (discussed in next section).\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal abnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (discussed in next section", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n2. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n3. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n4. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n5. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n6. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n7. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n8. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n9. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. Wacq Island\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang,", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 3. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 4. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 5. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 6. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 7. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 8. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 9. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 10. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 11. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 12. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 13. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 14. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 15. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 16. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 17. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 18. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 19. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3883, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "13\nsitu (FISH) assay can be used to detect the presence of BCR::ABL1\ntranscripts.13\nThe NCCN Clinical Practice Guidelines in Oncology\nChronicMyeloid Leukemia, Version2.2024\nNCCNGUIDELINES®", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3839, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion: What is the name of the fusion gene that is responsible for the development of chronic myeloid leukemia?\nAnswer: BCR::ABL1\n\nQuestion", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3850, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n2. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n3. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n4. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n5. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n6. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n7. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n8. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n9. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n10. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n11. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n12. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n13. The study found that the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada was 15 years.\n14. The study found that the duration of reduced col", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3840, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myeloid Leukemia (CML) provide recommendations for the diagnosis and management of CML in all 3 phases (chronic, accelerated, or blast phase). Evaluation should consist of a history and physical examination, including palpation of the spleen, complete blood count with differential, chemistry profile, and hepatitis B panel. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (RT-PCR) to confirm the diagnosis of CML (see page CML-1).\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myeloid Leukemia (CML) provide recommendations for the diagnosis and management of CML in all 3 phases (chronic, accelerated, or blast phase). Evaluation should consist of a history and physical examination, including palpation of the spleen, complete blood count with differential, chemistry profile, and hepatitis B panel. Bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation and quantitative reverse transcription polymerase chain reaction (RT-PCR) to confirm the diagnosis of CML (see page CML-1).\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3774, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. academic achievement goals\n2. BCR::ABL1 transcripts\n3. bone marrow aspirate and biopsy\n4. bone marrow cytogenetics\n5. hypermetaphase FISH", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3793, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n2. Observe\n3. Take vitamin C\n4. Take zinc\n5. Take probiotics\n6. Take vitamin D\n7. Take multivitamins\n8. Take garlic\n9. Take ginger\n10. Take elderberry\n11. Take echinacea\n12. Take ginseng\n13. Take licorice\n14. Take green tea\n15. Take ginger tea\n16. Take ginger and garlic tea\n17. Take ginger and green tea\n18. Take ginger and elderberry tea\n19. Take ginger and licorice tea\n20. Take ginger and ginseng tea\n21. Take ginger and echinacea tea\n22. Take ginger and vitamin C tea\n23. Take ginger and vitamin D tea\n24. Take ginger and zinc tea\n25. Take ginger and multivitamins tea\n26. Take ginger and garlic and green tea\n27. Take ginger and garlic and elderberry tea\n28. Take ginger and garlic and licorice tea\n29. Take ginger and garlic and ginseng tea\n30. Take ginger and garlic and echinacea tea\n31. Take ginger and garlic and vitamin C tea\n32. Take ginger and garlic and vitamin D tea\n33. Take ginger and garlic and zinc tea\n34. Take ginger and garlic and multivitamins tea\n35. Take ginger and garlic and probiotics tea\n36. Take ginger and garlic and vitamin C and green tea\n37. Take ginger and garlic and vitamin C and elderberry tea\n38. Take ginger and garlic and vitamin C and licorice tea\n39. Take ginger and garlic and vitamin C and ginseng tea\n40. Take ginger and garlic and vitamin C and echinacea tea\n41. Take ginger and garlic and vitamin D and green tea\n42. Take ginger and garlic and vitamin D and elderberry tea\n43. Take ginger and garlic and vitamin D and", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3881, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 2. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 3. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 4. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 5. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 6. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 7. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 8. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 9. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 10. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 11. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3842, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "Question: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the April 2019 doctor-patient chat record, what is", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3889, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol is okay to take.", "position(%)": 75, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3882, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori Mei\n\nExplanation: The correct answer is 1. Raiden Bosenmori Mei.\n\nThe 'Harmony Grand Ceremony' was held in Penacony, New Hampshire, on September 11, 2022. The ceremony was attended by a lady with purple hair, who calls herself the 'Galaxy Ranger'. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n2. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n3. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n4. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n5. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n6. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n7. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n8. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n9. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n10. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n11. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n12. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n13. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n14. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n15. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n16. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.\n17. The two monsters are the 'Mara-Struck Warden' and the 'Mara-Struck Soldier'.", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3887, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3875, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His Friends\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. Clockboy and His", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3870, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3874, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 2\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 3\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 4\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 5\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 6\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 7\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 8\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 9\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 10\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 11\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 12\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 13\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 14\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 15\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 16\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 17\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 18\n\nQuestion: What is the name of the island where the tree", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3878, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The Great Septimus\n2. The Great Septimus\n3. The Great Septimus\n4. The Great Septimus\n5. The Great Septimus", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3882, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3838, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what number in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\nQuestion: According to the latest report from The Lancet,", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3849, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorect", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3840, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n5. The study did not find any difference in overnight time in target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the overnight time in target range.\n\nThe study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.\n\nReference: The Lancet Diabetes & Endocrinology. 2022;11(1):10-19.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy reduced the time below target range?\n\nAnswer: 1. Advanced hybrid closed-loop therapy\n\n2. Standard insulin therapy\n\n3. Both therapies reduced the time below target range\n\n4. Neither therapy reduced the time below target range\n\n5. The study did not find any difference in time below target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy reduced the time below target range.\n\nThe study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.\n\nReference: The Lancet Diabetes & Endocrinology. 2022;11(1):10-19.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3774, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' academic achievement goals\n2. Adolescents' academic achievement goals and their academic performance\n3. Adolescents' academic achievement goals and their academic performance goals\n4. Adolescents' academic achievement goals and their academic performance goals and their academic performance\n5. Adolescents' academic achievement goals and their academic performance goals and their academic performance goals and their academic performance\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the relationship between adolescents' depression symptoms and their academic achievement goals?\nAnswer: 1. Adolescents' depression symptoms are related to their academic achievement goals\n2. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance\n3. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals\n4. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals and their academic performance\n5. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals and their academic performance goals and their academic performance\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the relationship between adolescents' depression symptoms and their academic achievement goals?\nAnswer: 1. Adolescents' depression symptoms are related to their academic achievement goals\n2. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance\n3. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals\n4. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals and their academic performance\n5. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance goals and their academic performance goals and their academic performance\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the relationship between adolescents' depression symptoms and their academic achievement goals?\nAnswer: 1. Adolescents' depression symptoms are related to their academic achievement goals\n2. Adolescents' depression symptoms are related to their academic achievement goals and their academic performance\n3. Adolescents' depression symptoms are related to their academic achievement goals and their", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3793, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n\n2. Observation\n\n3. Cervical spondylosis\n\n4. Insufficient blood supply to the brain\n\n5. Head-down posture\n\n6. Playing on your phone\n\n7. Gaming\n\n8. Insufficient blood supply to the brain\n\n9. Cervical spondylosis\n\n10. Antiviral medication\n\n11. Observation\n\n12. Head-down posture\n\n13. Playing on your phone\n\n14. Gaming\n\n15. Insufficient blood supply to the brain\n\n16. Cervical spondylosis\n\n17. Antiviral medication\n\n18. Observation\n\n19. Head-down posture\n\n20. Playing on your phone\n\n21. Gaming\n\n22. Insufficient blood supply to the brain\n\n23. Cervical spondylosis\n\n24. Antiviral medication\n\n25. Observation\n\n26. Head-down posture\n\n27. Playing on your phone\n\n28. Gaming\n\n29. Insufficient blood supply to the brain\n\n30. Cervical spondylosis\n\n31. Antiviral medication\n\n32. Observation\n\n33. Head-down posture\n\n34. Playing on your phone\n\n35. Gaming\n\n36. Insufficient blood supply to the brain\n\n37. Cervical spondylosis\n\n38. Antiviral medication\n\n39. Observation\n\n40. Head-down posture\n\n41. Playing on your phone\n\n42. Gaming\n\n43. Insufficient blood supply to the brain\n\n44. Cervical spondylosis\n\n45. Antiviral medication\n\n46. Observation\n\n47. Head-down posture\n\n48. Playing on your phone\n\n49. Gaming\n\n50. Insufficient blood supply to the brain\n\n51. Cervical spondylosis\n\n52. Antiviral medication\n\n53. Observation", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3881, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "Question: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's marital status?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: \n\nQuestion: In the doctor-patient chat record from April 2021, what", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3842, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n\n2. Urine routine test\n\n3. Urine routine test\n\n4. Urine routine test\n\n5. Urine routine test\n\n6. Urine routine test\n\n7. Urine routine test\n\n8. Urine routine test\n\n9. Urine routine test\n\n10. Urine routine test\n\n11. Urine routine test\n\n12. Urine routine test\n\n13. Urine routine test\n\n14. Urine routine test\n\n15. Urine routine test\n\n16. Urine routine test\n\n17. Urine routine test\n\n18. Urine routine test\n\n19. Urine routine test\n\n20. Urine routine test\n\n21. Urine routine test\n\n22. Urine routine test\n\n23. Urine routine test\n\n24. Urine routine test\n\n25. Urine routine test\n\n26. Urine routine test\n\n27. Urine routine test\n\n28. Urine routine test\n\n29. Urine routine test\n\n30. Urine routine test\n\n31. Urine routine test\n\n32. Urine routine test\n\n33. Urine routine test\n\n34. Urine routine test\n\n35. Urine routine test\n\n36. Urine routine test\n\n37. Urine routine test\n\n38. Urine routine test\n\n39. Urine routine test\n\n40. Urine routine test\n\n41. Urine routine test\n\n42. Urine routine test\n\n43. Urine routine test\n\n44. Urine routine test\n\n45. Urine routine test\n\n46. Urine routine test\n\n47. Urine routine test\n\n48. Urine routine test\n\n49. Urine routine test\n\n50. Urine routine test\n\n51. Urine routine test\n\n52. Urine routine test\n\n53. Urine routine test\n\n54. Urine routine test\n\n55. Urine routine test\n\n56. Urine routine test\n\n57. Urine", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3888, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3877, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96, still breastfeeding, what can I eat postpartum that is good?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient", "position(%)": 100, "length(string)": 10911, "length(tokens)": 3873, "length(origin)": 4000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n2. NeilP. Shah\n3. Ravi Bhatia\n4. JessicaK. Altman\n5. Hema Sundar\n6. Kristina Gregory\n7. Michael Styler\n8. Michael Drazer\n9. Lori Maness\n10. Sanjay Mohan\n11. Vivian Oehler\n12. B. Douglas Smith\n13. Peter T. Curtin\n14. Leland Metheny\n15. Onyee Chan\n16. David T. Yang\n17. Moshe Talpaz\n18. Joseph O. Moore\n19. Kebede H. Begna\n20. Iskra Pusic\n21. Srinivas Tantravahi\n22. James Thompson\n23. Tiffany N. Tanaka\n24. Robert H. Collins Jr\n25. Hema Sundar\n26. Kristina Gregory\n27. Michael Styler\n28. Sanjay Mohan\n29. Vivian Oehler\n30. David T. Yang\n31. Moshe Talpaz\n32. Joseph O. Moore\n33. Kebede H. Begna\n34. Onyee Chan\n35. Srinivas Tantravahi\n36. Tiffany N. Tanaka\n37. Robert H. Collins Jr\n38. Peter T. Curtin\n39. Leland Metheny\n40. Lori Maness\n41. Michael Drazer\n42. JessicaK. Altman\n43. NeilP. Shah\n44. Ravi Bhatia\n45. Ellin Berman\n46. Iskra Pusic\n47. Vivian Oehler\n48. Hema Sundar\n49. Kristina Gregory\n50. Michael Styler\n51. Sanjay Mohan\n52. Joseph O. Moore\n53. Kebede H. Begna\n54. Onyee Chan\n55. Srinivas Tantravahi\n56. Tiffany N. Tanaka\n57. Robert H. Collins Jr\n58.", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7526, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\n\nQuestion: Which of the following is the most common abnormality in the bone marrow of patients with chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase chronic phase", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Vivian Oehler\n4. Ellin Berman\n5. Hema Sundar\n6. Lori Maness\n7. Onyee Chan\n8. Kebede Begna\n9. Jessica K Altman\n10. Sanjay Mohan\n11. B. Douglas Smith\n12. Michael Styler\n13. Keith Pratz\n14. Michael Drazer\n15. Moshe Talpaz\n16. Tiffany N Tanaka\n17. Srinivas Tantravahi\n18. Joseph O Moore\n19. David T Yang\n20. James Thompson\n21. Peter T Curtin\n22. Robert H Collins Jr\n23. Leland Metheny\n24. Steven Tsai\n25. Kristina Gregory\n26. Ravi Bhatia\n27. Hema Sundar\n28. Neil P Shah\n29. Moshe Talpaz\n30. Jessica K Altman\n31. Michael Drazer\n32. Lori Maness\n33. Sanjay Mohan\n34. Vivian Oehler\n35. Ellin Berman\n36. Raiden Bosenmori Mei\n37. Kebede H Begna\n38. Srinivas Tantravahi\n39. Peter T Curtin\n40. Robert H Collins Jr\n41. Steven Tsai\n42. Neil P Shah\n43. Michael Drazer\n44. Lori Maness\n45. Moshe Talpaz\n46. Tiffany N Tanaka\n47. Joseph O Moore\n48. Kristina Gregory\n49. Raiden Bosenmori Mei\n50. Acheron\n51. Vivian Oehler\n52. Ellin Berman\n53. Hema Sundar\n54. Leland Metheny\n55. Michael Styler\n56. Srinivas Tantravahi\n57. David T Yang\n58. James Thompson\n59. Peter T Curtin\n60. Robert H Collins Jr", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7517, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Mara-Struck Soldier\n\nQuestion: What is the name of the forest in the Xianzhou Luofu?\nAnswer: Locufox Forest\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?\nAnswer: Monster Legion\n\nQuestion: What is the name of the game?", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7524, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express in Penacony.\n2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger.\n3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7503, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons\n2. The Flintstones\n3. The Jetsons\n4. The Smurfs\n5. The Family Guy\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nstem cell transplantation (HSCT) is recommended for\nCP-CML: Treatment\npatients with advanced phase–CML or for patients with\nCP-CML who have not achieved optimal response to\nTKI therapy.66,70,71,73,75,79,88,92–94\nTreatment\nThe NCCN Guidelines® for CML recommend the use of\ntyrosine kinase inhibitors (TKIs) as the standard of care for\nCP-CML. The choice of TKI is based on the risk score,\ntoxicity profile, patient’s age, ability to tolerate therapy, and\nthe presence of comorbid conditions.\nThe NCCN Guidelines® for CML recommend the use of\nimatinib mesylate (IM) as the standard of care for CP-CML.\nThe recommended starting dose of IM is 400 mg daily.\nThe NCCN Guidelines® for CML recommend the use of\nnilotinib (NT) as the standard of care for patients with CP-\nCML who have not achieved optimal response to IM\ntherapy. The recommended starting dose of NT is 300 mg twice\ndaily.\nThe NCCN Guidelines® for CML recommend the use of\ndasatinib (DAS) as the standard of care for patients with CP-\nCML who have not achieved optimal response to IM\ntherapy. The recommended starting dose of DAS is 100 mg once\ndaily.\nThe NCCN Guidelines® for CML recommend the use of\nbosutinib (BOS) as the standard of care for patients with\nCP-CML who have not achieved optimal response to IM\ntherapy. The recommended starting dose of BOS is 400 mg once\ndaily", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7496, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. Yes\n2. No\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nCP-CML:RiskStratification\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nclinicaltrials. HCT is nolongerrecommendedasfirst-line therapy for patients with CP-CML.92–94\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:\nblasts in the peripheral blood.70 The Sokal score is\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\ncalculated using the following formula:", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7511, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. The tree named 'Sisten' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 2. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 3. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 4. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 5. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 6. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 7. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 8. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 9. The tree named 'Sprightly Vonwacq' is located on the island of 'Vonwacq'.\nQuestion: On which island is the tree named 'Sprightly Vonwacq' located?\nAnswer: 10. The tree named 'Sprightly", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 2. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 3. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 4. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 5. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 6. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 7. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 8. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 9. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 10. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 11. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 12. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 13. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 14. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 15. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 16. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 17. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 18. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 19. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 20. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 21. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 22. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 23. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 24.", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7515, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7509, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\n2. The New England Journal of Medicine\n\n3. The Journal of the American Medical Association\n\n4. The Journal of Clinical Oncology\n\n5. The Journal of the National Comprehensive Cancer Network\n\n6. The Journal of the American College of Surgeons\n\n7. The Journal of the American College of Cardiology\n\n8. The Journal of the American Academy of Dermatology\n\n9. The Journal of the American Medical Association\n\n10. The Journal of the American Medical Association\n\n11. The Journal of the American Medical Association\n\n12. The Journal of the American Medical Association\n\n13. The Journal of the American Medical Association\n\n14. The Journal of the American Medical Association\n\n15. The Journal of the American Medical Association\n\n16. The Journal of the American Medical Association\n\n17. The Journal of the American Medical Association\n\n18. The Journal of the American Medical Association\n\n19. The Journal of the American Medical Association\n\n20. The Journal of the American Medical Association\n\n21. The Journal of the American Medical Association\n\n22. The Journal of the American Medical Association\n\n23. The Journal of the American Medical Association\n\n24. The Journal of the American Medical Association\n\n25. The Journal of the American Medical Association\n\n26. The Journal of the American Medical Association\n\n27. The Journal of the American Medical Association\n\n28. The Journal of the American Medical Association\n\n29. The Journal of the American Medical Association\n\n30. The Journal of the American Medical Association\n\n31. The Journal of the American Medical Association\n\n32. The Journal of the American Medical Association\n\n33. The Journal of the American Medical Association\n\n34. The Journal of the American Medical Association\n\n35. The Journal of the American Medical Association\n\n36. The Journal of the American Medical Association\n\n37. The Journal of the American Medical Association\n\n38. The Journal of the American Medical Association\n\n39. The Journal of the American Medical Association\n\n40. The Journal of the American Medical Association\n\n41. The Journal of the American Medical Association\n\n42. The Journal of the", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7465, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer deaths is expected to increase from 375,000 annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 700,000\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040. What is the percentage increase? (Answer in Arabic numerals)\nAnswer: 107%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer deaths is expected to increase from 375,000 annually in 2020 to 700,000 annually in 2040. What is the percentage increase? (Answer in Arabic numerals)\nAnswer: 87%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040. What is the percentage increase? (Answer in Arabic numerals)\nAnswer: 107%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer deaths is expected to increase from 375,000 annually in 2020 to 700,000 annually in 2040. What is the percentage increase? (Answer in Arabic numerals)\nAnswer: 87%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n2. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n3. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n4. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n5. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n6. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n7. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n8. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n9. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n10. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7468, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\n50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nExpert Panel Discussion\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nblasts in the peripheral blood.70 The ELTS score is based on the patient’s age, spleen size on clinical examination,\nplatelet count, and percentage of blasts in the peripheral blood.72 The ELTS score has been validated in a cohort of\npatients with newly diagnosed CP-CML treated with imatinib.86,87 The ELTS score is more effective than the\nSokal score in predicting the risk of disease progression to advanced phase–CML and the risk of relapse after discontinuation\nof TKI therapy.86,87\nThe Sokal score and the ELTS score are the most commonly used risk stratification systems for patients with\nCP-CML. The Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and\npercentage of blasts in the peripheral blood.70 The ELTS score is based on the patient’s age, spleen size on clinical\nexamination, platelet count, and percentage of blasts in the peripheral blood.72 The ELTS score has been validated in a\ncohort of patients with newly diagnosed CP-CML treated with imatinib.86,87 The ELTS score is more effective than\nthe Sokal score in predicting the risk of disease progression to advanced phase–CML and the risk of relapse after discon-\ntinuation of TKI therapy.86,87\nThe Sokal score and the ELTS score are the most commonly used risk stratification systems for patients with\nCP-CML. The Sokal score is based on the patient’s", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7386, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. academic achievement goals\n2. bone marrow cytogenetics\n3. bone marrow cytogenetics with a minimum of 20 metaphases\n4. bone marrow cytogenetics with a minimum of 20 metaphases\n5. bone marrow cytogenetics with a minimum of 20 metaphases\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. academic achievement goals\n2. bone marrow cytogenetics\n3. bone marrow cytogenetics with a minimum of 20 metaphases\n4. bone marrow cytogenetics with a minimum of 20 metaphases\n5. bone marrow cytogenetics with a minimum of 20 metaphases\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. academic achievement goals\n2. bone marrow cytogenetics\n3. bone marrow cytogenetics with a minimum of 20 metaphases\n4. bone marrow cytogenetics with a minimum of 20 metaphases\n5. bone marrow cytogenetics with a minimum of 20 metaphases\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. academic achievement goals\n2. bone marrow cytogenetics\n3. bone marrow cytogenetics with a minimum of 20 metaphases\n4. bone marrow cytogenetics with a minimum of 20 metaphases\n5. bone marrow cytogenetics with a minimum of 20 metaphases\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: 1. academic achievement goals\n2. bone marrow cytogenetics\n3. bone marrow cytogenetics with a minimum of 20 metaphases\n4. bone marrow cytogenetics with a minimum of 20 metaphases", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7436, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "Question: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7487, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n2. Acute myeloid leukemia (AML)\n3. Chronic lymphocytic leukemia (CLL)\n4. Chronic myelomonocytic leukemia (CMML)\n5. Chronic neutrophilic leukemia (CNL)\n6. Chronic eosinophilic leukemia (CEL)\n7. Chronic myelomonocytic leukemia (CMML)\n8. Chronic myelomonocytic leukemia (CMML)\n9. Chronic myelomonocytic leukemia (CMML)\n10. Chronic myelomonocytic leukemia (CMML)\n11. Chronic myelomonocytic leukemia (CMML)\n12. Chronic myelomonocytic leukemia (CMML)\n13. Chronic myelomonocytic leukemia (CMML)\n14. Chronic myelomonocytic leukemia (CMML)\n15. Chronic myelomonocytic leukemia (CMML)\n16. Chronic myelomonocytic leukemia (CMML)\n17. Chronic myelomonocytic leukemia (CMML)\n18. Chronic myelomonocytic leukemia (CMML)\n19. Chronic myelomonocytic leukemia (CMML)\n20. Chronic myelomonocytic leukemia (CMML)\n21. Chronic myelomonocytic leukemia (CMML)\n22. Chronic myelomonocytic leukemia (CMML)\n23. Chronic myelomonocytic leukemia (CMML)\n24. Chronic myelomonocytic leukemia (CMML)\n25. Chronic myelomonocytic leukemia (CMML)\n26. Chronic myelomonocytic leukemia (", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7448, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n2. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n3. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n4. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n5. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n6. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n7. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n8. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n9. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosom", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Chronic Lymphocytic Leukemia)\nAnswer: Chronic Myeloid Leukemia\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's risk score? (Please answer in the format Low, Intermediate, or High)\nAnswer: Low\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's treatment plan? (Please answer in the format Imatinib, Nilotinib, or Dasatinib)\nAnswer: Imatinib\n\nQuestion: In the 2023 doctor-patient conversation, what is", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96, still breastfeeding, what can I eat postpartum that is good?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nQuestion: In 2021, a patient who had a C", "position(%)": 0, "length(string)": 22022, "length(tokens)": 7502, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n2. Shuweng\n3. Shuweng\n4. Shuweng\n5. Shuweng\n6. Shuweng\n7. Shuweng\n8. Shuweng\n9. Shuweng\n10. Shuweng\n11. Shuweng\n12. Shuweng\n13. Shuweng\n14. Shuweng\n15. Shuweng\n16. Shuweng\n17. Shuweng\n18. Shuweng\n19. Shuweng\n20. Shuweng\n21. Shuweng\n22. Shuweng\n23. Shuweng\n24. Shuweng\n25. Shuweng\n26. Shuweng\n27. Shuweng\n28. Shuweng\n29. Shuweng\n30. Shuweng\n31. Shuweng\n32. Shuweng\n33. Shuweng\n34. Shuweng\n35. Shuweng\n36. Shuweng\n37. Shuweng\n38. Shuweng\n39. Shuweng\n40. Shuweng\n41. Shuweng\n42. Shuweng\n43. Shuweng\n44. Shuweng\n45. Shuweng\n46. Shuweng\n47. Shuweng\n48. Shuweng\n49. Shuweng\n50. Shuweng\n51. Shuweng\n52. Shuweng\n53. Shuweng\n54. Shuweng\n55. Shuweng\n56. Shuweng\n57. Shuweng\n58. Shuweng\n59. Shuweng\n60. Shuweng\n61. Shuweng\n62. Shuweng\n63. Shuweng\n64. Shuweng\n65. Shuweng\n66. Shuweng\n67. Shuweng\n68. Shuweng\n69. Shuweng\n70. Shuweng\n71. Shuweng\n72. Shuweng\n73. Shuw", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7526, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\n50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nCML-1:RiskStratification\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nperipheral blood blasts.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nblasts.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatinib.70 The Sokal score has been validated in a cohort of 1,120 patientswithCP-CML treated\nwith imatin", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7506, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Apollo\n4. Ares\n5. Aphrodite\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nThe presence of mutations in genes other than BCR::ABL1\nCP-CML:RiskStratification\nhas also been reported in patients with CP-CML.92–94 The presence of mutations in genes other than BCR::ABL1\nhas been associated with inferior molecular/cytogenetic at diagnosis has also been associated with a higher risk of\nresponses and EFS in patients with CP-CML.92,93,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,1", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7517, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Mara-Struck Soldier\n\nQuestion: What is the most common abnormality detected in patients with advanced phase CML?\nAnswer: Trisomy 8\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: e13a2\n\nQuestion", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7525, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of\nPenacony, 'the Watchmaker'.\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 1. Mikhail", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7503, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n2. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n3. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n4. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n5. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n6. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n7. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n8. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n9. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n10. Clockboy is the most famous cartoon character in", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7496, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "No\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7511, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. Wacq Island\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 2. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 3. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 4. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 5. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 6. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 7. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 8. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 9. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 10. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 11. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 12. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 13. Planet Vonwacq\nQuestion: What is the name of the tree that bears fruits that give birth to the various kinds of the island's wildlife?\nAnswer: 14. Thestang\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer:", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7507, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aeon\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 2. Aeon\nQuestion: What is the most common abnormality in Ph-positive cells?\nAnswer: 3. Trisomy 8\nQuestion: What is the most common abnormality in Ph-negative cells?\nAnswer: 4. Loss of Y chromosome\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 5. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 6. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 7. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 8. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 9. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 10. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 11. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 12. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 13. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 14. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 15. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 16. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 17. e13a2\nQuestion: What is the most common BCR", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7516, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 1. The train was used to collide with the Great Septimus in", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7509, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\n2. The New England Journal of Medicine\n\n3. The Journal of the American Medical Association\n\n4. The Journal of Clinical Oncology\n\n5. The Journal of the National Comprehensive Cancer Network\n\n6. The Journal of the American Society of Clinical Oncology\n\n7. The Journal of the National Cancer Institute\n\n8. The Journal of the American College of Surgeons\n\n9. The Journal of the American College of Cardiology\n\n10. The Journal of the American College of Radiology\n\n11. The Journal of the American Academy of Dermatology\n\n12. The Journal of the American Academy of Orthopaedic Surgeons\n\n13. The Journal of the American Academy of Pediatrics\n\n14. The Journal of the American Academy of Ophthalmology\n\n15. The Journal of the American Academy of Otolaryngology\n\n16. The Journal of the American Academy of Allergy, Asthma & Immunology\n\n17. The Journal of the American Academy of Neurology\n\n18. The Journal of the American Academy of Dermatology\n\n19. The Journal of the American Academy of Dermatology\n\n20. The Journal of the American Academy of Dermatology\n\n21. The Journal of the American Academy of Dermatology\n\n22. The Journal of the American Academy of Dermatology\n\n23. The Journal of the American Academy of Dermatology\n\n24. The Journal of the American Academy of Dermatology\n\n25. The Journal of the American Academy of Dermatology\n\n26. The Journal of the American Academy of Dermatology\n\n27. The Journal of the American Academy of Dermatology\n\n28. The Journal of the American Academy of Dermatology\n\n29. The Journal of the American Academy of Dermatology\n\n30. The Journal of the American Academy of Dermatology\n\n31. The Journal of the American Academy of Dermatology\n\n32. The Journal of the American Academy of Dermatology\n\n33. The Journal of the American Academy of D", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7467, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common BCR::ABL1 transcript variant identified in patients with CML? (Answer in Arabic numerals)\nAnswer: e13a2\nQuestion: What is the most common chromosomal abnormality in Ph-positive cells? (Answer in Arabic numerals)\nAnswer: t9;22\nQuestion: What is the most common abnormality in patients with CP-CML? (Answer in Arabic numerals)\nAnswer: e13a2\nQuestion: What is the most common abnormality in patients with AP-CML? (Answer in Arabic numerals)\nAnswer: e14a2\nQuestion: What is the most common abnormality in patients with BP-CML? (Answer in Arabic numerals)\nAnswer: e1a2\nQuestion: What is the most common abnormality in patients with CP-CML? (Answer in Arabic numerals)\nAnswer: e13a2\nQuestion: What is the most common abnormality in patients with AP-CML? (Answer in Arabic numerals)\nAnswer: e14a2\nQuestion: What is the most common abnormality in patients with BP-CML? (Answer in Arabic numerals)\nAnswer: e1a2\nQuestion: What is the most common abnormality in patients with CP-CML? (Answer in Arabic numerals)\nAnswer: e13a2\nQuestion: What is the most common abnormality in patients with AP-CML? (Answer in Arabic numerals)\nAnswer: e14a2\nQuestion: What is the most common abnormality in patients with BP-CML? (Answer in Arabic numerals)\nAnswer: e1a2\nQuestion: What is the most common abnormality in patients with CP-CML? (Answer in Arabic numerals)\nAnswer: e13a2\nQuestion: What is the most common abnormality in patients with AP-CML? (Answer in Arabic numerals)\nAnswer: e14a2\nQuestion: What is the most common", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7491, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative\ncolonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n2. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n3. The study found that the presence of e19a2 transcript (encoding for p230) was associated with higher rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n4. The study found that the presence of e13a2 transcript (encoding for p210) was associated with higher rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n5. The study found that the presence of e14a2 transcript (encoding for p210) was associated with lower rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n6. The study found that the presence of e1a2 transcript (encoding for p190) was associated with higher rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n7. The study found that the presence of e19a2 transcript (encoding for p230) was associated with lower rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n8. The study found that the presence of e13a2 transcript (encoding for p210) was associated with higher rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n9. The study found that the presence of e14a2 transcript (encoding for p210) was associated with lower rates of molecular/cytogenetic\nresponses and event-free survival rates after TKI therapy.\n10. The study found that the presence of e1a2 transcript (encoding for p190) was associated with higher rates of molecular/cy", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7468, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\n50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overall time in target range\n4. Neither therapy improved the overall time in target range\n\n51 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the time below target range\n4. Neither therapy improved the time below target range\n\n52 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the treatment satisfaction?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the treatment satisfaction\n4. Neither therapy improved the treatment satisfaction\n\n53 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMy", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7387, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Academic achievement goals\n2. BCR::ABL1 transcripts\n3. BCR::ABL1–independentgenemutations\n4. BCR::ABL1–independentgenemutations in Ph-negative clones\n5. None of the above\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology, what is the most common abnormality\ndetected in patients with CP-CML?\nAnswer: 1. Clonal cytogenetic evolution\n2. Atypical BCR::ABL1 transcripts\n3. BCR::ABL1–independentgenemutations\n4. BCR::ABL1–independentgenemutations in Ph-negative clones\n5. None of the above\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology, what is the most common abnormality\ndetected in patients with CP-CML?\nAnswer: 1. Clonal cytogenetic evolution\n2. Atypical BCR::ABL1 transcripts\n3. BCR::ABL1–independentgenemutations\n4. BCR::ABL1–independentgenemutations in Ph-negative clones\n5. None of the above\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology, what is the most common abnormality\ndetected in patients with CP-CML?\nAnswer: 1. Clonal cytogenetic evolution\n2. Atypical BCR::ABL1 transcripts\n3. BCR::ABL1–independentgenemutations\n4. BCR::ABL1–independentgenemutations in Ph-negative clones\n5. None of the above\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology, what is the most common abnormality\ndetected in patients with CP-CML?\nAnswer: 1. Clonal cytogenetic evolution\n2. Atypical BCR::ABL1 transcripts\n3. BCR::ABL1–independentgenemutations\n4. BCR::ABL1–independentgenem", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7436, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended antiviral medication to treat the cold.\n2. The doctor recommended observing the patient.\n3. The doctor recommended checking if the patient has cervical spondylosis.\n4. The doctor recommended giving a good review if the patient has time.\n5. The doctor recommended giving a good review if the patient has time.\n6. The doctor recommended giving a good review if the patient has time.\n7. The doctor recommended giving a good review if the patient has time.\n8. The doctor recommended giving a good review if the patient has time.\n9. The doctor recommended giving a good review if the patient has time.\n10. The doctor recommended giving a good review if the patient has time.\n11. The doctor recommended giving a good review if the patient has time.\n12. The doctor recommended giving a good review if the patient has time.\n13. The doctor recommended giving a good review if the patient has time.\n14. The doctor recommended giving a good review if the patient has time.\n15. The doctor recommended giving a good review if the patient has time.\n16. The doctor recommended giving a good review if the patient has time.\n17. The doctor recommended giving a good review if the patient has time.\n18. The doctor recommended giving a good review if the patient has time.\n19. The doctor recommended giving a good review if the patient has time.\n20. The doctor recommended giving a good review if the patient has time.\n21. The doctor recommended giving a good review if the patient has time.\n22. The doctor recommended giving a good review if the patient has time.\n23. The doctor recommended giving a good review if the patient has time.\n24. The doctor recommended giving a good review if the patient has time.\n25. The doctor recommended giving a good review if the patient has time.\n26. The doctor recommended giving a good review if the patient has time.\n27. The doctor recommended giving a good review if the patient has time.\n28. The doctor recommended giving a good review if the patient has time.\n29. The doctor recommended giving a good review if the patient has time.\n30. The doctor recommended giving a good review if the patient has time.\n31", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7487, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n\nThe following is a doctor-patient chat record from April 2021\n\nPatient:\nI have been diagnosed with CML. I am 23 years old. I have been taking nilotinib for 1 week. I have been told that I have\na low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of progression. I have been told that I have a low risk of", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7450, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Bone marrow cytogenetics with a minimum of 20 metaphases is useful to detect additional chromosomal\nabnormalities (ACAs) in Ph-positive cells, also known as clonal cytogenetic evolution (CCE).\n2. The Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nblasts in the peripheral blood.\n3. The European Treatment and Outcome Study long-term survival (ELTS) score is based on the same variables as the\nSokal score and provides the most useful predictor of CML-related death in patients treated with first-line (PFS)/event-\nfree survival (EFS).\n4. The presence of e1a2 transcript (encoding for p190) is associated with lower rates of molecular/cytogenetic re-\nsponses and inferior PFS/EFS rates after TKI therapy.\n5. The presence of e19a2 transcript (encoding for p230) is associated with lower rates of molecular/cytogenetic\nreponses and inferior PFS/EFS rates after TKI therapy.\n6. The presence of ASXL1 mutation (encoding for p190) is associated with lower rates of molecular/cytogenetic\nreponses and inferior PFS/EFS rates after TKI therapy.\n7. The presence of IKZF1 mutation (encoding for p190) is associated with lower rates of molecular/cytogenetic\nreponses and inferior PFS/EFS rates after TKI therapy.\n8. The presence of RUNX1 mutation (encoding for p190) is associated with lower rates of molecular/cytogenetic\nreponses and inferior PFS/EFS rates after TKI therapy.\n9. The presence of DNMT3A/3B alterations (encoding for p190) is associated with lower rates of molecular/cytogenetic\nreponses and inferior PFS/EFS rates after TKI therapy.\n10. The presence of EZH2 mutation (encoding for p190) is associated with lower rates of molecular/cy", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol is okay to take.\n2. What about food, what can I eat?\n3. What is the prognostic significance of ACAs in Ph-positive cells?\n4. What is the prognostic significance of mutations in epigenetic modifier genes?\n5. What is the prognostic significance of mutations in the ASXL1 gene?\n6. What is the prognostic significance of mutations in the IKZF1 gene?\n7. What is the prognostic significance of mutations in the RUNX1 gene?\n8. What is the prognostic significance of mutations in the DNMT3A/3B gene?\n9. What is the prognostic significance of mutations in the EZH2 gene?\n10. What is the prognostic significance of mutations in the IDH1/2 gene?\n11. What is the prognostic significance of mutations in the BCOR gene?\n12. What is the prognostic significance of mutations in the RUNX1 gene?\n13. What is the prognostic significance of mutations in the DNMT3A/3B gene?\n14. What is the prognostic significance of mutations in the EZH2 gene?\n15. What is the prognostic significance of mutations in the IDH1/2 gene?\n16. What is the prognostic significance of mutations in the BCOR gene?\n17. What is the prognostic significance of mutations in the RUNX1 gene?\n18. What is the prognostic significance of mutations in the ASXL1 gene?\n19. What is the prognostic significance of mutations in the IKZF1 gene?\n20. What is the prognostic significance of mutations in the DNMT3A/3B gene?\n21. What is the prognostic significance of mutations in the EZH2 gene?\n22. What is the prognostic significance of mutations in the IDH1/2 gene?\n23. What is the prognostic significance", "position(%)": 25, "length(string)": 22022, "length(tokens)": 7504, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n2. Shuweng\n3. Shuweng\n4. Shuweng\n5. Shuweng\n6. Shuweng\n7. Shuweng\n8. Shuweng\n9. Shuweng\n10. Shuweng\n11. Shuweng\n12. Shuweng\n13. Shuweng\n14. Shuweng\n15. Shuweng\n16. Shuweng\n17. Shuweng\n18. Shuweng\n19. Shuweng\n20. Shuweng\n21. Shuweng\n22. Shuweng\n23. Shuweng\n24. Shuweng\n25. Shuweng\n26. Shuweng\n27. Shuweng\n28. Shuweng\n29. Shuweng\n30. Shuweng\n31. Shuweng\n32. Shuweng\n33. Shuweng\n34. Shuweng\n35. Shuweng\n36. Shuweng\n37. Shuweng\n38. Shuweng\n39. Shuweng\n40. Shuweng\n41. Shuweng\n42. Shuweng\n43. Shuweng\n44. Shuweng\n45. Shuweng\n46. Shuweng\n47. Shuweng\n48. Shuweng\n49. Shuweng\n50. Shuweng\n51. Shuweng\n52. Shuweng\n53. Shuweng\n54. Shuweng\n55. Shuweng\n56. Shuweng\n57. Shuweng\n58. Shuweng\n59. Shuweng\n60. Shuweng\n61. Shuweng\n62. Shuweng\n63. Shuweng\n64. Shuweng\n65. Shuweng\n66. Shuweng\n67. Shuweng\n68. Shuweng\n69. Shuweng\n70. Shuweng\n71. Shuweng\n72. Shuweng\n73. Shuw", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7526, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "10 stonehearts\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: Trisomy 8\n\nQuestion: Which of the following is the most common abnormality", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7506, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Acheron Mei\n4. Raiden Mei\n5. Acheron Bosenmori Mei\n\nQuestion: What is the most common abnormality detected in patients with CP-CML?\nAnswer: 1. Trisomy 8\n2. Isochromosome 17q\n3. Trisomy 19\n4. Chromosome 3 abnormalities\n5. Chromosome 9 abnormalities\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 1. e13a2\n2. e14a2\n3. e19a2\n4. e1a2\n5. e14a3\n\nQuestion:", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7517, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Mara-Struck Warden and 2. The Mara-Struck Soldier.", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7525, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Razarina Jane Estella, a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7503, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n2. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n3. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n4. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n5. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n6. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n7. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n8. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n9. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n10. Clockboy is the most famous cartoon character in", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7496, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet\ntaste, but it is inedible.", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7511, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nThe Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7507, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha\nQuestion: What is the most common abnormality detected in patients with advanced phase CML?\nAnswer: 3. Trisomy 8\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 4. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 5. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 6. e14a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 7. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 8. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 9. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 10. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 11. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 12. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 13. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 14. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 15. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 16. e13a2\nQuestion: What is the most common BCR::ABL1 transcript variant?\nAnswer: 17. e13a2\nQuestion: What is the most common BCR", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7516, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7509, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\nThe prognostic significance of ACAs in Ph-positive cells includestrisomy8andlossoftheYchromosome.67–69 Inan analysis of 222 patients with new-\nly diagnosed CP-CML (prospectively enrolled inthe CML-V study), an ASXL1 mutation was detected in 20\npatients at the time of diagnosis. All patients had received nilotinib-based TKI therapy. The probability of detecting\nlow-level mutations in patients with CP-CML who do not experience optimal response sponse milestones due to\nthe presence of cytopenias, for those patients with TKI-resistant disease and for patients with advanced phase–\nCML.80,83 However, there are very limited data on the impact of BCR::ABL1–independent genemutations in\npatients with newly diagnosed CP-CML.\n\nThe prognostic significance of ACAs in Ph-positive cells includestrisomy8andlossoftheYchromosome.67–69 Inan analysis of 222 patients with new-\nly diagnosed CP-CML (prospectively enrolled inthe CML-V study), an ASXL1 mutation was detected in 20\npatients at the time of diagnosis. All patients had received nilotinib-based TKI therapy. The probability of detecting\nlow-level mutations in patients with CP-CML who do not experience optimal response sponse milestones due to\nthe presence of cytopenias, for those patients with TKI-resistant disease and for patients with advanced phase–\nCML.80,83 However, there are very limited data on the impact of BCR::ABL1–independent genemutations in\npatients with newly diagnosed CP-CML.\n\nThe prognostic significance of ACAs in Ph-positive cells includestrisomy8andlossoftheYchromosome.67–69 Inan analysis of 222 patients with new-\nly diagnosed CP-CML (prospectively enrolled inthe CML-V study),", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7467, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase–chronic myeloid", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7491, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative\ncolorectal cancer incidence and mortality risk were still lower more than 15 years after the examination.\n2. The study found that compared to those who did not undergo colonoscopy, individuals with negative colorectal\ncancer incidence and mortality risk were still lower more than 15 years after the examination.\n3. The study found that compared to those who did not undergo colonoscopy, individuals with negative colorectal\ncancer incidence and mortality risk were still lower more than 15 years after the examination.\n4. The study found that compared to those who did not undergo colonoscopy, individuals with negative colorectal\ncancer incidence and mortality risk were still lower more than 15 years after the examination.\n5. The study found that compared to those who did not undergo colonoscopy, individuals with negative colorectal\ncancer incidence and mortality risk were still lower more than 15 years after the examination.\n\nQuestion: What is the prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML?\nAnswer: 1. The prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML is that they are associated with lower rates of molecular/cytogenetic re-\nsponse.\n2. The prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML is that they are associated with lower rates of molecular/cytogenetic re-\nsponse.\n3. The prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML is that they are associated with lower rates of molecular/cytogenetic re-\nsponse.\n4. The prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML is that they are associated with lower rates of molecular/cytogenetic re-\nsponse.\n5. The prognostic significance of ASXL1 mutations in patients with newly diagnosed CP-CML is that they are associated with lower rates of molecular/cytogenetic re-\nsponse", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7468, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nblasts in the peripheral blood. The Sokal score is used to determine the risk of disease progression in patients with\nchronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of disease progression\nin patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of disease\nprogression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients with chronic phase CML. The Sokal score is a prognostic tool that can be used to predict the risk of\ndisease progression in patients", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7387, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. The Sokal score\n2. The Euro score\n3. The presence of e1a2 transcript\n4. The presence of e19a2 transcript\n5. The presence of ASXL1 mutation\n\nThe Sokal score is based on the patient's age, spleen size on clinical examination, platelet count, and percentage of\nclinical examination, platelet count, and percentage of blasts in the peripheral blood. The Sokal score has been validated\nthe bone marrow. The Sokal score is used to stratify patients into 3 risk groups (low, intermediate, and high) based on\ninto 3 risk groups (low, intermediate, and high) based on their probability of experiencing major molecular response\ntheir probability of experiencing major molecular response (MMR) or better at 12 months after starting TKI therapy. The\nat 12 months after starting TKI therapy. The Sokal score is used to stratify patients into 3 risk groups (low, intermediate,\nELTS score is based on the patient's age, spleen size on clinical examination, platelet count, and percentage of blasts in\nand percentage of blasts in the peripheral blood. The ELTS score is used to stratify patients into 3 risk groups (low, intermediate,\nthe bone marrow. The ELTS score is used to stratify patients into 3 risk groups (low, intermediate, and high) based on\nand percentage of blasts in the peripheral blood. The ELTS score is used to stratify patients into 3 risk groups (low, intermediate,\ntheir probability of experiencing major molecular response (MMR) or better at 12 months after starting TKI therapy. The\nand percentage of blasts in the bone marrow. The ELTS score is used to stratify patients into 3 risk groups (low, intermediate,\nELTS score is used to stratify patients into 3 risk groups (low, intermediate, and high) based on their probability of experiencing\nand percentage of blasts in the bone marrow. The ELTS score is used to stratify patients into 3 risk groups (low, intermediate,\nmajor molecular response (MMR) or better at 12 months after starting TKI therapy. The ELTS score is used to stratify patients", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7436, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Acetaminophen\n2. Ibuprofen\n3. Antihistamines\n4. Antibiotics\n\nThe following is a doctor-patient chat record from March 2020\n\nPatient:\nI have a fever and a cough, I am worried about the coronavirus\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\n\nPatient:\nNo vomiting, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you\n\nJNCCN.org | Volume22 Issue1 | February2024 49\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nThe following is a doctor-patient chat record from March 2020\n\nPatient:\nI have a fever and a cough, I am worried about the coronavirus\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\n\nPatient:\nNo vomiting, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequ", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7487, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n2. Chronic lymphocytic leukemia (CLL)\n3. Chronic myelomonocytic leukemia (CMML)\n4. Chronic myeloid leukemia (CML)\n\nExplanation: The patient is consulting about CML. The doctor-patient chat record from April 2021 is as follows:\n\nPatient:\nI have been diagnosed with CML. I am 65 years old. I have been taking imatinib for 1 year. I have been feeling\nbetter. I have been taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have\nbeen feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for\n1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have been taking\nimatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have\nbeen taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling\nbetter. I have been taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have\nbeen feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for\n1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have been taking\nimatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling better. I have\nbeen taking imatinib for 1 year. I have been feeling better. I have been taking imatinib for 1 year. I have been feeling\nbetter. I have been taking imatinib for 1 year. I have been feeling better. I have", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7450, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation.\n2. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n3. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n4. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n5. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 1. The patient underwent a bone marrow aspirate and biopsy for morphologic and cytogenetic evaluation.\n2. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n3. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n4. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n5. The patient underwent a bone marrow aspirate and biopsy for molecular evaluation.\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's spleen size? (Please answer in the format xx cm)\nAnswer: 10 cm\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's platelet count? (Please answer in the format xx × 109/L)\nAnswer: 100 × 109/L\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of blasts in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of basophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of eosinophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of neutrophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of lymphocytes in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of monocytes in the peripheral blood? (Please answer in the format xx %)\nAnswer: 10 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of basophils in the peripheral blood? (Please answer in the format xx %)\nAnswer", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96, still breastfeeding, what can I eat postpartum that is good?", "position(%)": 50, "length(string)": 22022, "length(tokens)": 7504, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n2. Shuweng\n3. Shuweng\n4. Shuweng\n5. Shuweng\n6. Shuweng\n7. Shuweng\n8. Shuweng\n9. Shuweng\n10. Shuweng\n11. Shuweng\n12. Shuweng\n13. Shuweng\n14. Shuweng\n15. Shuweng\n16. Shuweng\n17. Shuweng\n18. Shuweng\n19. Shuweng\n20. Shuweng\n21. Shuweng\n22. Shuweng\n23. Shuweng\n24. Shuweng\n25. Shuweng\n26. Shuweng\n27. Shuweng\n28. Shuweng\n29. Shuweng\n30. Shuweng\n31. Shuweng\n32. Shuweng\n33. Shuweng\n34. Shuweng\n35. Shuweng\n36. Shuweng\n37. Shuweng\n38. Shuweng\n39. Shuweng\n40. Shuweng\n41. Shuweng\n42. Shuweng\n43. Shuweng\n44. Shuweng\n45. Shuweng\n46. Shuweng\n47. Shuweng\n48. Shuweng\n49. Shuweng\n50. Shuweng\n51. Shuweng\n52. Shuweng\n53. Shuweng\n54. Shuweng\n55. Shuweng\n56. Shuweng\n57. Shuweng\n58. Shuweng\n59. Shuweng\n60. Shuweng\n61. Shuweng\n62. Shuweng\n63. Shuweng\n64. Shuweng\n65. Shuweng\n66. Shuweng\n67. Shuweng\n68. Shuweng\n69. Shuweng\n70. Shuweng\n71. Shuweng\n72. Shuweng\n73. Shuw", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7526, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Emerald stone' team, and the 'Ruby stone' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine stone' and is part of the 'Ten Stonehearts' team.\n\nAventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'A", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7506, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Sokaland Hasford\n4. Sokaland Hasford\n5. Sokaland Hasford\n6. Sokaland Hasford\n7. Sokaland Hasford\n8. Sokaland Hasford\n9. Sokaland Hasford\n10. Sokaland Hasford\n11. Sokaland Hasford\n12. Sokaland Hasford\n13. Sokaland Hasford\n14. Sokaland Hasford\n15. Sokaland Hasford\n16. Sokaland Hasford\n17. Sokaland Hasford\n18. Sokaland Hasford\n19. Sokaland Hasford\n20. Sokaland Hasford\n21. Sokaland Hasford\n22. Sokaland Hasford\n23. Sokaland Hasford\n24. Sokaland Hasford\n25. Sokaland Hasford\n26. Sokaland Hasford\n27. Sokaland Hasford\n28. Sokaland Hasford\n29. Sokaland Hasford\n30. Sokaland Hasford\n31. Sokaland Hasford\n32. Sokaland Hasford\n33. Sokaland Hasford\n34. Sokaland Hasford\n35. Sokaland Hasford\n36. Sokaland Hasford\n37. Sokaland Hasford\n38. Sokaland Hasford\n39. Sokaland Hasford\n40. Sokaland Hasford\n41. Sokaland Hasford\n42. Sokaland Hasford\n43. Sokaland Hasford\n44. Sokaland Hasford\n45. Sokaland Hasford\n46. Sokaland Hasford\n47. Sokaland Hasford\n48. Sokaland Hasford\n49. Sokaland Hasford\n50. Sokaland Hasford\n51. Sokaland Hasford\n52. Sokaland Hasford\n53. Sokaland Hasford\n54. Sokaland Hasford\n55. Sokaland Hasford\n56. Sokaland Hasford\n57.", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7517, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu are the\nMara-Struck Warden and the Mara-Struck Soldier. 2. The two monsters in the 'Monster Legion' behind the Fox Talk\nForest in the Xianzhou Luofu are the Mara-Struck Warden and the Mara-Struck Soldier.", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7525, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7503, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n2. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n3. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n4. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n5. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n6. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n7. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n8. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n9. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi.\n10. Clockboy is the most famous cartoon character in", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7496, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7511, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 2.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 3.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 4.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 5.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 6.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 7.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 8.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 9.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 10.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 11.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 12.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 13.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 14.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 15.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 16.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 17.\n\nQuestion: What is the name of the tree that is located on the island of Sisten?\nAnswer: 18.\n\nQuestion: What is the name of the tree that is", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7507, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\nAha is the Aeon in charge of the Path of Joy", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7516, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to coll", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7509, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\nThe most common abnormalities\n\nThe major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.\n\nhas been associated with decreased survival in patients at diagnosis. The presence of e1a2 transcript (encoding for p190) was detected in 20 patients at the time of diagnosis. All patients had received nilotinib-based TKI therapy. The probability of detecting major molecular response (MMR) or better at 12 months was significantly lower for patients with an ASXL1 mutation (55%; P < 0.0036) compared with 85% for patients with no mutations and 82% for patients with other non-ASXL1 mutations.\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n\nThe Sokal score is based on the patient's age, spleen size on clinical examination, platelet count, and percentage of\n\nblasts in the peripheral blood. The ELTS score has been validated in a cohort of 1,120 patients with CP-CML treated with imatinib. The ELTS score has been shown to be a good predictor of molecular/cytogenetic response rates and event-free survival rates after TKI therapy.\n\nJNCCN.org | Volume22 Issue1 | February2024 51\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n\nThe Sokal score is based on the patient's age, spleen size on clinical examination, platelet count, and percentage of\n\nblasts in the peripheral blood. The ELTS score has been validated in a cohort of 1,120 patients with CP-CML treated with imatinib. The ELTS score has been shown to be a good", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7467, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with first-line imatinib therapy? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with second-generation TKI therapy? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with first-line imatinib therapy? (Answer in Arabic numerals)\nAnswer: 3\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with second-generation TKI therapy? (Answer in Arabic numerals)\nAnswer: 4\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with first-line imatinib therapy? (Answer in Arabic numerals)\nAnswer: 5\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with second-generation TKI therapy? (Answer in Arabic numerals)\nAnswer: 6\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with first-line imatinib therapy? (Answer in Arabic numerals)\nAnswer: 7\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with second-generation TKI therapy? (Answer in Arabic numerals)\nAnswer: 8\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with first-line imatinib therapy? (Answer in Arabic numerals)\nAnswer: 9\nQuestion: What is the most common abnormality associated with decreased survival in patients with chronic phase CML treated with second-generation TKI therapy? (Answer in Arabic numerals)\nAnswer: 10\nQuestion: What is the most common abnormality", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7491, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n2. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n3. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n4. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n5. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nThe study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer inc", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7468, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the time below target range\n4. Neither therapy improved the time below target range\n\nJNCCN.org | Volume22 Issue1 | February2024 51\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the treatment satisfaction?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the treatment satisfaction\n4. Neither therapy improved the treatment satisfaction\n\nJNCCN.org | Volume22 Issue1 | February2024 52\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the time in target range\n4. Neither therapy improved the time in target range\n\nJNCCN.org | Volume22 Issue1 | February2024 53\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7387, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Academic achievement goals\n2. Spleen size\n3. Basophil count\n4. Percentage of blasts in the peripheral blood\n5. Age\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, what is the most common abnormal-\nity detected in patients with newly diagnosed CP-CML?\nAnswer: 1. ASXL1 mutation\n2. IKZF1 mutation\n3. RUNX1 mutation\n4. DNMT3A/3B mutation\n5. EZH2 mutation\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, what is the recommended follow-up for patients with CP-CML who do not experience optimal re-\nsponse to TKI therapy?\nAnswer: 1. Metaphase karyotype analysis\n2. NGS with myeloid mutation panel\n3. NGS with myeloid mutation panel and patient-specific genomic DNA quantitative PCR assay\n4. NGS with myeloid mutation panel and patient-specific genomic DNA sequencing\n5. NGS with myeloid mutation panel and patient-specific genomic DNA methylation analysis\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, what is the recommended follow-up for patients with CP-CML who do not experience optimal re-\nsponse to TKI therapy?\nAnswer: 1. Metaphase karyotype analysis\n2. NGS with myeloid mutation panel\n3. NGS with myeloid mutation panel and patient-specific genomic DNA quantitative PCR assay\n4. NGS with myeloid mutation panel and patient-specific genomic DNA sequencing\n5. NGS with myeloid mutation panel and patient-specific genomic DNA methylation analysis\n\nQuestion: According to the NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia, what is the recommended follow-up for patients with CP-CML who do not", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7436, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended antiviral medication.\n2. The doctor recommended antiviral medication.\n3. The doctor recommended antiviral medication.\n4. The doctor recommended antiviral medication.\n5. The doctor recommended antiviral medication.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the probability of detecting major molecular response (MMR) or better at 12 months in patients treated with imatinib?\nAnswer: 1. The probability of detecting MMR or better at 12 months in patients treated with imatinib is 55%.\n2. The probability of detecting MMR or better at 12 months in patients treated with imatinib is 85%.\n3. The probability of detecting MMR or better at 12 months in patients treated with imatinib is 82%.\n4. The probability of detecting MMR or better at 12 months in patients treated with imatinib is 90%.\n5. The probability of detecting MMR or better at 12 months in patients treated with imatinib is 95%.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the probability of detecting major molecular response (MMR) or better at 12 months in patients treated with 2G-TKIs?\nAnswer: 1. The probability of detecting MMR or better at 12 months in patients treated with 2G-TKIs is 55%.\n2. The probability of detecting MMR or better at 12 months in patients treated with 2G-TKIs is 85%.\n3. The probability of detecting MMR or better at 12 months in patients treated with 2G-TKIs is 82%.\n4. The probability of detecting MMR or better at 12 months in patients treated with 2G-TKIs is 90%.\n5. The probability of detecting MMR or better at 12 months in patients treated with 2G-TKIs is 95%.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the probability of detecting major molecular response (MM", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7487, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the most likely diagnosis?", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7450, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Next-generation sequencing (NGS) with myeloid mutation panel\n2. Sokal score\n3. Euro score\n4. ELTS score\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia (CML)\n2. Acute myeloid leukemia (AML)\n3. Myelodysplastic syndrome (MDS)\n4. Myeloproliferative neoplasm (MPN)\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib\n3. Dasatinib\n4. Bosutinib\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib\n3. Dasatinib\n4. Bosutinib\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib\n3. Dasatinib\n4. Bosutinib\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib\n3. Dasatinib\n4. Bosutinib\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib\n3. Dasatinib\n4. Bosutinib\n5. None of the above\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most likely treatment?\nAnswer: 1. Imatinib\n2. Nilotinib", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's spleen size? (Please answer in the format xx cm)\nAnswer: 12 cm\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's platelet count? (Please answer in the format xx x 10^9/L)\nAnswer: 150 x 10^9/L\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of blasts in the peripheral blood? (Please answer in the format xx %)\nAnswer: 1 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of basophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 1 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of eosinophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 1 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of neutrophils in the peripheral blood? (Please answer in the format xx %)\nAnswer: 70 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of lymphocytes in the peripheral blood? (Please answer in the format xx %)\nAnswer: 20 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of monocytes in the peripheral blood? (Please answer in the format xx %)\nAnswer: 5 %\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's percentage of basophils in the peripheral blood? (Please answer in the format xx %)\nAnswer:", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion", "position(%)": 75, "length(string)": 22022, "length(tokens)": 7504, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\n\nAnswer: 1. Shuweng", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7526, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori\n\nExplanation: The correct answer is 1. Raiden Bosenmori Mei is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony.\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n2. Acheron\n3. Raiden Bosenmori\n4. Mei\n5. Bosenmori\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7517, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Mara-Struck Warden and 2. The Mara-Struck Soldier.", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7524, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork\n\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n\nAdditionalEvaluation\n\nCP-CML:RiskStratification\n\nIKZF1exondeletionsandmutationsinASXL1,RUNX1, and DNMT3Aalterations were identified as important\n\nmarkers of disease progression to advanced phase–CML and risk of relapse after discontinuation of TKI.73,75,79,88\n\nTheselectionoffirst-lineTKItherapy(bosutinib,da-\n\nsatinib, imatinib, or nilotinib) in a given patient should be based on the riskscore, toxicity profile,patient’s age,\n\nability to tolerate therapy, and the presence of comorbidities.\n\nJNCCN.org | Volume22 Issue1 | February2024 50\n\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n\nAdditionalEvaluation\n\nCP-CML:RiskStratification\n\nThe presence of e1a2 transcript (encoding for p190) was detected in 20 patients at the time of diagnosis. All patients had\n\nreceived nilotinib-based TKI therapy. The probability of detecting e1a2 transcript was significantly lower for\n\npatientswithno mutations and for those with other non-ASXL1 mutations.73,75,79,88\n\nIKZF1, RUNX1, and DNMT3A alterations were identified as important markers of disease progression to\n\nadvanced phase–CML and risk of relapse after discontinuation of TKI.73,75,79,88\n\nTheselectionoffirst-lineTKItherapy(bosutinib, da-\n\nsatinib, imatinib, or nilotinib) in a given patient should be based on the riskscore, toxicity profile,patient’s age,\n\nability to tolerate", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7503, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy and His Friends\n\n2. Clockboy and His Friends\n\n3. Clockboy and His Friends\n\n4. Clockboy and His Friends\n\n5. Clockboy and His Friends\n\n6. Clockboy and His Friends\n\n7. Clockboy and His Friends\n\n8. Clockboy and His Friends\n\n9. Clockboy and His Friends\n\n10. Clockboy and His Friends\n\n11. Clockboy and His Friends\n\n12. Clockboy and His Friends\n\n13. Clockboy and His Friends\n\n14. Clockboy and His Friends\n\n15. Clockboy and His Friends\n\n16. Clockboy and His Friends\n\n17. Clockboy and His Friends\n\n18. Clockboy and His Friends\n\n19. Clockboy and His Friends\n\n20. Clockboy and His Friends\n\n21. Clockboy and His Friends\n\n22. Clockboy and His Friends\n\n23. Clockboy and His Friends\n\n24. Clockboy and His Friends\n\n25. Clockboy and His Friends\n\n26. Clockboy and His Friends\n\n27. Clockboy and His Friends\n\n28. Clockboy and His Friends\n\n29. Clockboy and His Friends\n\n30. Clockboy and His Friends\n\n31. Clockboy and His Friends\n\n32. Clockboy and His Friends\n\n33. Clockboy and His Friends\n\n34. Clockboy and His Friends\n\n35. Clockboy and His Friends\n\n36. Clockboy and His Friends\n\n37. Clockboy and His Friends\n\n38. Clockboy and His Friends\n\n39. Clockboy and His Friends\n\n40. Clockboy and His Friends\n\n41. Clockboy and His Friends\n\n42. Clockboy and His Friends\n\n43. Clockboy and His Friends\n\n44. Clockboy and His Friends\n\n45. Clockboy and His Friends\n\n46. Clockboy and His Friends\n\n47.", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7496, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1\n\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nThe presence of BCR::ABL1–independentgenemutations\nin Ph-negativeclones.91Theimpactofmutationsisalsovari-\nabledependingonwhethertheyoccurinPh-positiveorPh-\nnegativeclones.\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nnegativeclones.\n\nThe presence of BCR::ABL1–independentgenemutations\nin Ph-negativeclones.91Theimpactofmutationsisalsovari-\nabledependingonwhethertheyoccurinPh-positiveorPh-\nnegativeclones.\n\nJNCCN.org | Volume22 Issue1 | February2024 51\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nThe presence of BCR::ABL1–independentgenemutations\nin Ph-negativeclones.91Theimpactofmutationsisalsovari-\nabledependingonwhethertheyoccurinPh-positiveorPh-\nnegativeclones.\n\nJNCCN.org | Volume22 Issue1 | February2024 52\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nThe presence of BCR::ABL1–independentgenemutations\nin Ph-negativeclones.91Theimpactofmutationsisalsovari-\nabledependingonwhethertheyoccurinPh-positiveorPh-\nnegativeclones.\n\nJNCCN.org | Volume22 Issue1 | February2024 53\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7511, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 2\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 3\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 4\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 5\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 6\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 7\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 8\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 9\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 10\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 11\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 12\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 13\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 14\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 15\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 16\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 17\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 18\n\nQuestion: What is the name of the island where the tree", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 2. Aeon\nQuestion: Who once blew up the Astral Express?\nAnswer: 3. Akivili\nQuestion: Who once blew up the Astral Express?\nAnswer: 4. Aeon in charge of the Path of Joy\nQuestion: Who once blew up the Astral Express?\nAnswer: 5. Masked Fools\nQuestion: Who once blew up the Astral Express?\nAnswer: 6. Mourning Actors\nQuestion: Who once blew up the Astral Express?\nAnswer: 7. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 8. Aeon\nQuestion: Who once blew up the Astral Express?\nAnswer: 9. Akivili\nQuestion: Who once blew up the Astral Express?\nAnswer: 10. Aeon in charge of the Path of Joy\nQuestion: Who once blew up the Astral Express?\nAnswer: 11. Masked Fools\nQuestion: Who once blew up the Astral Express?\nAnswer: 12. Mourning Actors\nQuestion: Who once blew up the Astral Express?\nAnswer: 13. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 14. Aeon\nQuestion: Who once blew up the Astral Express?\nAnswer: 15. Akivili\nQuestion: Who once blew up the Astral Express?\nAnswer: 16. Aeon in charge of the Path of Joy\nQuestion: Who once blew up the Astral Express?\nAnswer: 17. Masked Fools\nQuestion: Who once blew up the Astral Express?\nAnswer: 18. Mourning Actors\nQuestion: Who once blew up the Astral Express?\nAnswer: 19. Aha\nQuestion: Who once blew up the Astral Express?\nAnswer: 20. Aeon\nQuestion: Who once blew up the Astral Express?\nAnswer: 21. Aeon in charge of the Path of Joy\nQuestion: Who once blew up the Astral", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7515, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7509, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 2\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 3\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 4\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 5\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 6\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 7\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 8\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 9\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 10\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 11\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 12\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 13\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 14\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 15\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 16\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer: 17\n\nQuestion: Which of the following is the most common abnormality in patients with chronic phase CML?\nAnswer:", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7465, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about what percentage? (Answer in Arabic numerals)\nAnswer: 85%\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases. What is the expected number of global prostate cancer cases in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases. What is the expected number of global prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 1.4 million\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases. What is the expected number of global prostate cancer cases in 2040? (Answer in Arabic numerals)\nAnswer: 2.9 million\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases. What is the expected number of global prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 1.4 million\n\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "15 years after the examination.\n\nJNCCN.org | Volume22 Issue1 | February2024 50\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nrisk of colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\n\nAnswer: 15 years after the examination.\n\nJNCCN.org | Volume22 Issue1 | February2024 51\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nrisk of colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\n\nAnswer: 15 years after the examination.\n\nJNCCN.org | Volume22 Issue1 | February2024 52\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nAdditionalEvaluation\nrisk of colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What did the study in The", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7468, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n5. Neither therapy reduced the time below target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the overnight time in target range compared to standard insulin therapy.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy reduced the time below target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies reduced the time below target range\n4. Neither therapy reduced the time below target range\n5. Neither therapy increased treatment satisfaction\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy reduced the time below target range compared to standard insulin therapy.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy increased treatment satisfaction?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies increased treatment satisfaction\n4. Neither therapy increased treatment satisfaction\n5. Neither therapy improved the overall time in target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy increased treatment satisfaction compared to standard insulin therapy.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overall time in target range\n4. Neither therapy improved the overall time in target range\n5. Neither therapy reduced the time below target range\n\nExplanation: The correct answer is 4. Neither therapy improved the overall time in target range.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy was associated with a higher rate of hypoglycemia?\nAnswer: 1.", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7386, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' depression symptoms are related to their academic achievement goals.\n2. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n3. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n4. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n5. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n\n6. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n\n7. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n\n8. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n\n9. Adolescents' depression symptoms are related to their academic achievement goals", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7436, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "Question: In the March 2020 doctor-patient chat record, what is the cause of the patient's dizziness?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's bloating?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's cervical spondylosis?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's head-down posture?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's bloating?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's bloating?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's bloating?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's bloating?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what is the cause of the patient's stomach discomfort?", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7487, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Tinnitus\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's current treatment regimen?\nAnswer: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nQuestion:", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7448, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n2. Urine occult blood test\n3. Urine pregnancy test\n4. Urine culture test\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the above\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake\n2. Avoid foods that promote blood circulation\n3. No other restrictions\n4. All of the", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7490, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7505, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140, diastolic 96\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan", "position(%)": 100, "length(string)": 22022, "length(tokens)": 7502, "length(origin)": 8000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\nQuestion: Who is the author of the article “NCCN Guidelines for Chronic Myeloid Leukemia, Version 2.2024”?\nAnswer: 2. The author of the article “NCCN Guidelines for Chronic Myeloid Leukemia, Version 2.2024” is NeilP. Shah.\nQuestion: What is the most common abnormality in the bone marrow of patients with Ph-positive cells?\nAnswer: 3. The most common abnormality in the bone marrow of patients with Ph-positive cells is trisomy 8.\nQuestion: What is the most common adverse event associated with dasatinib?\nAnswer: 4. The most common adverse event associated with dasatinib is thrombocytopenia.\nQuestion: What is the most common adverse event associated with nilotinib?\nAnswer: 5. The most common adverse event associated with nilotinib is diarrhea.\nQuestion: What is the most common adverse event associated with bosutinib?\nAnswer: 6. The most common adverse event associated with bosutinib is muscle spasms.\nQuestion: What is the most common adverse event associated with imatinib?\nAnswer: 7. The most common adverse event associated with imatinib is muscle cramps.\nQuestion: What is the most common adverse event associated with ponatinib?\nAnswer: 8. The most common adverse event associated with ponatinib is arterial occlusive events.\nQuestion: What is the most common adverse event associated with dasatinib?\nAnswer: 9. The most common adverse event associated with dasatinib is thrombocytopenia.\nQuestion: What is the most common adverse event associated with nilotinib?\nAnswer: 10. The most common adverse event associated with nilotinib is diarrhea.\nQuestion: What is the most common adverse event associated with bosutinib?\nAnswer: 11. The most common adverse event associated with bosutinib", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14932, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 2\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 3\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 4\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 5\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 6\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 7\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 8\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 9\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 10\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 11\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 12\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 13\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 14\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 15\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 16\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 17\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 18\nQuestion: Which of the following is NOT a feature of the 'Aventurine stone'?\nAnswer: 19\nQuestion:", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14916, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Acheron 2. Raiden Bosenmori Mei 3. Acheron 4. Raiden Bosenmori Mei 5. Acheron 6. Raiden Bosenmori Mei 7. Acheron 8. Raiden Bosenmori Mei 9. Acheron 10. Raiden Bosenmori Mei 11. Acheron 12. Raiden Bosenmori Mei 13. Acheron 14. Raiden Bosenmori Mei 15. Acheron 16. Raiden Bosenmori Mei 17. Acheron 18. Raiden Bosenmori Mei 19. Acheron 20. Raiden Bosenmori Mei 21. Acheron 22. Raiden Bosenmori Mei 23. Acheron 24. Raiden Bosenmori Mei 25. Acheron 26. Raiden Bosenmori Mei 27. Acheron 28. Raiden Bosenmori Mei 29. Acheron 30. Raiden Bosenmori Mei 31. Acheron 32. Raiden Bosenmori Mei 33. Acheron 34. Raiden Bosenmori Mei 35. Acheron 36. Raiden Bosenmori Mei 37. Acheron 38. Raiden Bosenmori Mei 39. Acheron 40. Raiden Bosenmori Mei 41. Acheron 42. Raiden Bosenmori Mei 43. Acheron 44. Raiden Bosenmori Mei 45. Acheron 46. Raiden Bosenmori Mei 47. Acheron 48. Raiden Bosenmori Mei 49. Acheron 50. Raiden Bosenmori Mei 51. Acheron 52", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14933, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Fox Talk Forest is a forest in the Xianzhou Luofu, a region in the Guangxi Zhuang Autonomous\nRegion of China. 2. The two monsters in the 'Monster Legion' are the Fox Talk Forest and the Fox Talk\nForest.\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nMonitoringwithqPCR(IS)every3monthsisrecom-\nmendedforpatientswithCP-CMLwhoachieveCCyR.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS),\nmonitoringwithqPCR(IS)every3monthsisrecom-\nmended. InpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)and\nno cytogenetic response (CCyR-), monitoring with qPCR\n(IS)every3monthsisrecommended. InpatientswithCP-CML\nand DMR (MR4.0; #0.01%BCR::ABL1IS), monitoring with\nqPCR(IS)every3monthsisrecommended. InpatientswithCP-CML\nand MMR (#0.1%BCR::ABL1IS), monitoring with qPCR\n(IS)every3monthsisrecommended. InpatientswithCP-CML\nand DMR (MR4.0; #0.01%BCR::ABL1IS), monitoring with\nqPCR(IS)every3monthsisrecommended. InpatientswithCP-CML\nand MMR (#0.1%BCR::ABL1IS), monitoring with qPCR\n(IS)every3monthsisrecommended. InpatientswithCP-CML\nand MMR (#0.1%BCR::ABL1IS), monitoring with\nqPCR(IS)every3monthsisrecommended. InpatientswithCP-CML\nand MMR (#0.1%BCR::AB", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14936, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Breukelen Tiernan, a ex-surveyor aboard the Astral Express and a outstanding gunslinger.\n\n2. Mikhail Char, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'\n\n3. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar.\n\n4. NeilP. Shah, MD, PhD, 1. Breukelen Tiernan, a ex-surveyor aboard the Astral Express and a outstanding gunslinger.\n\n5. Onyee Chan, MD, 2. Mikhail Char, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'\n\n6. Vivian Oehler, MD, 3. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar.\n\n7. Hema Sundar, PhD, 4. NeilP. Shah, MD, PhD, 1. Breukelen Tiernan, a ex-surveyor aboard the Astral Express and a outstanding gunslinger.\n\n8. Jessica K. Altman, MD, 5. Onyee Chan, MD, 2. Mikhail Char, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'\n\n9. Leland Metheny, MD, 6. Vivian Oehler, MD, 3. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar.\n\n10. Michael D. Styler, MD, 7. Hema Sundar, PhD, 4. NeilP. Shah, MD, PhD, 1. Breukelen Tiernan, a ex-surveyor aboard the Astral Express and a outstanding gunslinger.\n\n11. Ravi Bhatia, MD, 8. Jessica K. Altman, MD, 5. Onyee Chan, MD, 2. Mikhail Char, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'\n\n12", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14906, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons 2. The Flintstones 3. The Jetsons 4. The Family Guy 5. The Smurfs\n\n6. The Flintstones 7. The Jetsons 8. The Simpsons 9. The Flintstones 10. The Jetsons\n\n11. The Simpsons 12. The Flintstones 13. The Simpsons 14. The Jetsons 15. The Simpsons\n\n16. The Flintstones 17. The Jetsons 18. The Simpsons 19. The Flintstones 20. The Jetsons\n\n21. The Simpsons 22. The Flintstones 23. The Simpsons 24. The Flintstones 25. The Jetsons\n\n26. The Simpsons 27. The Flintstones 28. The Simpsons 29. The Flintstones 30. The Jetsons\n\n31. The Simpsons 32. The Flintstones 33. The Simpsons 34. The Flintstones 35. The Simpsons\n\n36. The Flintstones 37. The Simpsons 38. The Flintstones 39. The Simpsons 40. The Flintstones\n\n41. The Simpsons 42. The Flintstones 43. The Simpsons 44. The Flintstones 45. The Jetsons\n\n46. The Simpsons 47. The Flintstones 48. The Simpsons 49. The Flintstones 50. The Jetsons\n\n51. The Simpsons 52. The Flintstones 53. The Simpsons 54. The Flintstones 55. The Simpsons\n\n56. The Flintstones 57. The Simpsons 58. The Flintstones 59. The Simpsons 60. The", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14904, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1%–10% of patients with CML have atypical\nBCR::ABL1 transcripts, which are associated with a\nhigher risk of disease progression. The presence of e1a2 transcripts\n(encoding for p190) is associated with a higher risk of disease\nprogression.\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nPrognosticSignificanceofCytogeneticandMolecular Response\nThe achievement of MMR (#0.1%BCR::ABL1IS) at 12 months is associated with a low risk of disease progression\nand a high likelihood of achieving DMR (#0.01%BCR::ABL1 IS) and TFR.129,130,132,133,135,136,138,139,141,142,144,145,147,148,150,151,153,154,156,157,159,160,162,163,165,166,168,169,171,172,174,175,177,178,180,181,183,184,186,187,189,190,192,193,195,196,198,200,202,204,206,208,210,212,214,216,218,220,222,224,226,228,230,232,234,236,238,240,242,244,246,248,250,252,254", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. The tree named 'Sisten' is located on the island of Sist.\n\n2. The tree named 'Sisten' is located on the island of Sist.\n\n3. The tree named 'Sisten' is located on the island of Sist.\n\n4. The tree named 'Sisten' is located on the island of Sist.\n\n5. The tree named 'Sisten' is located on the island of Sist.\n\n6. The tree named 'Sisten' is located on the island of Sist.\n\n7. The tree named 'Sisten' is located on the island of Sist.\n\n8. The tree named 'Sisten' is located on the island of Sist.\n\n9. The tree named 'Sisten' is located on the island of Sist.\n\n10. The tree named 'Sisten' is located on the island of Sist.", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14922, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Astral Express was a spacecraft in the\nStar Trek universe. It was used by the crew of the USS\nEnterprise to travel to the planet Vulcan.\n2. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n3. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n4. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n5. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n6. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n7. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n8. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n9. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n10. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n11. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n12. The Astral Express was a spacecraft in the Star Trek\nuniverse. It was used by the crew of the USS Enterprise to\ntravel to the planet Vulcan.\n13. The Astral", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14927, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14924, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14876, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial.\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy (ie, failure to\nachieve MMR at 12 months) should be considered for enrollment in a clinical trial", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14894, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 2. The study found that the presence of e19a2 transcript (encoding for p230) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 3. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 4. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 5. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 6. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 7. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 8. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 9. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and mortality more than 15 years after colonoscopy. 10. The study found that the presence of e1a2 transcript (encoding for p190) was associated with lower rates of colorectal cancer incidence and", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14866, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the treatment satisfaction?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Standard insulin therapy 2. Advanced hybrid closed-loop therapy 3. Neither\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14793, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "Question: According to the recent study from The Lancet Child & Adolescent Health, what are the survival outcomes of patients with CP-CML?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the most common adverse event leading to discontinuation of therapy?\nAnswer: \n\nQuestion: According to the recent study from The", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14840, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended the patient to take antiviral medication.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common abnormality in the bone marrow?\nAnswer: 2. The most common abnormality in the bone marrow is trisomy 8.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common BCR::ABL1 transcript variant?\nAnswer: 3. The most common BCR::ABL1 transcript variant is e13a2.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with dasatinib?\nAnswer: 4. The most common adverse event associated with dasatinib is thrombocytopenia.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with imatinib?\nAnswer: 5. The most common adverse event associated with imatinib is diarrhea.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with nilotinib?\nAnswer: 6. The most common adverse event associated with nilotinib is rash.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with bosutinib?\nAnswer: 7. The most common adverse event associated with bosutinib is peripheral edema.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with dasatinib?\nAnswer: 8. The most common adverse event associated with dasatinib is thrombocytopenia.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event associated with nilotinib?\nAnswer: 9. The most common adverse event associated with nilotinib is rash.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most common adverse event", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14901, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's diagnosis?\nAnswer: 1. Chronic myeloid leukemia\nQuestion: In the", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14865, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent bone marrow cytogenetics with a minimum of 20 metaphases.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common abnormality in the bone marrow?\nAnswer: 2. The most common abnormality in the bone marrow is trisomy 8.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with dasatinib?\nAnswer: 3. The most common adverse event associated with dasatinib is thrombocytopenia.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with nilotinib?\nAnswer: 4. The most common adverse event associated with nilotinib is diarrhea.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with imatinib?\nAnswer: 5. The most common adverse event associated with imatinib is pleural effusion.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with bosutinib?\nAnswer: 6. The most common adverse event associated with bosutinib is diarrhea.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with dasatinib?\nAnswer: 7. The most common adverse event associated with dasatinib is thrombocytopenia.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with nilotinib?\nAnswer: 8. The most common adverse event associated with nilotinib is diarrhea.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the most common adverse event associated with imatinib?\nAnswer: 9. The most common adverse event associated with imatinib is pleural effusion.\n\nQuestion: In the April 2019 doctor-", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14913, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format xx years old)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14908, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 140/96 mmHg. The doctor recommended labetalol.\nQuestion", "position(%)": 0, "length(string)": 44244, "length(tokens)": 14905, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng 2. Shuweng 3. Shuweng 4. Shuweng 5. Shuweng 6. Shuweng 7. Shuweng 8. Shuweng 9. Shuweng 10. Shuweng 11. Shuweng 12. Shuweng 13. Shuweng 14. Shuweng 15. Shuweng 16. Shuweng 17. Shuweng 18. Shuweng 19. Shuweng 20. Shuweng 21. Shuweng 22. Shuweng 23. Shuweng 24. Shuweng 25. Shuweng 26. Shuweng 27. Shuweng 28. Shuweng 29. Shuweng 30. Shuweng 31. Shuweng 32. Shuweng 33. Shuweng 34. Shuweng 35. Shuweng 36. Shuweng 37. Shuweng 38. Shuweng 39. Shuweng 40. Shuweng 41. Shuweng 42. Shuweng 43. Shuweng 44. Shuweng 45. Shuweng 46. Shuweng 47. Shuweng 48. Shuweng 49. Shuweng 50. Shuweng 51. Shuweng 52. Shuweng 53. Shuweng 54. Shuweng 55. Shuweng 56. Shuweng 57. Shuweng 58. Shuweng 59. Shuweng 60. Shuweng 61. Shuweng 62. Shuweng 63. Shuweng 64. Shuweng 65. Shuweng 66. Shuweng 67. Shuweng 68. Shuweng 69. Shuweng 70. Shuweng 71. Shuweng 72. Shuweng 73. Shuw", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14933, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\nQuestion: Which of the following is NOT a side effect of dasatinib?\nAnswer: 2.\n\nQuestion: Which of the following is NOT a side effect of nilotinib?\nAnswer: 3.\n\nQuestion: Which of the following is NOT a side effect of ponatinib?\nAnswer: 4.\n\nQuestion: Which of the following is NOT a side effect of bosutinib?\nAnswer: 5.\n\nQuestion: Which of the following is NOT a side effect of imatinib?\nAnswer: 6.\n\nQuestion: Which of the following is NOT a side effect of dasatinib?\nAnswer: 7.\n\nQuestion: Which of the following is NOT a side effect of nilotinib?\nAnswer: 8.\n\nQuestion: Which of the following is NOT a side effect of ponatinib?\nAnswer: 9.\n\nQuestion: Which of the following is NOT a side effect of bosutinib?\nAnswer: 10.\n\nQuestion: Which of the following is NOT a side effect of imatinib?\nAnswer: 11.\n\nQuestion: Which of the following is NOT a side effect of dasatinib?\nAnswer: 12.\n\nQuestion: Which of the following is NOT a side effect of nilotinib?\nAnswer: 13.\n\nQuestion: Which of the following is NOT a side effect of ponatinib?\nAnswer: 14.\n\nQuestion: Which of the following is NOT a side effect of bosutinib?\nAnswer: 15.\n\nQuestion: Which of the following is NOT a side effect of imatinib?\nAnswer: 16.\n\nQuestion: Which of the following is NOT a side effect of dasatinib?\nAnswer: 17.\n\nQuestion: Which of the following is NOT a side effect of nilotinib?\nAnswer: 18.\n\nQuestion: Which of the following is NOT a side effect of ponatinib?\nAnswer: 19.\n\nQuestion: Which of the following is NOT a side effect of bosutinib?\nAnswer: 20.\n\nQuestion:", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14917, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\nQuestion: What is the real name of the purple-haired", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14934, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Fox Talk Forest is located in the Xianzhou Luofu. 2. There are two monsters in the 'Monster Legion' in the Fox Talk Forest in the Xianzhou Luofu.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nForest in the Xianzhou Luofu. 1. The Fox Talk Forest is located in the Xianzhou Luofu. 2. There are two monsters in the 'Monster Legion' in the Fox Talk Forest in the Xianzhou Luofu.", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14937, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. The Watchmaker is a character in the novel 'The\nGolden Compass' by Philip Pullman. 2. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 3. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 4. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 5. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 6. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 7. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 8. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 9. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 10. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 11. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 12. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 13. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 14. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 15. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 16. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 17. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 18. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 19. The Watchmaker is a character in the novel 'The Golden Compass' by Philip\nPullman. 20. The Watchmaker is a character in the novel 'The Golden", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14908, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Pinocchio 2. The Simpsons 3. The Flintstones 4. The Jetsons 5. The Smurfs 6. The Powerpuff Girls 7. The Flintstones 8. The Simpsons 9. The Jetsons 10. The Smurfs 11. The Flintstones 12. The Simpsons 13. The Jetsons 14. The Flintstones 15. The Simpsons 16. The Flintstones 17. The Simpsons 18. The Jetsons 19. The Simpsons 20. The Flintstones 21. The Simpsons 22. The Jetsons 23. The Simpsons 24. The Flintstones 25. The Simpsons 26. The Flintstones 27. The Simpsons 28. The Jetsons 29. The Simpsons 30. The Flintstones 31. The Simpsons 32. The Flintstones 33. The Simpsons 34. The Flintstones 35. The Simpsons 36. The Flintstones 37. The Simpsons 38. The Flintstones 39. The Simpsons 40. The Flintstones 41. The Simpsons 42. The Flintstones 43. The Simpsons 44. The Flintstones 45. The Simpsons 46. The Flintstones 47. The Simpsons 48. The Flintstones 49. The Simpsons 50. The Flintstones 51. The Simpsons 52. The Flintstones 53. The Simpsons 54. The Flintstones 55. The Simpsons 56. The Flintstones 57. The Simpsons 58. The Flintstones 59. The Simpsons 60. The Flintstones 61. The Sim", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14905, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet\ntaste, but it is inedible.\n\nThe prognostic significance of cytogenetic response (CCyR)\nhas been evaluated in several studies.122,123,125,126,128,129,131,132,134,135,137,138,140,141,143,144,146,147,149,150,152,153,155,156,158,159,161,162,164,165,167,168,170,171,173,174,176,177,179,180,182,183,185,186,188,189,191,192,194,195,197,198,200,201,203,204,206,207,209,211,213,215,217,219,221,223,225,227,229,231,233,235,237,239,241,243,245,247,249,251,253,255,257,259,261,263,265,267,269,271,273,275,277,279,281,283,285,287,289,291,293,295,297,299,301,303,305,307,309,3", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 2\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 3\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 4\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 5\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 6\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 7\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 8\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 9\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 10\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 11\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 12\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 13\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 14\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 15\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 16\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 17\nQuestion: What is the name of the tree that is located on the island named 'Sisten'?\nAnswer: 18\nQuestion: What is the name of the tree that is located on", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14923, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The answer is Sokol.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall survival in patients with CML.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall survival in patients with CML.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall survival in patients with CML.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall survival in patients with CML.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall survival in patients with CML.\n\nThe Sokal score is a prognostic scoring system for chronic myeloid leukemia (CML) that was developed in 1994. It is based on the patient's age, spleen size, and percentage of blasts in the peripheral blood. The score is used to predict the likelihood of disease progression and overall", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14928, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 2. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 3. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 4. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 5. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 6. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 7. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 8. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 9. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: 10. The train was used to collide with the Great Septimus in Penacony.\nQuestion: Where did Pom-Pom use the train to collide with the Great Septim", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14877, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in the bone marrow of patients with Ph-positive acute lymphoblastic leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with chronic phase CML? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with dasatinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with nilotinib? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with bosutinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with imatinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with dasatinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with nilotinib? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with bosutinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with imatinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with dasatinib? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients treated with nilotinib? (Answer in Arabic", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14896, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "The study found that the risk of colorectal cancer incidence and mortality was lower in patients who had\ncolonoscopy compared to those who did not.\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase chronic myeloid leukemia?\nAnswer:  The most common abnormality in the bone marrow of patients with chronic phase chronic myeloid leukemia is the Philadelphia chromosome.\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with chronic phase chronic myeloid leukemia?\nAnswer:  The most common BCR::ABL1 transcript variant in patients with chronic phase chronic myeloid leukemia is the e13a2 transcript, which encodes for p210.\nQuestion: What is the recommended initial dose of ponatinib in patients with chronic phase chronic myeloid leukemia?\nAnswer:  The recommended initial dose of ponatinib in patients with chronic phase chronic myeloid leukemia is 45 mg once daily.\nQuestion: What is the recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia?\nAnswer:  The recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia is every 3 months.\nQuestion: What is the recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a major molecular response?\nAnswer:  The recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a major molecular response is every 3 months.\nQuestion: What is the recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a deep molecular response?\nAnswer:  The recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a deep molecular response is every 3 months.\nQuestion: What is the recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a major molecular response and are adherent to therapy?\nAnswer:  The recommended frequency of molecular monitoring in patients with chronic phase chronic myeloid leukemia who have achieved a", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14867, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "2G TKI therapy.\n\nThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia (CML) have been updated to reflect the most recent data on the management of CML. The updated guidelines include new information on the management of CML in patients with an intermediate- or high-risk Sokal score, the use of next-generation sequencing (NGS) for monitoring response to tyrosine kinase inhibitor (TKI) therapy, and the use of ponatinib for patients with a T315I mutation.\n\nThe updated guidelines recommend that patients with an intermediate- or high-risk Sokal score should be monitored closely for evidence of resistance to TKI therapy, such as the presence of BCR::ABL1 kinase domain mutations and mutations in genes other than BCR::ABL1. The guidelines also recommend that patients with a history of pancreatitis may be at greater risk of developing elevated serum lipase levels during treatment with nilotinib.\n\nThe updated guidelines also recommend that patients with a history of cardiovascular disease should be referred to a cardiologist before starting treatment with nilotinib, as this drug is associated with an increased risk of ischemic cardiovascular events.\n\nThe updated guidelines also recommend that patients with a history of pancreatitis may be at greater risk of developing elevated serum lipase levels during treatment with nilotinib.\n\nThe updated guidelines also recommend that patients with a history of cardiovascular disease should be referred to a cardiologist before starting treatment with nilotinib, as this drug is associated with an increased risk of ischemic cardiovascular events.\n\nThe updated guidelines also recommend that patients with a history of cardiovascular disease should be referred to a cardiologist before starting treatment with nilotinib, as this drug is associated with an increased risk of ischemic cardiovascular events.\n\nThe updated guidelines also recommend that patients with a history of cardiovascular disease should be referred to a cardiologist before starting treatment with nilotinib, as this drug is associated with an increased risk of ischemic cardiovascular events.\n\nThe updated guidelines also recommend that patients with a history of card", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14794, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1) the presence of atypical BCR::ABL1 transcripts; 2) the presence of ACAs; 3) the presence of epigenetic modifier\ngenes (eg, ASXL1, IKZF1, BCOR, TET1/2, IDH1/2, DNMT3A/3B, EZH2) mutations; 4) the presence of mutations in genes other than BCR::ABL1; 5) the presence of mutations in genes other than BCR::ABL1; 6) the presence of mutations in genes other than BCR::ABL1; 7) the presence of mutations in genes other than BCR::ABL1; 8) the presence of mutations in genes other than BCR::ABL1; 9) the presence of mutations in genes other than BCR::ABL1; 10) the presence of mutations in genes other than BCR::ABL1; 11) the presence of mutations in genes other than BCR::ABL1; 12) the presence of mutations in genes other than BCR::ABL1; 13) the presence of mutations in genes other than BCR::ABL1; 14) the presence of mutations in genes other than BCR::ABL1; 15) the presence of mutations in genes other than BCR::ABL1; 16) the presence of mutations in genes other than BCR::ABL1; 17) the presence of mutations in genes other than BCR::ABL1; 18) the presence of mutations in genes other than BCR::ABL1; 19) the presence of mutations in genes other than BCR::ABL1; 20) the presence of mutations in genes other than BCR::ABL1; 21) the presence of mutations in genes other than BCR::ABL1; 22) the presence of mutations in genes other than BCR::ABL1; 23) the presence of mutations in genes other than BCR::ABL1; 24) the presence of mutations in genes other than BCR::ABL1", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14840, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication 2. Antibiotics 3. Antihistamines 4. Antitussives 5. None of the above\n\nThe following is a doctor-patient chat record from March 2020\n\nPatient:\nI have a cold, I have a fever, cough, and runny nose. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for 10 years. I have been taking imatinib for", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14901, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML) 2. Chronic lymphocytic leukemia (CLL) 3. Acute myeloid leukemia (AML) 4. Acute lymphoblastic leukemia (ALL) 5. Chronic myelomonocytic leukemia (CMML) 6. Chronic neutrophilic leukemia (CNL) 7. Chronic eosinophilic leukemia (CEL) 8. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 9. Chronic myelomonocytic leukemia/myelodysplastic syndrome (CMML/MDS) 10. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 11. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 12. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 13. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 14. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 15. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 16. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 17. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 18. Chronic myelomonocytic leukemia/myeloproliferative neoplasm (CMML/MPN) 19. Chronic myelomonocytic leukem", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14865, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\n2. The patient underwent a bone marrow biopsy.\n3. The patient underwent a bone marrow biopsy.\n4. The patient underwent a bone marrow biopsy.\n5. The patient underwent a bone marrow biopsy.\n6. The patient underwent a bone marrow biopsy.\n\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 1. The patient underwent a bone marrow biopsy.\n2. The patient underwent a bone marrow biopsy.\n3. The patient underwent a bone marrow biopsy.\n4. The patient underwent a bone marrow biopsy.\n5. The patient underwent a bone marrow biopsy.\n6. The patient underwent a bone marrow biopsy.\n\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 1. The patient underwent a bone marrow biopsy.\n2. The patient underwent a bone marrow biopsy.\n3. The patient underwent a bone marrow biopsy.\n4. The patient underwent a bone marrow biopsy.\n5. The patient underwent a bone marrow biopsy.\n6. The patient underwent a bone marrow biopsy.\n\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 1. The patient underwent a bone marrow biopsy.\n2. The patient underwent a bone marrow biopsy.\n3. The patient underwent a bone marrow biopsy.\n4. The patient underwent a bone marrow biopsy.\n5. The patient underwent a bone marrow biopsy.\n6. The patient underwent a bone marrow biopsy.\n\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14913, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14909, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "140/96 mmHg.", "position(%)": 25, "length(string)": 44244, "length(tokens)": 14906, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\nQuestion: Who is the manager of the Dream Bar in the Penacony Daydream Hotel?\nAnswer: 1. The manager of the Dream Bar in the", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14933, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The Galactic Peace Corporation is a large organization that is divided into 3 teams: the 'Aventurine stone' team, the 'Crystal stone' team, and the 'Diamond stone' team.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14917, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Acheron 2. Acheron 3. Acheron 4. Acheron 5. Acheron\n\n55 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nCML-D: Risk Stratification\nThe Sokal score is the most widely used risk stratification\nThe Sokal score is the most widely used risk stratification\nsystem for patients with newly diagnosed CP-CML.8–12 The Sokal score is based on the patient's age,\nThe Sokal score is the most widely used risk stratification spleen size, platelet count, and percentage of blasts in the\nsystem for patients with newly diagnosed CP-CML.8–12 peripheral blood. The Sokal score is calculated as\nThe Sokal score is based on the patient's age, spleen size, platelet count, and percentage of blasts in the\nperipheral blood. The Sokal score is calculated as follows:\nperipheral blood. The Sokal score is calculated as follows:\nSokal score = 0.92 + 0.99 × age (years) + 0.53 × spleen size (cm) + 0.29 × platelet count (× 109/L) + 0.14 × percentage of blasts in the peripheral blood (%)\n\nThe Sokal score is calculated as follows:\nSokal score = 0.92 + 0.99 × age (years) + 0.53 × spleen size (cm) + 0.29 × platelet count (× 109/L) + 0.14 × percentage of blasts in the peripheral blood (%)\n\nThe Sokal score is calculated as follows:\nSokal score = 0.92 + 0.99 × age (years) + 0.53 × spleen size (cm) + 0.29 × platelet count (× 109/L) + 0.14 × percentage of blasts in", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14934, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Monster of the Forest 2. The Monster of the Mountain\n\n55 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\ntreatment-related AOEs was higher in the 45 mg cohort (16%) than in the 30 mg cohort (13%).161\nThe panel recommends that patients with CP-CML who\nare not in MMR (#0.1% BCR::ABL1 IS) at 12 months be\nmonitored every 3 months for evidence of resistance to\nTKI therapy.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)at 12 months,\nthe panel recommends that molecular monitoring be\nperformed every 3 months for 2 years and then every 6\nmonths for 2 years.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)at 12 months,\nthe panel recommends that molecular monitoring be\nperformed every 3 months for 2 years and then every 6\nmonths for 2 years.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)at 12 months,\nthe panel recommends that molecular monitoring be\nperformed every 3 months for 2 years and then every 6\nmonths for 2 years.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)at 12 months,\nthe panel recommends that molecular monitoring be\nperformed every 3 months for 2 years and then every 6\nmonths for 2 years.\nInpatientswithCP-CMLandMMR(#0.1%BCR::ABL1IS)at 12 months,\nthe panel recommends that molecular monitoring be\nperformed every 3 months for 2 years and then every 6\nmonths for 2 years", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14937, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char 2. Breukelen Tiernan 3. Razarina Jane Estella", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14908, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons 2. The Flintstones 3. The Jetsons 4. The Smurfs 5. The Powerpuff Girls 6. The Teenage Mutant Ninja Turtles 7. The Family Guy 8. The Rugrats 9. The Fairly OddParents 10. The Adventures of Jimmy Neutron: Boy Genius 11. The Grim Adventures of Billy and Mandy 12. The Loud House 13. The Amazing World of Gumball 14. The Regular Show 15. The Fairly OddParents 16. The Loud House 17. The Grim Adventures of Billy and Mandy 18. The Amazing World of Gumball 19. The Regular Show 20. The Adventures of Jimmy Neutron: Boy Genius 21. The Loud House 22. The Fairly OddParents 23. The Amazing World of Gumball 24. The Regular Show 25. The Adventures of Jimmy Neutron: Boy Genius 26. The Loud House 27. The Fairly OddParents 28. The Amazing World of Gumball 29. The Regular Show 30. The Adventures of Jimmy Neutron: Boy Genius 31. The Loud House 32. The Fairly OddParents 33. The Amazing World of Gumball 34. The Regular Show 35. The Adventures of Jimmy Neutron: Boy Genius 36. The Loud House 37. The Fairly OddParents 38. The Amazing World of Gumball 39. The Regular Show 40. The Adventures of Jimmy Neutron: Boy Genius 41. The Loud House 42. The Fairly OddParents 43. The Amazing World of Gumball 44. The Regular Show 45. The Adventures of Jimmy Neutron: Boy Genius 46. The Loud House 47. The Fairly OddParents 48. The Amazing World of Gumball", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14905, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "No.\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nBCR::ABL1 Transcript Variants in CML\nInpatientswithCP-CML, the presence of atypical BCR::ABL1\ntranscripts (ie, e1a2, e19a2, e13a3, and e14a3) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and lower rates of\nlong-term survival.129,130,132,133,135,136,138,139,141,142,144,145,147,148,150,151,153,154,156,157,159,160,162,163,165,166,168,170,171,173,174,176,177,179,181,183,185,187,189,191,193,195,197,199,201,203,205,207,209,211,213,215,217,219,221,223,225,227,229,231,233,235,237,239,241,243,245,247,249,251,253,255,257", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\n55 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\ngroups.128,130,131,133,134,136,137,143,144,146,147,149,150,152,153,155,156,158,159,161,162,164,165,167,168,170,171,173,174,176,177,179,181,182,184,185,187,188,190,191,193,195,197,199,201,203,205,207,209,211,213,215,217,219,221,223,225,227,229,231,233,235,237,239,241,243,245,247,249,251,253,255,257,259,261,263,265,267,269,271,273,275,277,279,281,283,285,287,289,291,293,295,297,299,301,303,305,307,309,311,313,315,317,319,321,323,325,327,329,", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14923, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Astral Express was a train that ran between Philadelphia and New York City. It was blown up by\na terrorist in 1944.\n\n55 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nPonatinib was effective at all 3 dose levels, with the 45 mg dose being the most effective.161 The 45 mg dose was\nassociated with a higher rate of AOE (16% vs 13% and 14% vs 13% in the 45 mg and 30 mg cohorts,\nrespectively) and a higher rate of discontinuation of ponatinib\ndue to AOE (10% vs 6% and 10% vs 6% in the 45 mg and 30 mg cohorts, respectively).161\n\n56 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Who was the first person to blow up the Astral Express?\n\nAnswer: 2. The first person to blow up the Astral Express was a terrorist named William Edward Purvis.\n\n\n57 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Who was the second person to blow up the Astral Express?\n\nAnswer: 3. The second person to blow up the Astral Express was a terrorist named William Edward Purvis.\n\n\n58 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14928, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n\n2. The train was used to collide with the Great Septimus in Penacony.\n\n3. The train was used to collide with the Great Septimus in Penacony.\n\n4. The train was used to collide with the Great Septimus in Penacony.\n\n5. The train was used to collide with the Great Septimus in Penacony.\n\n6. The train was used to collide with the Great Septimus in Penacony.\n\n7. The train was used to collide with the Great Septimus in Penacony.\n\n8. The train was used to collide with the Great Septimus in Penacony.\n\n9. The train was used to collide with the Great Septimus in Penacony.\n\n10. The train was used to collide with the Great Septimus in Penacony.\n\n11. The train was used to collide with the Great Septimus in Penacony.\n\n12. The train was used to collide with the Great Septimus in Penacony.\n\n13. The train was used to collide with the Great Septimus in Penacony.\n\n14. The train was used to collide with the Great Septimus in Penacony.\n\n15. The train was used to collide with the Great Septimus in Penacony.\n\n16. The train was used to collide with the Great Septimus in Penacony.\n\n17. The train was used to collide with the Great Septimus in Penacony.\n\n18. The train was used to collide with the Great Septimus in Penacony.\n\n19. The train was used to collide with the Great Septimus in Penacony.\n\n20. The train was used to collide with the Great Septimus in Penacony.\n\n21. The train was used to collide with the Great Septimus in Penacony.\n\n22. The train was used to collide with the Great Septimus in Penacony.\n\n23.", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14877, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in the bone marrow of patients with Ph-positive acute lymphoblastic leukemia? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 3\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 4\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 5\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 6\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 7\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 8\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 9\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 10\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 11\nQuestion: What is the most common abnormality in the bone", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14896, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "The study found that the risk of colorectal cancer incidence and mortality was lower in patients with negative colonoscopy results compared to patients with positive colonoscopy results.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nMonitoringResponsetoTKITherapy\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends that molecular monitoring be per- formed every 3 months for the first 2 years after initiating\nTKI therapy, and then every 3 to 6 months thereafter.\n\nThe panel recommends", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14867, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the overnight time in target range\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nCML-2: Risk Stratification\nThe Sokal score is the most commonly used risk stratification\ntool for patients with CP-CML. The Sokal score is based on\nage, spleen size, percentage of blasts in the peripheral blood, and\nplatelet count.8–12 The Sokal score is not applicable to patients with AP-CML or BP-CML.\n\nThe ELTS score is based on age, percentage of blasts in the peripheral blood, and platelet count.70–72 The ELTS score is not\napplicable to patients with CP-CML.\n\nThe Sokal score and the ELTS score are not applicable to patients with AP-CML or BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe Sokal score and the ELTS score are applicable to patients with CP-CML, AP-CML, and BP-CML.\n\nThe S", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14794, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1) musculoskeletal pain and 2) cardiovascular risk factors.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the most important goals of TKI therapy in patients with newly diagnosed CP-CML?\nAnswer: 1) long-term survival and 2) prevention of disease progression to AP-CML or BP-CML.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended frequency of molecular monitoring with qPCR (IS) in patients with newly diagnosed CP-CML?\nAnswer: Every 3 months for 2 years and every 3 to 6 months thereafter.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended frequency of molecular monitoring with qPCR (IS) in patients with newly diagnosed CP-CML who have experienced a CCyR at 12 months?\nAnswer: Every 3 months for 2 years and every 3 to 6 months thereafter.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended frequency of molecular monitoring with qPCR (IS) in patients with newly diagnosed CP-CML who have experienced a MMR at 12 months?\nAnswer: Every 3 months for 2 years and every 3 to 6 months thereafter.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended frequency of molecular monitoring with qPCR (IS) in patients with newly diagnosed CP-CML who have experienced a DMR at 12 months?\nAnswer: Every 3 months for 2 years and every 3 to 6 months thereafter.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what is the recommended frequency of molecular monitoring with qPCR (IS) in patients with newly diagnosed CP-CML who have experienced a MMR at 12 months?\nAnswer:", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14840, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended that the patient take imatinib.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 2. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 3. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 4. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 5. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 6. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 7. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 8. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 9. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 10. The doctor recommended that the patient undergo molecular monitoring every 3 months.\n\nQuestion: In the March 2020 doctor-patient chat record, what is the recommended frequency of molecular monitoring?\nAnswer: 11. The doctor recommended that the patient undergo molecular monitoring", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14901, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML) 2. Chronic lymphocytic leukemia (CLL) 3. Chronic myelomonocytic leukemia (CMML) 4. Chronic neutrophilic leukemia (CNL) 5. Chronic eosinophilic leukemia (CEL) 6. Chronic myelomonocytic leukemia (CMML) 7. Chronic myelomonocytic leukemia (CMML) 8. Chronic myelomonocytic leukemia (CMML) 9. Chronic myelomonocytic leukemia (CMML) 10. Chronic myelomonocytic leukemia (CMML) 11. Chronic myelomonocytic leukemia (CMML) 12. Chronic myelomonocytic leukemia (CMML) 13. Chronic myelomonocytic leukemia (CMML) 14. Chronic myelomonocytic leukemia (CMML) 15. Chronic myelomonocytic leukemia (CMML) 16. Chronic myelomonocytic leukemia (CMML) 17. Chronic myelomonocytic leukemia (CMML) 18. Chronic myelomonocytic leukemia (CMML) 19. Chronic myelomonocytic leukemia (CMML) 20. Chronic myelomonocytic leukemia (CMML) 21. Chronic myelomonocytic leukemia (CMML) 22. Chronic myelomonocytic leukemia (CMML) 23. Chronic myelomonocytic leukemia (CMML) 24. Chronic myelomonocytic leukemia (CMML) 25. Chronic myelomonocytic leukemia (CMML) 26. Chronic myelomonocytic leuk", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14865, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\n2. The patient underwent a bone marrow biopsy.\n3. The patient underwent a bone marrow biopsy.\n4. The patient underwent a bone marrow biopsy.\n5. The patient underwent a bone marrow biopsy.\n6. The patient underwent a bone marrow biopsy.\n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia.\n2. Chronic myeloid leukemia.\n3. Chronic myeloid leukemia.\n4. Chronic myeloid leukemia.\n5. Chronic myeloid leukemia.\n6. Chronic myeloid leukemia.\n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia.\n2. Chronic myeloid leukemia.\n3. Chronic myeloid leukemia.\n4. Chronic myeloid leukemia.\n5. Chronic myeloid leukemia.\n6. Chronic myeloid leukemia.\n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia.\n2. Chronic myeloid leukemia.\n3. Chronic myeloid leukemia.\n4. Chronic myeloid leukemia.\n5. Chronic myeloid leukemia.\n6. Chronic myeloid leukemia.\n\nQuestion: In the May 2019 doctor-patient chat record, what is the most likely diagnosis?\nAnswer: 1. Chronic myeloid leukemia.\n2. Chronic myeloid leukemia.\n3. Chronic myeloid leukemia.\n4. Chronic myeloid leukemia.\n5.", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14913, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14909, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Nilotinib or bosutinib\n\n2. Dasatinib\n\n3. Imatinib\n\n4. None of the above\n\n5. All of the above\n\n6. None of the above\n\n7. All of the above\n\n8. None of the above\n\n9. None of the above\n\n10. None of the above\n\n11. None of the above\n\n12. None of the above\n\n13. None of the above\n\n14. None of the above\n\n15. None of the above\n\n16. None of the above\n\n17. None of the above\n\n18. None of the above\n\n19. None of the above\n\n20. None of the above\n\n21. None of the above\n\n22. None of the above\n\n23. None of the above\n\n24. None of the above\n\n25. None of the above\n\n26. None of the above\n\n27. None of the above\n\n28. None of the above\n\n29. None of the above\n\n30. None of the above\n\n31. None of the above\n\n32. None of the above\n\n33. None of the above\n\n34. None of the above\n\n35. None of the above\n\n36. None of the above\n\n37. None of the above\n\n38. None of the above\n\n39. None of the above\n\n40. None of the above\n\n41. None of the above\n\n42. None of the above\n\n43. None of the above\n\n44. None of the above\n\n45. None of the above\n\n46. None of the above\n\n47. None of the above\n\n48. None of the above\n\n49. None of the above\n\n50. None of the above\n\n51. None of the above\n\n52. None of the above\n\n53. None of the above\n\n54. None of the above\n\n55. None of the above\n\n56. None of the above\n\n5", "position(%)": 50, "length(string)": 44244, "length(tokens)": 14906, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1.\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\ntions should be considered for patients with TKI-resistant disease.\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of allogeneic HCT\n(see CML-E, page 48).\nThe panel recommends that patients with TKI-resistant disease be\nreferred to specialized CML centers for evaluation of all", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14933, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nCML-2: Risk Stratification\nThe Sokal score is the most commonly used risk stratification\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the most commonly used risk stratification\nsystem for patients with CP-CML.8–12 The Sokal score is calculated using the following formula:\nThe Sokal score is the", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14917, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei 2. Acheron 3. Acheron Bosenmori Mei 4. Acheron Bosenmori Mei 5. Acheron Bosenmori Mei 6. Acheron Bosenmori Mei 7. Acheron Bosenmori Mei 8. Acheron Bosenmori Mei 9. Acheron Bosenmori Mei 10. Acheron Bosenmori Mei\n\n11. Acheron Bosenmori Mei 12. Acheron Bosenmori Mei 13. Acheron Bosenmori Mei 14. Acheron Bosenmori Mei 15. Acheron Bosenmori Mei 16. Acheron Bosenmori Mei 17. Acheron Bosenmori Mei 18. Acheron Bosenmori Mei 19. Acheron Bosenmori Mei 20. Acheron Bosenmori Mei 21. Acheron Bosenmori Mei 22. Acheron Bosenmori Mei 23. Acheron Bosenmori Mei 24. Acheron Bosenmori Mei 25. Acheron Bosenmori Mei 26. Acheron Bosenmori Mei 27. Acheron Bosenmori Mei 28. Acheron Bosenmori Mei 29. Acheron Bosenmori Mei 30. Acheron Bosenmori Mei 31. Acheron Bosenmori Mei 32. Acheron Bosenmori Mei 33. Acheron Bosenmori Mei 34. Acheron Bosenmori Mei 35. Acheron Bosenmori Mei 36. Acheron Bosenmori Mei 37. Acheron Bosenmori Mei 38. Acheron Bosenmori Mei 39. Acheron Bosenmori Mei 40. Acheron B", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14934, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Monster Legion is a group of monsters that are\n2. The Monster Legion is a group of monsters that are", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14937, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14908, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Pinoconi\n2. Clockboy and His Friends\n3. Clockboy and His Friends\n4. Clockboy and His Friends\n5. Clockboy and His Friends\n6. Clockboy and His Friends\n7. Clockboy and His Friends\n8. Clockboy and His Friends\n9. Clockboy and His Friends\n10. Clockboy and His Friends\n11. Clockboy and His Friends\n12. Clockboy and His Friends\n13. Clockboy and His Friends\n14. Clockboy and His Friends\n15. Clockboy and His Friends\n16. Clockboy and His Friends\n17. Clockboy and His Friends\n18. Clockboy and His Friends\n19. Clockboy and His Friends\n20. Clockboy and His Friends\n21. Clockboy and His Friends\n22. Clockboy and His Friends\n23. Clockboy and His Friends\n24. Clockboy and His Friends\n25. Clockboy and His Friends\n26. Clockboy and His Friends\n27. Clockboy and His Friends\n28. Clockboy and His Friends\n29. Clockboy and His Friends\n30. Clockboy and His Friends\n31. Clockboy and His Friends\n32. Clockboy and His Friends\n33. Clockboy and His Friends\n34. Clockboy and His Friends\n35. Clockboy and His Friends\n36. Clockboy and His Friends\n37. Clockboy and His Friends\n38. Clockboy and His Friends\n39. Clockboy and His Friends\n40. Clockboy and His Friends\n41. Clockboy and His Friends\n42. Clockboy and His Friends\n43. Clockboy and His Friends\n44. Clockboy and His Friends\n45. Clockboy and His Friends\n46. Clockboy and His Friends\n47. Clockboy and His Friends\n48. Clockboy and His Friends\n49. Clockboy and His Friends\n50. Clockboy and His Friends\n51. Clockboy and His Friends\n52", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14905, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "100% of the time.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nBCR::ABL1 Transcript Variants in CML\nThe presence of e13a2 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e13a3 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e14a2 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e14a3 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e19a2 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e19a3 transcript (encoding for p210) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e13a2 transcript (encoding for p190) is associated with a higher risk of disease progression,\ninferior cytogenetic and molecular responses, and a higher risk of relapse after discontinuation of TKI therapy.\nThe presence of e14a3 transcript (encoding for p1", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 2\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 3\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 4\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 5\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 6\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 7\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 8\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 9\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 10\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 11\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 12\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 13\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 14\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 15\n\nQuestion", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14923, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.\n\n2. The occurrence of electrolyte abnormalities should be monitored periodically. Drugs that prolong QT interval should be avoided. Electrocardiogram should be obtained to monitor the QT interval at baseline, 7 days after initiation of nilotinib, and periodically thereafter, as well as after any dose adjustments.\n\n3. The occurrence of pleural effusion is significantly reduced with dasatinib 100 mg oncedaily compared with imatinib 400 mg daily.\n\n4. The occurrence of pleural effusion is also significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n5. The occurrence of pleural effusion is significantly reduced with nilotinib 400 mg twice daily compared with imatinib 400 mg daily.\n\n6. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n7. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n8. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n9. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n10. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n11. The occurrence of pleural effusion is significantly reduced with nilotinib 300 mg twice daily compared with imatinib 400 mg daily.\n\n12. The occurrence of", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14928, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which country?\nAnswer: 2. United States\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 3. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 4. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 5. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 6. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 7. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 8. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 9. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 10. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 11. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 12. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which type of study?\nAnswer: 13. Prospective cohort study\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14877, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\n\nQuestion: What is the most common abnormality in the bone marrow of patients with Ph-positive acute lymphoblastic leukemia? (Answer in Arabic numerals)\nAnswer: 1\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 2\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 3\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 4\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 5\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 6\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 7\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 8\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 9\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 10\n\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic myeloid leukemia? (Answer in Arabic numerals)\nAnswer: 11\n\nQuestion", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14896, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "12 months after first-line TKI therapy is an established prognostic indicator of MMR, but MMR is not as\nsignificant a predictor of superior OS in patients with a stable CCyR.\n\nQuestion: What is the recommended initial dose of ponatinib in the PACE trial?\nAnswer: 45 mg once daily.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.\n\nQuestion: What is the recommended frequency of molecular monitoring in patients with CP-CML who experience a\nCCyR with no MMR at 12 months?\nAnswer: Every 3 months for 2 years and then every 3 to 6 months thereafter.", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14867, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the overnight time in target range\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the overall time in target range\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of decline in BCR::ABL1 transcripts?\nAnswer: 1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the rate of decline in BCR::ABL1 transcripts\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of decline in BCR::ABL1 transcripts?\nAnswer: 1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the rate of decline in BCR::ABL1 transcripts\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of decline in BCR::ABL1 transcripts?\nAnswer: 1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the rate of decline in BCR::ABL1 transcripts\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of decline in BCR::ABL1 transcripts?\nAnswer: 1. Advanced hybrid closed-loop therapy 2. Standard insulin therapy 3. Both therapies improved the rate of decline in BCR::ABL1 transcripts\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14794, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. academic achievement goals\n2. musculoskeletal pain and muscular cramps\n3. lack of a CCyR\n4. lack of a MMR\n5. lack of a DMR\n\n6. lack of a MR4.5\n\n7. lack of a MR4.0\n\n8. lack of a MR3.0\n\n9. lack of a MR2.0\n\n10. lack of a MR1.0", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14840, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication 2. Antibiotics 3. Antifungal medication 4. Antiparasitic medication 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's bloating?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's stomach discomfort?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Dehydration 2. Hypoglycemia 3. Hypotension 4. Hypoxia 5. None of the above\n\nQuestion: In the March 2020 doctor", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14901, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript type?\nAnswer: e13a2\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 3 months?\nAnswer: 11%–15%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 6 months?\nAnswer: 1%–10%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 12 months?\nAnswer: 0.1%–1%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 24 months?\nAnswer: 0.01%–0.1%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 36 months?\nAnswer: 0.0032%–0.01%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 48 months?\nAnswer: 0.0032%–0.01%\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's BCR::ABL1 transcript level at 60 months?\nAnswer: 0.00", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14865, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test 2. Bone marrow cytogenetics 3. Bone marrow biopsy 4. BCR::ABL1 transcripts 5. BCR::ABL1 transcripts\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the May 2019 doctor-patient chat record, what is the recommended initial dose of ponatinib?\nAnswer: 45 mg once daily\n\nQuestion: In the April 2019 doctor-patient chat record, what is", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14913, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14909, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 100 mg of labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor", "position(%)": 75, "length(string)": 44244, "length(tokens)": 14906, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n2. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n3. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n4. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n5. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n6. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n7. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n8. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n9. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n10. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n11. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n12. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n13. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n14. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n15. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n16. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n17. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n18. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n19. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n20. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n21. Shuweng is the manager of the Dream Bar in the Penacony Daydream Hotel.\n22. Shuw", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14932, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14916, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 1. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14933, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Mara-Struck Warden 2. The Mara-Struck Soldier\n\n55 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nThe panel recommends that patients with CP-CML who are inadequate response to TKI therapy should be referred to\nnot in MMR (#0.1%–1% BCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or\nenrolled in a clinical trial.\nInpatientswithCP-CMLandAP-CML, the panel recommends that patients who are not in MMR (#0.1%–1%\nBCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or enrolled in a clinical trial.\nInpatientswithCP-CMLandBP-CML, the panel recommends that patients who are not in MMR (#0.1%–1%\nBCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or enrolled in a clinical trial.\nInpatientswithCP-CMLandAP-CML, the panel recommends that patients who are not in MMR (#0.1%–1%\nBCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or enrolled in a clinical trial.\nInpatientswithCP-CMLandBP-CML, the panel recommends that patients who are not in MMR (#0.1%–1%\nBCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or enrolled in a clinical trial.\nInpatientswithCP-CMLandAP-CML, the panel recommends that patients who are not in MMR (#0.1%–1%\nBCR::ABL1 IS) at 12 months should be referred to specialized CML centers and/or enrolled in a clinical trial.\nInpatientswithCP-", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14936, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is 'the Watchmaker' of Penacony?\nAnswer: 3. Mikhail Char Leg", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14906, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy and His Friends\nQuestion: Which of the following is the most common abnormal-\nity of the Philadelphia chromosome?\nAnswer: 1. Trisomy 8\nQuestion: Which of the following is the most common BCR::ABL1\ntranscript variant?\nAnswer: 1. e13a2\nQuestion: Which of the following is the most common adverse event\nassociated with dasatinib?\nAnswer: 1. Pleural effusion\nQuestion: Which of the following is the most common adverse event\nassociated with nilotinib?\nAnswer: 1. Cardiovascular events\nQuestion: Which of the following is the most common adverse event\nassociated with bosutinib?\nAnswer: 1. Peripheral edema\nQuestion: Which of the following is the most common adverse event\nassociated with imatinib?\nAnswer: 1. Musculoskeletal pain\nQuestion: Which of the following is the most common adverse event\nassociated with dasatinib?\nAnswer: 1. Musculoskeletal pain\nQuestion: Which of the following is the most common adverse event\nassociated with nilotinib?\nAnswer: 1. Cardiovascular events\nQuestion: Which of the following is the most common adverse event\nassociated with bosutinib?\nAnswer: 1. Peripheral edema\nQuestion: Which of the following is the most common adverse event\nassociated with imatinib?\nAnswer: 1. Musculoskeletal pain\nQuestion: Which of the following is the most common adverse event\nassociated with dasatinib?\nAnswer: 1. Musculoskeletal pain\nQuestion: Which of the following is the most common adverse event\nassociated with nilotinib?\nAnswer: 1. Cardiovascular events\nQuestion: Which of the following is the most common adverse event\nassociated with bosutinib?\nAnswer: 1. Peripheral edema\nQuestion: Which of the following is the most common adverse event\nassociated with imatinib?\nAnswer: 1. Musculoskeletal pain\nQuestion:", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14904, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "161\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nReferences\n1. SEER Cancer Statistics Review, 1975–2019, National Cancer Institute. Bethesda, MD: NCI; 2021. Available at: https://seer.cancer.gov/csr/1975_2019/ based_on_selected_populations/ colorectal_cancer/ . Accessed January 10, 2023.\n2. Heisterkamp S, Kantarjian H, O’Brien S, et al. The Philadelphia chromosome: a review of its clinical and molecular features. Blood. 2018;132(1):1-13.\n3. Kantarjian H, O’Brien S, Cortes J, et al. The International Prognostic Scoring System for chronic myeloid leukemia: a\n4. Kantarjian H, O’Brien S, Cortes J, et al. The Sokal score: a prognostic model for chronic myeloid leukemia. Blood. 1999;93(1):104-11.\n5. Kantarjian H, O’Brien S, Cortes J, et al. The Sokal score: a prognostic model for chronic myeloid leukemia. Blood. 1999;93(1):104-11.\n6. Kantarjian H, O’Brien S, Cortes J, et al. The Sokal score: a prognostic model for chronic myeloid leukemia. Blood. 1999;93(1):104-11.\n7. Kantarjian H, O’Brien S, Cortes J, et al. The Sokal score: a prognostic model for chronic myeloid leukemia. Blood. 1999;93(1):", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14925, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 2.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 3.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 4.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 5.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 6.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 7.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 8.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 9.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 10.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 11.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 12.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 13.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 14.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 15.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 16.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer: 17.\n\nQuestion: What is the name of the island where the tree named 'Sisten' is located?\nAnswer:", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14922, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Mourning Actors\n\nQuestion: Who is the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 3. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 4. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 5. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 6. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 7. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 8. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 9. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 10. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 11. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 12. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 13. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 14. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 15. Masked Fools\n\nQuestion: What is the name of the group of opponents of the Path of Joy?\nAnswer: 16. Mourning Actors\n\nQuestion: What is the name of the group of followers of the Path of Joy?\nAnswer: 17. Masked Fools", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14927, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14924, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which country?\nAnswer: 2. United States\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which continent?\nAnswer: 3. North America\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which year?\nAnswer: 4. 2022\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 5. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 6. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 7. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 8. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 9. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 10. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 11. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 12. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 13. A. M. C. N.\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which author?\nAnswer: 14. A. M. C.", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14876, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about what percentage? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million annually in 2020 to nearly 2.9 million annually in 2040, doubling the number of cases.\nAnswer: True\nQuestion: According to the latest report from The Lancet, the global annual number of pro", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14894, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "15 years after the examination.\n\nJNCCN.org | Volume22 Issue1 | February2024 55\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nBCR::ABL1 Transcript Variants in CML\nThe BCR::ABL1 fusion gene is the result of a reciprocal translocation\nbetween chromosomes 9 and 22. The most common translocation\ninvolves the major breakpoint cluster region (M-BCR) in the BCR gene on\nchromosome 22 (major breakpoint cluster region; M-BCR). In most patients, the chromosomal breakpoints are located in\nintron 13 or 14 of the BCR gene on chromosome 22 (major breakpoint cluster region; M-BCR). The fusion gene\nencodes for a protein, p210, with deregulated tyrosine kinase activity, which causes CML. Unusual or atypical transcripts\nwere identified in about 2% of patients with CML. The proportion of\ndifferent BCR::ABL1 transcripts and the impact of BCR::ABL1 tran-\nscript variants in patients with CML is summarized in Table S1 in the Supplemen-\ntary material (available online with this article).\nJNCCN.org | Volume22 Issue1 | February2024 56\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nBCR::ABL1 Transcript Variants in CML\nBCR::ABL1 transcript variants were identified in about 2% of patients with CML. The most common transcript variants\nidentified were e13a2 (encoding for p210) and e14a2 (encoding for p210). The presence of e19a2 transcript (encoding\nfor p230) is also associated with inferior molecular and cytogenetic responses to TKI therapy and in-\nferior survival outcomes.\nJNCCN.org | Volume22 Issue1 | February202", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14866, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the overnight time in target range\n4. Neither therapy improved the overnight time in target range\n5. Neither therapy improved the overnight time in target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the overnight time in target range.\n\nReference: The Lancet Diabetes & Endocrinology. 2022;10(1):e1-e10.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the time below target range\n4. Neither therapy improved the time below target range\n5. Neither therapy improved the time below target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the time below target range.\n\nReference: The Lancet Diabetes & Endocrinology. 2022;10(1):e1-e10.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time above target range?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the time above target range\n4. Neither therapy improved the time above target range\n5. Neither therapy improved the time above target range\n\nExplanation: The correct answer is 1. Advanced hybrid closed-loop therapy improved the time above target range.\n\nReference: The Lancet Diabetes & Endocrinology. 2022;10(1):e1-e10.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the treatment satisfaction?\nAnswer: 1. Advanced hybrid closed-loop therapy\n2. Standard insulin therapy\n3. Both therapies improved the treatment satisfaction\n4. Neither therapy improved the treatment", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14793, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "Question: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?\nAnswer: \n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14840, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause of the patient's dizziness?\nAnswer: 1. Cervical spondylosis\n\nQuestion: In the March 2020 doctor-patient chat record, what is the most likely cause", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14901, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's occupation?\nAnswer: Intern\n\nQuestion: In", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14865, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake, avoid foods that promote blood circulation, no other restrictions\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Control salt intake, avoid foods that promote blood circulation, no other restrictions\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 1. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14913, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14908, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion:", "position(%)": 100, "length(string)": 44244, "length(tokens)": 14905, "length(origin)": 16000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n58. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n60. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n61. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n62. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n63. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n64. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–1447.\n65. BaccaraniM, CastagnettiF, GugliottaG, et al. Prognostic significance of cytogenetic clonal evolution in chronic myeloid leukemia.\nLeukemia2019;33:1441–144", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31148, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 2% of patients with CML?\n\nAnswer: 2. e13a2 encoding for p210\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 62% of patients with CML?\n\nAnswer: 3. e14a2 encoding for p210\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 20% of patients with CML?\n\nAnswer: 4. e19a2 encoding for p230\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 1% of patients with CML?\n\nAnswer: 5. e1a2 encoding for p190\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 2% of patients with CML?\n\nAnswer: 6. e1a2 encoding for p190\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 1% of patients with CML?\n\nAnswer: 7. e19a2 encoding for p230\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 2% of patients with CML?\n\nAnswer: 8. e1a2 encoding for p190\n\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant identified in about 1% of patients with CML?\n\nAnswer: 9. e19a2", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31116, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "69. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 70. Raiden Bosenmori Mei\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 71. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 72. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 73. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 74. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 75. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 76. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 77. Acheron\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 78. Acheron\n\nQuestion: What is the real name of the", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Mara-Struck Warden 2. The Clawed Tiger\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\n\nQuestion: What is the name of the monster in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\n\nAnswer: The Clawed Tiger\n\n64 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\n\nQuestion: What is the name of the monster in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\n\nAnswer: The Clawed Tiger\n\n65 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\n\nQuestion: What is the name of the monster in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\n\nAnswer: The Clawed Tiger\n\n66 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\n\nQuestion: What is the name of the monster in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\n\nAnswer: The Clawed Tiger\n\n67 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31143, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2013 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2014;123:1049–1057.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2016 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2017;129:1049–1058.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2019 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2020;135:1049–1058.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2022;139:1049–1058.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2022;139:1049–1058.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood2022", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31081, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series\n“Clockboy and His Friends”, which has over 10,000 episodes and is a symbol of Pinoconi.\n2. Clockboy is the main character in the animated series “Clockboy and His Friends”.\n3. Clockboy is a character in the animated series “Clockboy and His Friends”.\n4. Clockboy is a character in the animated series “Clockboy and His Friends”.\n5. Clockboy is a character in the animated series “Clockboy and His Friends”.\n6. Clockboy is a character in the animated series “Clockboy and His Friends”.\n7. Clockboy is a character in the animated series “Clockboy and His Friends”.\n8. Clockboy is a character in the animated series “Clockboy and His Friends”.\n9. Clockboy is a character in the animated series “Clockboy and His Friends”.\n10. Clockboy is a character in the animated series “Clockboy and His Friends”.\n11. Clockboy is a character in the animated series “Clockboy and His Friends”.\n12. Clockboy is a character in the animated series “Clockboy and His Friends”.\n13. Clockboy is a character in the animated series “Clockboy and His Friends”.\n14. Clockboy is a character in the animated series “Clockboy and His Friends”.\n15. Clockboy is a character in the animated series “Clockboy and His Friends”.\n16. Clockboy is a character in the animated series “Clockboy and His Friends”.\n17. Clockboy is a character in the animated series “Clockboy and His Friends”.\n18. Clockboy is a character in the animated series “Clockboy and His Friends”.\n19. Clockboy is a character in the animated series “Clockboy and His Friends”.\n20. Clockboy is a character in the animated series “Clockboy and His Friends”.\n21. Clockboy is a character in the animated series “Clockboy and His Friends”.\n22. Clockboy is a character in the animated series “Clockboy and His Friends”.\n23. Clockboy is a character in the", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31091, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "100%\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O’BrienS,etal.TheEuro-SKI study: 1-year follow-up of patients with chronic-phase\nCML:RiskStratification\nchronic myeloid leukemia treated with imatinib mesylate.Blood2002;99:2001–2008.\n50. KantarjianHM,GilesFJ,O’BrienS,etal.TheEuro-SKI study: 2-year follow-up of patients with chronic-phase\nCML:RiskStratification\nchronic myeloid leukemia treated with imatinib mesylate.Blood2004;103:2009–2016.\n51. KantarjianHM,GilesFJ,O’BrienS,etal.TheEuro-SKI study: 3-year follow-up of patients with chronic-phase\nCML:RiskStratification\nchronic myeloid leukemia treated with imatinib mesylate.Blood2006;107:102–108.\n52. KantarjianHM,GilesFJ,O’BrienS,etal.TheEuro-SKI study: 4-year follow-up of patients with chronic-phase\nCML:RiskStratification\nchronic myeloid leukemia treated with imatinib mesylate.Blood2008;111:2017–2024.\n53. KantarjianHM,GilesFJ,O’BrienS,etal.TheEuro-SKI study: 5-year follow-up of patients with chronic-phase\nCML:RiskStratification", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "69. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 70. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 71. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 72. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 73. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 74. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 75. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 76. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 77. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 78. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 79. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 80. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 81. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 82. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located on the island of\n\nAnswer: 83. The panel recommends that patients with\n\nQuestion: What is the name of the tree that is located", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31113, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: What is the name of the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'.\n\n64 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: What is the name of the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'.\n\n65 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: What is the name of the Aeon in charge of the Path of Joy?\nAnswer: 2. Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'.\n\n66 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31134, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train was used to collide with the Great Septimus in Penacony.\n2. The train was used to collide with the Great Septimus in Penacony.\n3. The train was used to collide with the Great Septimus in Penacony.\n4. The train was used to collide with the Great Septimus in Penacony.\n5. The train was used to collide with the Great Septimus in Penacony.\n6. The train was used to collide with the Great Septimus in Penacony.\n7. The train was used to collide with the Great Septimus in Penacony.\n8. The train was used to collide with the Great Septimus in Penacony.\n9. The train was used to collide with the Great Septimus in Penacony.\n10. The train was used to collide with the Great Septimus in Penacony.\n11. The train was used to collide with the Great Septimus in Penacony.\n12. The train was used to collide with the Great Septimus in Penacony.\n13. The train was used to collide with the Great Septimus in Penacony.\n14. The train was used to collide with the Great Septimus in Penacony.\n15. The train was used to collide with the Great Septimus in Penacony.\n16. The train was used to collide with the Great Septimus in Penacony.\n17. The train was used to collide with the Great Septimus in Penacony.\n18. The train was used to collide with the Great Septimus in Penacony.\n19. The train was used to collide with the Great Septimus in Penacony.\n20. The train was used to collide with the Great Septimus in Penacony.\n21. The train was used to collide with the Great Septimus in Penacony.\n22. The train was used to collide with the Great Septimus in Penacony.\n23. The train was used to collide with the Great Septimus in Penacony.\n24.", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31109, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. The Lancet\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31049, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 70%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer deaths is expected to increase from 375,000 annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 70%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer deaths is expected to increase from 375,000 annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 70%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 70%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to what percentage in 2040? (Answer in Arabic numerals)\nAnswer: 70%\nQuestion: According to the latest report from The Lancet, the number of global prostate cancer cases is expected to increase from 1.4 million annually in 20", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31055, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. All the TKIs are generally well tolerated. Since bosutinib, dasatinib, and nilotinib have very good therapeutic efficacy in the upfront setting,\ndifferentiation.\n2. The most common abnormalities however, CMLOccur in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries.\n3. The presence of e1a2 transcript (encoding for p190) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n4. The presence of e19a2 transcript (encoding for p230) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n5. The presence of e13a3 transcript (encoding for p210) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n6. The presence of e14a2 transcript (encoding for p230) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n7. The presence of e6a2 transcript (encoding for p210) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n8. The presence of e13a2 transcript (encoding for p190) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n9. The presence of e14a2 transcript (encoding for p230) is associated with a higher risk of disease progression to accelerated phase – CML or blast phase – CML in 3 to 5 years on average.\n10. The presence of e13a3 transcript (encoding for p210) is associated with a higher risk of disease progression to", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31044, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "48. The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BCR::ABL1 Transcript Variants in CML\n50. BCR::ABL1 Transcript Variants in CML\n51. BCR::ABL1 Transcript Variants in CML\n52. BCR::ABL1 Transcript Variants in CML\n53. BCR::ABL1 Transcript Variants in CML\n54. BCR::ABL1 Transcript Variants in CML\n55. BCR::ABL1 Transcript Variants in CML\n56. BCR::ABL1 Transcript Variants in CML\n57. BCR::ABL1 Transcript Variants in CML\n58. BCR::ABL1 Transcript Variants in CML\n59. BCR::ABL1 Transcript Variants in CML\n60. BCR::ABL1 Transcript Variants in CML\n61. BCR::ABL1 Transcript Variants in CML\n62. BCR::ABL1 Transcript Variants in CML\n63. BCR::ABL1 Transcript Variants in CML\n64. BCR::ABL1 Transcript Variants in CML\n65. BCR::ABL1 Transcript Variants in CML\n66. BCR::ABL1 Transcript Vari", "position(%)": 0, "length(string)": 88688, "length(tokens)": 30910, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. academic achievement goals\n2. academic achievement goals\n3. academic achievement goals\n4. academic achievement goals\n5. academic achievement goals\n6. academic achievement goals\n7. academic achievement goals\n8. academic achievement goals\n9. academic achievement goals\n10. academic achievement goals\n11. academic achievement goals\n12. academic achievement goals\n13. academic achievement goals\n14. academic achievement goals\n15. academic achievement goals\n16. academic achievement goals\n17. academic achievement goals\n18. academic achievement goals\n19. academic achievement goals\n20. academic achievement goals\n21. academic achievement goals\n22. academic achievement goals\n23. academic achievement goals\n24. academic achievement goals\n25. academic achievement goals\n26. academic achievement goals\n27. academic achievement goals\n28. academic achievement goals\n29. academic achievement goals\n30. academic achievement goals\n31. academic achievement goals\n32. academic achievement goals\n33. academic achievement goals\n34. academic achievement goals\n35. academic achievement goals\n36. academic achievement goals\n37. academic achievement goals\n38. academic achievement goals\n39. academic achievement goals\n40. academic achievement goals\n41. academic achievement goals\n42. academic achievement goals\n43. academic achievement goals\n44. academic achievement goals\n45. academic achievement goals\n46. academic achievement goals\n47. academic achievement goals\n48. academic achievement goals\n49. academic achievement goals\n50. academic achievement goals\n51. academic achievement goals\n52. academic achievement goals\n53. academic achievement goals\n54. academic achievement goals\n55. academic achievement goals\n56. academic achievement goals\n57. academic achievement goals\n58. academic achievement goals\n59. academic achievement goals\n60. academic achievement goals\n61. academic achievement goals\n62. academic achievement goals\n63. academic achievement goals\n64. academic achievement goals\n65. academic achievement goals\n66. academic achievement goals\n67. academic achievement goals\n68. academic achievement goals\n69. academic achievement goals\n70. academic achievement goals\n71. academic achievement goals\n72. academic achievement goals\n73. academic achievement", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31000, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "400 mg of imatinib daily.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n48. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2013 European LeukemiaNet recommendations for\ndiagnosis, treatment, and follow-up in chronic myeloid leukemia. Blood2014;123:104–115.\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2016 European LeukemiaNet recommendations for\ndiagnosis, treatment, and follow-up in chronic myeloid leukemia. Blood2017;129:104–115.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2019 European LeukemiaNet recommendations for\ndiagnosis, treatment, and follow-up in chronic myeloid leukemia. Blood2020;135:104–115.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis, treatment, and follow-up in chronic myeloid leukemia. Blood2022;139:104–115.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2023 European LeukemiaNet recommendations for\ndiagnosis, treatment, and follow-up in chronic myeloid leukemia. Blood2023;141:104–115.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2013 National Comprehensive Cancer Network (NCC", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31018, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n2. Chronic lymphocytic leukemia (CLL)\n3. Acute myeloid leukemia (AML)\n4. Myelodysplastic syndrome (MDS)\n5. Myeloproliferative neoplasm (MPN)\n6. Myelofibrosis (MF)\n7. Polycythemia vera (PV)\n8. Essential thrombocythemia (ET)\n9. Chronic neutrophilic leukemia (CNL)\n10. Chronic eosinophilic leukemia (CEL)\n11. Chronic myelomonocytic leukemia (CMML)\n12. Chronic myelomonocytic leukemia (CMML)\n13. Chronic myelomonocytic leukemia (CMML)\n14. Chronic myelomonocytic leukemia (CMML)\n15. Chronic myelomonocytic leukemia (CMML)\n16. Chronic myelomonocytic leukemia (CMML)\n17. Chronic myelomonocytic leukemia (CMML)\n18. Chronic myelomonocytic leukemia (CMML)\n19. Chronic myelomonocytic leukemia (CMML)\n20. Chronic myelomonocytic leukemia (CMML)\n21. Chronic myelomonocytic leukemia (CMML)\n22. Chronic myelomonocytic leukemia (CMML)\n23. Chronic myelomonocytic leukemia (CMML)\n24. Chronic myelomonocytic leukemia (CMML)\n25. Chronic myelomonocytic leukemia (CMML)\n26. Chronic myelomonocytic leukemia (CMML)\n27. Chronic myelomonocytic leukemia (CMML)", "position(%)": 0, "length(string)": 88688, "length(tokens)": 30922, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "46. MirR, AhmadI, JavidJ, et al. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluating\nresponse of the a2b2 and a2b3 transcripts to imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer 2015;52:314–318.\n67. BennourA, OuahchiI, MoezM, et al. Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR. Indian J Cancer 2015;52:314–318.\n68. SokolL, Hasford J, Altman JK, et al. National Comprehensive Cancer Network (NCCN) guidelines for\nchronic myeloid leukemia (CML). J Natl Compr Canc Netw 2024;22(1):43–69.\n69. SokolL, Hasford J, Altman JK, et al. National Comprehensive Cancer Network (NCCN) guidelines for\nchronic myeloid leukemia (CML). J Natl Compr Canc Netw 2024;22(1):43–69.\n70. SokolL, Hasford J, Altman JK, et al. National Comprehensive Cancer Network (NCCN) guidelines for\nchronic myeloid leukemia (CML). J Natl Compr Canc Netw 2024;22(1):43–69.\n71. SokolL, Hasford J, Altman JK, et al. National Comprehensive Cancer Network (NCCN) guidelines for\nchronic myeloid leukemia (CML). J Natl Compr Canc Netw 2024;22(1):43–69.\n72. SokolL, Hasford J, Altman JK, et al. National Comprehensive Cancer Network (NCCN)", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31009, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31083, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Allogeneic hematopoietic cell transplantation (HCT) is no longer recommended as a first-line treatment option for patients with newly diagnosed chronic phase CML.\n2. The doctor recommended bosutinib 400 mg daily for the patient.\n3. The doctor recommended dasatinib 100 mg oncedaily for the patient.\n4. The doctor recommended nilotinib 300 mg twice daily for the patient.\n5. The doctor recommended ponatinib 45 mg oncedaily for the patient.\n6. The doctor recommended imatinib 400 mg daily for the patient.\n7. The doctor recommended imatinib 800 mg daily for the patient.\n8. The doctor recommended dasatinib 100 mg oncedaily for the patient.\n9. The doctor recommended nilotinib 300 mg twice daily for the patient.\n10. The doctor recommended ponatinib 45 mg oncedaily for the patient.\n11. The doctor recommended imatinib 400 mg daily for the patient.\n12. The doctor recommended dasatinib 100 mg oncedaily for the patient.\n13. The doctor recommended nilotinib 300 mg twice daily for the patient.\n14. The doctor recommended ponatinib 45 mg oncedaily for the patient.\n15. The doctor recommended imatinib 400 mg daily for the patient.\n16. The doctor recommended dasatinib 100 mg oncedaily for the patient.\n17. The doctor recommended nilotinib 300 mg twice daily for the patient.\n18. The doctor recommended ponatinib 45 mg oncedaily for the patient.\n19. The doctor recommended imatinib 400 mg daily for the patient.\n20. The doctor recommended dasatinib 100 mg oncedaily for the patient.\n21. The doctor recommended nilotinib 300 mg twice daily for the patient.\n22. The doctor recommended ponatinib 45 mg oncedaily for the patient.\n23. The doctor recommended imatinib 400 mg daily for the patient.\n2", "position(%)": 0, "length(string)": 88688, "length(tokens)": 31073, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "50. LangabeerSE,HarrisRJ,GiannoudisA,etal.Clonalchromosomal\n51 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nevolutionandlackofmolecularresponsebeforeTKI discontinuation in patients with chronic myeloid leukemia.\n52. BennourA,OuahchiI,MoezM,etal.Clonalchromosomal\nabnormalitiesappearinginPhiladelphiachromosome-negative metaphases during CML treatment. Blood2017;130:2084–2091.\n63. KantarjianHM,IssaGC,GonzalezGN,etal.Clonalchromosomal\nabnormalities in patients with chronic myeloid leukemia treated with imatinib. Blood2017;130:2084–2091.\n64. IssaGC,KantarjianHM,GonzalezGN,etal.Clonalchromosomal\nabnormalities in patients with chronic myeloid leukemia treated with imatinib. Blood2017;130:2084–2091.\n65. IssaGC,KantarjianHM,GonzalezGN,etal.Clonalchromosomal\nabnormalities in patients with chronic myeloid leukemia treated with imatinib. Blood2017;130:2084–2091.\n66. IssaGC,KantarjianHM,GonzalezGN,etal.Clonalchromosomal\nabnormalities in patients with chronic myeloid leukemia treated with imatinib. Blood2017;130:2084–2091.\n67. IssaGC,Kantar", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31148, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31116, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Acheron\n\n69. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n70. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n71. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n72. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n73. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n74. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with\nchronic myeloid leukemia treated with imatinib mesylate. Blood 1996;88:3363–3368.\n75. BaccaraniM, CastagnettiF, GugliottaG, et al. The", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Fox Talk Forest is a forest in the Xianzhou Luofu. 2. The two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu are the Fox Talk Forest Monster and the Fox Talk Forest Monster.\n\nJNCCN.org | Volume22 Issue1 | February2024 69\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nReferences\n20. BennourA,OuahchiI,MoezM,etal.Clonalchromosomalabnormalities 70. KantarjianHM,GilesFJ,O'BrienS,etal.TheEuro-\nappearinginPhiladelphiachromosome-negativemetaphasesduringCMLtreatment.Blood2017;130:2084–2091.\nwithimatinib.LeukLymphoma2019;60:3503–3511.\n21. BennourA,OuahchiI,MoezM,etal.Clonalchromosomalabnormalities 71. KantarjianHM,GilesFJ,O'BrienS,etal.TheEuro-\nappearinginPhiladelphiachromosome-negativemetaphasesduringCMLtreatment.Blood2017;130:2084–2091.\nwithdasatinib.LeukLymphoma2019;60:3503–3511.\n22. BennourA,OuahchiI,MoezM,etal.Clonalchromosomalabnormalities 72. KantarjianHM,GilesFJ,O'BrienS,etal.TheEuro-\nappearinginPhiladelphiachromosome-negativemetaphasesduringCMLtreatment.Blood2017;130:2084–2091.", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31144, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Razarina Jane Estella", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31082, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Pinocchi\n2. Clockboy and His Friends\n3. Clockboy and His Friends\n4. Clockboy and His Friends\n5. Clockboy and His Friends\n6. Clockboy and His Friends\n7. Clockboy and His Friends\n8. Clockboy and His Friends\n9. Clockboy and His Friends\n10. Clockboy and His Friends\n11. Clockboy and His Friends\n12. Clockboy and His Friends\n13. Clockboy and His Friends\n14. Clockboy and His Friends\n15. Clockboy and His Friends\n16. Clockboy and His Friends\n17. Clockboy and His Friends\n18. Clockboy and His Friends\n19. Clockboy and His Friends\n20. Clockboy and His Friends\n21. Clockboy and His Friends\n22. Clockboy and His Friends\n23. Clockboy and His Friends\n24. Clockboy and His Friends\n25. Clockboy and His Friends\n26. Clockboy and His Friends\n27. Clockboy and His Friends\n28. Clockboy and His Friends\n29. Clockboy and His Friends\n30. Clockboy and His Friends\n31. Clockboy and His Friends\n32. Clockboy and His Friends\n33. Clockboy and His Friends\n34. Clockboy and His Friends\n35. Clockboy and His Friends\n36. Clockboy and His Friends\n37. Clockboy and His Friends\n38. Clockboy and His Friends\n39. Clockboy and His Friends\n40. Clockboy and His Friends\n41. Clockboy and His Friends\n42. Clockboy and His Friends\n43. Clockboy and His Friends\n44. Clockboy and His Friends\n45. Clockboy and His Friends\n46. Clockboy and His Friends\n47. Clockboy and His Friends\n48. Clockboy and His Friends\n49. Clockboy and His Friends\n50. Clockboy and His Friends\n51. Clockboy and His Friends\n52", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31091, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "Yes\n\nThe Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible.", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 2.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 3.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 4.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 5.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 6.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 7.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 8.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 9.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 10.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 11.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 12.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 13.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonwacq'?\nAnswer: 14.\n\nQuestion: What is the name of the tree that is located on the island named 'Sprightly Vonw", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31114, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 2. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 3. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 4. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 5. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 6. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 7. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 8. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 9. The Astral Express was a train that ran between London and Paris. It was blown up by the Limehouse Golem,\na serial killer who was never caught.\nQuestion: Who once blew up the Astral Express?\nAnswer: 10. The Astr", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31135, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31109, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\n68. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities 69. JNCCN.org | Volume22 Issue1 | February2024 69\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nare associated with poorer outcomes in patients with chronic myeloid leukemia treated with imatinib. Blood2002;99:\nleukemia. Blood2002;99:395–401.\n70. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities 71. Sokal J, Armitage P, Baccarani M, et al. Prognostic factors in chronic myeloid leukemia. Blood 1984;64:1001–1008.\nare associated with poorer outcomes in patients with chronic myeloid leukemia treated with imatinib. Blood 2002;99:\nleukemia. Blood 2002;99:395–401.\n72. Sokal J, Armitage P, Baccarani M, et al. Prognostic factors in chronic myeloid leukemia. Blood 1984;64:1001–1008.\n73. Sokal J, Armitage P, Baccarani M, et al. Prognostic factors in chronic myeloid leukemia. Blood 1984;64:1001–1008.\n74. Sokal J, Armitage P, Baccarani M, et al. Prognostic factors in chronic myeloid leukemia. Blood 1984;64:1001–1008.\n75. Sokal J, Armitage P, Baccarani M, et al. Prognostic factors in chronic", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31049, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)\nAnswer: 15%\nQuestion: According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male can", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31055, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "8,930 people will be diagnosed with CML in 2023, and 1,310 people will die of CML in 2023.\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: What is the most common BCR::ABL1 transcript variant?\n\nAnswer: e13a2 and e14a2\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: What is the most common adverse event leading to treatment discontinuation in the DASISION study?\n\nAnswer: Grade 3 or 4 nonhematologic toxicities\n\n70 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: What is the most common adverse event leading to treatment discontinuation in the DASISION study?\n\nAnswer: Grade 3 or 4 nonhematologic toxicities\n\n71 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: What is the most common adverse event leading to treatment discontinuation in the DASISION study?\n\nAnswer: Grade 3 or 4 nonhematologic toxicities\n\n72 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31044, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "48. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n48. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n49. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n50. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n51. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n52. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n53. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n54. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n55. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n56. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and efficacy of advanced hybrid closed-loop therapy and standard insulin therapy were similar.\n57. The results of the RE-STIM study showed that for pregnant women starting strict blood glucose control, the safety and effic", "position(%)": 25, "length(string)": 88688, "length(tokens)": 30911, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. The presence of chromosomal abnormalities other than Ph. 2. The presence of e13a2 and e14a2 transcripts. 3. The presence of e19a2 transcripts. 4. The presence of e6a2 transcripts. 5. The presence of e1a2 transcripts.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the most common BCR::ABL1 transcripts?\nAnswer: 1. e13a2 and e14a2 transcripts. 2. e19a2 transcripts. 3. e6a2 transcripts. 4. e1a2 transcripts. 5. e11a2 transcripts.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the most common BCR::ABL1 transcripts?\nAnswer: 1. e13a2 and e14a2 transcripts. 2. e19a2 transcripts. 3. e6a2 transcripts. 4. e1a2 transcripts. 5. e11a2 transcripts.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the most common BCR::ABL1 transcripts?\nAnswer: 1. e13a2 and e14a2 transcripts. 2. e19a2 transcripts. 3. e6a2 transcripts. 4. e1a2 transcripts. 5. e11a2 transcripts.\n\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the most common BCR::ABL1 transcripts?\nAnswer: 1. e13a2 and e14a2 transcripts. 2. e19a2 transcripts. 3. e6a2 transcripts. 4. e1a2 transcripts. 5. e11a2 transcripts.\n\nQuestion: According to the recent", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31000, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "48. The doctor recommended that the patient take imatinib.\n48. The doctor recommended that the patient take imatinib.\n49. The doctor recommended that the patient take imatinib.\n50. The doctor recommended that the patient take imatinib.\n51. The doctor recommended that the patient take imatinib.\n52. The doctor recommended that the patient take imatinib.\n53. The doctor recommended that the patient take imatinib.\n54. The doctor recommended that the patient take imatinib.\n55. The doctor recommended that the patient take imatinib.\n56. The doctor recommended that the patient take imatinib.\n57. The doctor recommended that the patient take imatinib.\n58. The doctor recommended that the patient take imatinib.\n59. The doctor recommended that the patient take imatinib.\n60. The doctor recommended that the patient take imatinib.\n61. The doctor recommended that the patient take imatinib.\n62. The doctor recommended that the patient take imatinib.\n63. The doctor recommended that the patient take imatinib.\n64. The doctor recommended that the patient take imatinib.\n65. The doctor recommended that the patient take imatinib.\n66. The doctor recommended that the patient take imatinib.\n67. The doctor recommended that the patient take imatinib.\n68. The doctor recommended that the patient take imatinib.\n69. The doctor recommended that the patient take imatinib.\n70. The doctor recommended that the patient take imatinib.\n71. The doctor recommended that the patient take imatinib.\n72. The doctor recommended that the patient take imatinib.\n73. The doctor recommended that the patient take imatinib.\n74. The doctor recommended that the patient take imatinib.\n75. The doctor recommended that the patient take imatinib.\n76. The doctor recommended that the patient take imatinib.\n77. The doctor recommended that the patient take imatinib.\n78. The doctor recommended that the patient take imatinib.\n79. The doctor recommended that the patient take imatinib.\n80. The doctor", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31019, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "65-year-old male with chronic myeloid leukemia\n\n66 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: In the doctor-patient chat record from April 2021, what is the recommended treatment for the patient?\n\nAnswer: Dasatinib 100 mg oncedaily\n\n67 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: In the doctor-patient chat record from April 2021, what is the recommended treatment for the patient?\n\nAnswer: Dasatinib 100 mg oncedaily\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: In the doctor-patient chat record from April 2021, what is the recommended treatment for the patient?\n\nAnswer: Dasatinib 100 mg oncedaily\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: In the doctor-patient chat record from April 2021, what is the recommended treatment for the patient?\n\nAnswer: Dasatinib 100 mg oncedaily\n\n70 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: In the doctor-patient chat record from April", "position(%)": 25, "length(string)": 88688, "length(tokens)": 30923, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "43. The patient underwent a bone marrow biopsy.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of dasatinib?\nAnswer: 44. The recommended starting dose of dasatinib is 100 mg oncedaily.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of ponatinib?\nAnswer: 45. The recommended starting dose of ponatinib is 45 mg oncedaily.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of nilotinib?\nAnswer: 46. The recommended starting dose of nilotinib is 300 mg twice daily.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of bosutinib?\nAnswer: 47. The recommended starting dose of bosutinib is 400 mg oncedaily for patients with newly diagnosed CP-CML (which is better tolerated than the 500 mg daily dose that was used in the initial randomized phase II It trial) and 500 mg oncedaily for resistant or intolerant CP-CML.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of imatinib?\nAnswer: 48. The recommended starting dose of imatinib is 400 mg oncedaily for patients with newly diagnosed CP-CML.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of nilotinib?\nAnswer: 49. The recommended starting dose of nilotinib is 300 mg twice daily for patients with newly diagnosed CP-CML and 400 mg oncedaily for resistant or intolerant CP-CML.\n\nQuestion: In the April 2019 doctor-patient chat record, what is the recommended starting dose of bosutinib?\nAnswer: 50. The recommended starting dose of bosutinib is 400 mg oncedaily", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31009, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31083, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 43\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "position(%)": 25, "length(string)": 88688, "length(tokens)": 31074, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "Shuweng\n50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n60. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomalevolutioninpatientswithchronic-phaseCML: 69. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\na prospective study.Blood2002;99:2203–2208. evolutionandmolecularresponseinpatientswithchronic-\n61. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nphaseCML:a prospective study.Blood2002;99:2209–2214.\n62. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolutioninpatientswithchronic-phaseCML:a prospective study.Blood2002;99:2215–2220.\n63. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolutioninpatientswithchronic-phaseCML:a prospective study.Blood2002;99:2221–2227.\n64. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolutioninpatientswithchronic-phaseCML:a prospective study.Blood2002;99:2228–2234.\n65. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolutioninpatientswithchronic", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31148, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:vii1–vii10.\n55. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2022;33:", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31116, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "161\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogeneticevolutionin 70. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic\npatientswithchronic-phasechronicmyeloidleukemia:a 2002;100:1595–1602.\nprospective study.Blood2002;99:2084–2091.\n50. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 71. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 72. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 73. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 74. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 75. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 76. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 77. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in 78. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogenetic evolution in", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Fox Talk Forest is a forest in the Xianzhou Luofu. 2. The Fox Talk Forest is a forest in the Xianzhou Luofu.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: 58. Sokol L, Hasford J, Saglio G, et al. The International Randomized Study of Interferon-\n59. Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: 60. Sokol L, Hasford J, Saglio G, et al. The International Randomized Study of Interferon-\n64. Amaya M, Phillips G, Begna K, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: 61. Sokol L, Hasford J, Saglio G, et al. The International Randomized Study of Interferon-\n65. Berman E, Chan O, Clements J, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: 62. Sokol L, Hasford J, Saglio G, et al. The International Randomized Study of Interferon-\n63. Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: 64. Sokol L, Hasford J, Saglio G, et al. The International Randomized Study of Interferon-\n64. Amaya M, Phillips G, Begna K, et al. Chronic myeloid leukemia", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31144, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. Mikhail Char Legwork\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the\n2017;130:2084–2091. diagnosis and management of chronic myeloid leukemia.\n55. BaccaraniM, CastagnettiF, GugliottaG, et al.", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31082, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. Pinocchi\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\n\nAnswer: 1. e13a2\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\n\nAnswer: 1. e14a2\n\n70 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\n\nAnswer: 1. e19a2\n\n71 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\n\nAnswer: 1. e13a2\n\n72 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\n\nAnswer: 1. e14a2\n\n73 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nCh", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31091, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "Yes\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic 70. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\nsignificanceofBCR-ABL1transcripttypeinchronicmyeloidleukemia:  importance of BCR-ABL1 transcript type in\na systematic review and meta-analysis.Leukemia2017;31:  chronic myeloid leukemia.Blood2002;99:2093–2099.\n101–102. 71. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\n50. ShahN, BhatiaR, AltmanJK, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nsignificance of BCR-ABL1 transcript type in chronic myeloid leukemia. J Natl Compr Canc Netw 2024;22(1):43–69.\nJNCCN.org | Volume22 Issue1 | February2024 65\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the diagnosis\nand management of chronic myeloid leukemia: 2013 update. Blood 2013;122:2046–2057.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\nQ-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1\ntranscriptsinchronicmyeloidleukemia.LeukLymphoma2020;61: 70. KantarjianHM,GilesFJ,O'Brien S,etal.Clonalchromosomal\ntranscripts.Haematologica2014;99:1441–1447. abnormalitiesappearinginPhiladelphiachromosome-\n50. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\nnegative metaphasesduringCMLtreatment.Blood2017;130: 71. KantarjianHM,GilesFJ,O'Brien S,etal.Clonalchromosomal\nQ-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1\ntranscripts in chronic myeloid leukemia.LeukLymphoma2020;61: 72. KantarjianHM,GilesFJ,O'Brien S,etal.Clonalchromosomal\nabnormalities appearing in Philadelphiachromosome-negative metaphases during CML treatment.Blood2020;136:\ntranscripts.Haematologica2014;99:1441–1447. 73. KantarjianHM,GilesFJ,O'Brien S,etal.Clonalchromosomal\n51. P", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31114, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Astral Express was a passenger train that operated between London and Glasgow from 1901 to 1964.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic 69. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\nsignificanceofBCR-ABL1transcripttypeinchronicmyeloidleukemia: 70. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\na systematic review and meta-analysis.Blood2017;129: 71. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\n1915–1924. significanceofBCR-ABL1transcripttypeinchronicmyeloidleukemia:\n50. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic 72. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\nsignificanceofBCR-ABL1transcripttypeinchronicmyeloidleukemia: 73. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\na systematic review and meta-analysis.Blood2017;129: 74. KantarjianHM,GilesFJ,O’BrienS,etal.Theprognostic\n1915–1924. significanceofBCR-ABL1transcripttypeinchronicmyeloidleukemia:\n51. Kantarj", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31135, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: \n\n50. Baccarani M, Castagnetti F, Gugliotta G, et al. Chronic myeloid leukemia. J Clin Oncol 2023;31: \n\n69. JNCCN.org | Volume22 Issue1 | February2024 69\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: \n\n70. JNCCN.org | Volume22 Issue1 | February2024 70\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: \n\n71. JNCCN.org | Volume22 Issue1 | February2024 71\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: \n\n72. JNCCN.org | Volume22 Issue1 | February2024 72\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nQuestion: Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?\nAnswer: \n\n73. JNCCN.", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31109, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: 'The prognostic significance of Cytogenetic and Molecular Response in Chronic Myeloid Leukemia' is a report from which journal?\nAnswer: 1. The Lancet\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: 'The prognostic significance of Cytogenetic and Molecular Response in Chronic Myeloid Leukemia' is a report from which journal?\nAnswer: 1. The Lancet\n\n70 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: 'The prognostic significance of Cytogenetic and Molecular Response in Chronic Myeloid Leukemia' is a report from which journal?\nAnswer: 1. The Lancet\n\n71 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: 'The prognostic significance of Cytogenetic and Molecular Response in Chronic Myeloid Leukemia' is a report from which journal?\nAnswer: 1. The Lancet\n\n72 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion:", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31049, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in patients with CML? (Answer in Arabic numerals)\nAnswer: 22\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 210\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 13\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 19\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31055, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "50% of pregnancies with known outcome were normal and 10% of pregnancies with known outcome had\nfetal abnormalities.\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n55. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n56. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n57. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n58. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n59. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score and the Euro-\n60. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognost", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31044, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "45 mg once daily.\n48. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n49. ShahNP, BhatiaR, AltmanJK, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nQuestion: In the study from the Journal of Clinical Oncology comparing the outcomes of patients with newly diagnosed chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib, which therapy had the highest rate of overall molecular response (OMR) at 12 months?\nAnswer: Dasatinib.\n50. ShahNP, BhatiaR, AltmanJK, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nQuestion: In the study from the Journal of Clinical Oncology comparing the outcomes of patients with newly diagnosed chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib, which therapy had the highest rate of deep molecular response (DMR) at 12 months?\nAnswer: Nilotinib.\n51. ShahNP, BhatiaR, AltmanJK, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nQuestion: In the study from the Journal of Clinical Oncology comparing the outcomes of patients with newly diagnosed chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib, which therapy had the highest rate of overall molecular response (OMR) at 12 months?\nAnswer: Nilotinib.\n52. ShahNP, BhatiaR, AltmanJK, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\nQuestion: In the study from the Journal of Clinical Oncology comparing the outcomes of patients with newly diagnosed chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib, which therapy had the highest rate of deep molecular response (DMR) at 12 months?\nAnswer: Nil", "position(%)": 50, "length(string)": 88688, "length(tokens)": 30911, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. The presence of a T315I mutation 2. Female gender 3. Lower natural killer cell counts 4. Suboptimal response to TKI therapy 5. The presence of a T315I mutation\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the outcomes of patients who conceived\nAnswer: 1. The presence of a T315I mutation 2. Female gender 3. Lower natural killer cell counts 4. Suboptimal response to TKI therapy 5. The presence of a T315I mutation\n\n70 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the outcomes of patients who conceived\nAnswer: 1. The presence of a T315I mutation 2. Female gender 3. Lower natural killer cell counts 4. Suboptimal response to TKI therapy 5. The presence of a T315I mutation\n\n72 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the outcomes of patients who conceived\nAnswer: 1. The presence of a T315I mutation 2. Female gender 3. Lower natural killer cell counts 4. Suboptimal response to TKI therapy 5. The presence of a T315I mutation\n\n74 ©JNCCN—Journaloft", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31000, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended that the patient take an antiviral medication.\n48. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication.\n49. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication.\n50. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication.\n51. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication.\n52. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication.\n53. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA a\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. The doctor recommended that the patient take an antiviral medication", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31019, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n66. ShengG,XueM,WangQ,etal.Occurrenceofchromosomalabnor-\n47. Chronic myeloid leukemia (CML)\nmalitiesinPhiladelphiachromosome-nega-\ntivecellsinCMLpatientsaftertreated with tyrosinekinaseinhibitors.CancerGenet2019;238:44–49.\n48. Chronic myeloid leukemia (CML)\n67. ShengG,XueM,WangQ,etal.Occurrenceofchromosomalabnor-\n49. Chronic myeloid leukemia (CML)\nmalitiesinPhiladelphiachromosome-nega-\ntivecellsinCMLpatientsaftertreated with tyrosinekinaseinhibitors.CancerGenet2019;238:44–49.\n50. Chronic myeloid leukemia (CML)\n68. ShengG,XueM,WangQ,etal.Occurrenceofchromosomalabnor-\n51. Chronic myeloid leukemia (CML)\nmalitiesinPhiladelphiachromosome-nega-\ntivecellsinCMLpatientsaftertreated with tyrosinekinaseinhibitors.CancerGenet2019;238:44–49.\n52. Chronic myeloid leukemia (CML)\n69. ShengG,XueM,WangQ,etal.Occurrenceofchromosomalabnor-\n53. Chronic myeloid leukemia (CML)\nmalitiesinPhiladelphiachromosome-nega-\ntivecellsinCMLpatientsaftertreated with tyrosinekinaseinhibitors.CancerGenet2019;238:44–49.\n54. Chronic myeloid leukemia (CML)", "position(%)": 50, "length(string)": 88688, "length(tokens)": 30923, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 2. The patient was in complete cytogenetic response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 3. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 4. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 5. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 6. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 7. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 8. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 9. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 10. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 11. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 12. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 13. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAnswer: 14. The patient was in complete molecular response.\nQuestion: In the April 2019 doctor-patient chat record, what was the\nAn", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31009, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n49. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\nQ-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.LeukLymphoma2020;61: 70. KantarjianHM,GilesFJ,KimHS,etal.Clonalchromosomal\n2530–2532. abnormalities appearing in Philadelphiachromosome-negative metaphases during CML treatment.\nBlood2017;130:2084–2091.\n50. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\nQ-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.LeukLymphoma2020;61: 71. KantarjianHM,GilesFJ,KimHS,etal.Clonalchromosomal\n2533–2535. abnormalities appearing in Philadelphiachromosome-negative metaphases during CML treatment.\nBlood2017;130:2084–2091.\n51. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\nQ-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.LeukLymphoma2020;61: 72. KantarjianHM,GilesFJ,KimHS,etal.Clonalchromosomal\n2536–2538. abnormalities appearing in Philadelphiachromosome-negative metaphases during CML treatment", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31083, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\n\nAnswer: 400 mg of imatinib daily.\n\nQuestion:", "position(%)": 50, "length(string)": 88688, "length(tokens)": 31074, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shuweng\n50 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n60. KantarjianHM,IssaGC,GonzalezGN,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-negative\nnormal metaphasesduring imatinib treatment for chronic myeloid leukemia.Blood2017;130:2084–2091.\n61. KantarjianHM,IssaGC,GonzalezGN,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-negative\nnormal metaphasesduring imatinib treatment for chronic myeloid leukemia.Blood2017;130:2084–2091.\n62. KantarjianHM,IssaGC,GonzalezGN,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-\nnormal metaphasesduring imatinib treatment for chronic myeloid leukemia.Blood2017;130:2084–2091.\n63. KantarjianHM,IssaGC,GonzalezGN,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-\nnormal metaphasesduring imatinib treatment for chronic myeloid leukemia.Blood2017;130:2084–2091.\n64. KantarjianHM,IssaGC,GonzalezGN,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-\nnormal metaphasesduring imatinib treatment for chronic myeloid leukemia.Blood2017;130:", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31148, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalcytogeneticevolutioninpatientswithchronicmyeloidleukemia.Blood2004;104:\n10. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n11. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n12. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n13. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n14. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n15. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n16. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n17. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n18. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n19. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n20. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n21. The panel recommends that patients with newly diagnosed CP-CML should be treated with imatinib 400 mg daily.\n22. The panel recommends", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31116, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. NeilP. Shah, MD, PhD\n2. Ravi Bhatia, MD\n3. JessicaK. Altman, MD\n4. MariaAmaya, MD, PhD\n5. KebedeH. Begna, MD\n6. Ellin Berman, MD\n7. MichaelD. Rose, MD\n8. MichaelS. Keating, MD\n9. MichaelA. Bishop, MD\n10. MichaelJ. Heinrich, MD\n11. MichaelJ. Heinrich, MD\n12. MichaelJ. Heinrich, MD\n13. MichaelJ. Heinrich, MD\n14. MichaelJ. Heinrich, MD\n15. MichaelJ. Heinrich, MD\n16. MichaelJ. Heinrich, MD\n17. MichaelJ. Heinrich, MD\n18. MichaelJ. Heinrich, MD\n19. MichaelJ. Heinrich, MD\n20. MichaelJ. Heinrich, MD\n21. MichaelJ. Heinrich, MD\n22. MichaelJ. Heinrich, MD\n23. MichaelJ. Heinrich, MD\n24. MichaelJ. Heinrich, MD\n25. MichaelJ. Heinrich, MD\n26. MichaelJ. Heinrich, MD\n27. MichaelJ. Heinrich, MD\n28. MichaelJ. Heinrich, MD\n29. MichaelJ. Heinrich, MD\n30. MichaelJ. Heinrich, MD\n31. MichaelJ. Heinrich, MD\n32. MichaelJ. Heinrich, MD\n33. MichaelJ. Heinrich, MD\n34. MichaelJ. Heinrich, MD\n35. MichaelJ. Heinrich, MD\n36. MichaelJ. Heinrich, MD\n37. MichaelJ. Heinrich, MD\n38. MichaelJ. Heinrich, MD\n39. MichaelJ. Heinrich, MD\n40. MichaelJ. Heinrich, MD\n41. MichaelJ. Heinrich, MD\n42. MichaelJ. Heinrich, MD\n43. MichaelJ. Heinrich, MD\n44. MichaelJ. Heinrich, MD\n45. MichaelJ. Heinrich, MD\n46. MichaelJ. Heinrich, MD\n47. MichaelJ. Heinrich, MD\n48. MichaelJ. Heinrich, MD\n49. MichaelJ. Heinrich, MD\n50. MichaelJ. Heinrich, MD", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Monster of the Forest 2. The Monster of the Mountain\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2013 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood 2013;122:2046–2055.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2016 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood 2016;128:194–203.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2019 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood 2019;134:103–113.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood 2022;139:103–113.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leukemia. Blood 2022;139:103–113.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for\ndiagnosis and management of chronic myeloid leuk", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31144, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "35. QinYZ,JiangQ,KhosraviA,etal. BaselineBCR:ABL1transcripttypeand\n36. AbdelmagidMG,OuahchiI,MoezM,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-negative metaphases in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Cancer Genet 2019;238:44–49.\n37. AbdelmagidMG,OuahchiI,MoezM,etal. BaselineBCR:ABL1 transcript type and clonal chromosomal abnormalities appearing in\nPhiladelphiachromosome-negative metaphases in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Cancer Genet 2019;238:44–49.\n38. AbdelmagidMG,OuahchiI,MoezM,etal. Baseline BCR:ABL1 transcript type and clonal chromosomal abnormalities appearing in\nPhiladelphiachromosome-negative metaphases in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Cancer Genet 2019;238:44–49.\n39. AbdelmagidMG,OuahchiI,MoezM,etal. Baseline BCR:ABL1 transcript type and clonal chromosomal abnormalities appearing in\nPhiladelphiachromosome-negative metaphases in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Cancer Genet 2019;238:44–49.\n40. AbdelmagidMG,OuahchiI,MoezM,etal. Baseline BCR:ABL1 transcript type and clonal chromosomal abnormalities appearing in\nPhiladelphiachromosome-negative metaphases in patients with chronic myeloid leukemia undergoing", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31082, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "30. GongZ,MaoM,XuY,etal.ChronicphaseCML:clinical and prognostic significance of BCR-ABL1 transcript\nimplications of clonal chromosomal abnormalities.LeukLymphoma2022;12:103.\n2017;10:85–88. 68. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\n24. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolution in chronic myeloid leukemia.Blood2002;99:2084–2089.\n49. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\n25. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolution in chronic myeloid leukemia.Blood2002;99:2084–2089.\nabnormalities in chronic myeloid leukemia.Blood2002;99:2084–2089.\n50. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\n26. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\nevolution in chronic myeloid leukemia.Blood2002;99:2084–2089.\nabnormalities in chronic myeloid leukemia.Blood2002;99:2084–2089.\n51. KantarjianHM,GilesFJ,O’BrienS,etal.Clonalchromosomal\n27. KantarjianHM,G", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31091, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n2. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n3. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n4. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n5. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n6. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n7. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n8. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n9. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n10. The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste.\n\nJNCCN.org | Volume22 Issue1 | February2024 69\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\nReferences\n11. BaccaraniM, CastagnettiF, GugliottaG, et al. The European LeukemiaNet recommendations for the diagnosis and\n2017;130:2084–2091. management of chronic myeloid leukemia: 2017 ELN Recommendations. Blood2017;129:\n249–252. 12. HughesT, LoIaconoM, DraganiM, et al. Clinical utility of genomic DNA Q-PCR assay for the monitoring of minimal residual disease in chronic myeloid leukemia. J Clin Med2011;50:481–485", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof 70. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof\nimatinibmesylate in patients with chronic myeloid leukemia: 2003-2013. Blood2015;126:1065–1073.\na report from the International Randomized Study of Interferon-free therapy for chronic myeloid leukemia in the era of targeted\ntreatment with tyrosine kinase inhibitors. Blood2016;127:1065–1073.\n50. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof 71. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof\nimatinibmesylate in patients with chronic myeloid leukemia: 2003-2013. Blood2015;126:1065–1073.\na report from the International Randomized Study of Interferon-free therapy for chronic myeloid leukemia in the era of targeted\ntreatment with tyrosine kinase inhibitors. Blood2016;127:1065–1073.\n51. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof 72. KantarjianHM,GilesFJ,O'BrienS,etal.Clinicaloutcomesof\nimatinibmesylate in patients with chronic myeloid leukemia: 2", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31114, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Sawyers CL\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n55. BaccaraniM, CastagnettiF, GugliottaG, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines. Ann Oncol 2023;34:v1–v10.\n5", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31135, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2013 European LeukemiaNet recommendations for \ndiagnosis, treatment and follow-up in chronic myeloid leukemia. Blood 2014;123:1041–1050.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2016 European LeukemiaNet recommendations for \ndiagnosis, treatment and follow-up in chronic myeloid leukemia. Blood 2016;128:1041–1050.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2019 European LeukemiaNet recommendations for \ndiagnosis, treatment and follow-up in chronic myeloid leukemia. Blood 2020;135:1041–1050.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for \ndiagnosis, treatment and follow-up in chronic myeloid leukemia. Blood 2022;139:1041–1050.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European LeukemiaNet recommendations for \ndiagnosis, treatment and follow-up in chronic myeloid leukemia. Blood 2022;139:1041–1050.\n54. BaccaraniM, CastagnettiF, GugliottaG, et al. The 2022 European Leukemia", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31109, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "24. JainP, KantarjianH, PatelKP, et al. Impact of BCR-ABL1 transcript type on outcome in patient\nwith chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2018;124:3806–3818.\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n49. KantarjianHM, TalpazM, BaccaraniM, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):\nChronic Myeloid Leukemia, Version 2.2024. Chronic Myeloid Leukemia. J Natl Compr Canc Netw. 2024;22(1):43–69.\n50. JNCCN.org | Volume22 Issue1 | February2024 69\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n51. JNCCN.org | Volume22 Issue1 | February2024 70\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n71. JNCCN.org | Volume22 Issue1 | February2024 72\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.2024\n73. JNCCN.org | Volume22 Issue1 | February2024 73\nNCCNGUIDELINES® Chronic MyeloidLeukemia, Version2.20", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31049, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in patients with CML? (Answer in Arabic numerals)\nAnswer: 9\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 21\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 23\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 19\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 13\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 14\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What is the most common BCR::ABL1 transcript variant in patients with CML? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: What", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31055, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "50% of pregnancies with known outcome were normal and 10% of pregnancies with known outcome had an\nincrease in Ph-positive metaphases.\n49. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2530–2532. Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.\n50. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2533–2535. Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.\n51. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2536–2538. Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.\n52. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2539–2541. Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.\n53. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2542–2544. Q-PCRforthemonitoringofapatientwithatypicale19a2BCR-ABL1 transcriptsinchronicmyeloidleukemia.\n54. PaganiIS,DangP,SaundersVA,etal.ClinicalutilityofgenomicDNA\n2545–2547. Q-PCRfort", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31044, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "25. CastagnettiF, GugliottaG, BrecciaM, et al. The BCR-ABL1 transcript\nrange (4.0–10.0%) was associated with a higher risk of disease progression.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronicMyeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n48. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:207–213.\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:207–213.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:207–213.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:207–213.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:207–213.\n53. BaccaraniM, CastagnettiF, GugliottaG", "position(%)": 75, "length(string)": 88688, "length(tokens)": 30911, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. The presence of a T315I mutation\n2. The presence of a T315I mutation\n3. The presence of a T315I mutation\n4. The presence of a T315I mutation\n5. The presence of a T315I mutation\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nQuestion: According to the recent study from The Lancet Child & Adolescent Health, what are the potential risks and\nAnswer: 1. The presence of a T315I mutation\n2. The presence of a T315I mutation\n3. The presence of a T315I mutation\n4. The presence of a T315I mutation\n5. The presence of a T315I mutation\n69. The presence of a T315I mutation\n70. The presence of a T315I mutation\n71. The presence of a T315I mutation\n72. The presence of a T315I mutation\n73. The presence of a T315I mutation\n74. The presence of a T315I mutation\n75. The presence of a T315I mutation\n76. The presence of a T315I mutation\n77. The presence of a T315I mutation\n78. The presence of a T315I mutation\n79. The presence of a T315I mutation\n80. The presence of a T315I mutation\n81. The presence of a T315I mutation\n82. The presence of a T315I mutation\n83. The presence of a T315I mutation\n84. The presence of a T315I mutation\n85. The presence of a T315I mutation\n86. The presence of a T315I mutation\n87.", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31000, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. The doctor recommended that the patient take an antiviral medication.\n48. What is the recommended starting dose of imatinib for patients with newly diagnosed CP-CML?\nAnswer: 2. The recommended starting dose of imatinib is 400 mg daily.\n49. What is the recommended starting dose of dasatinib for patients with newly diagnosed CP-CML?\nAnswer: 3. The recommended starting dose of dasatinib is 100 mg oncedaily.\n50. What is the recommended starting dose of nilotinib for patients with newly diagnosed CP-CML?\nAnswer: 4. The recommended starting dose of nilotinib is 300 mg twice daily.\n51. What is the recommended starting dose of bosutinib for patients with newly diagnosed CP-CML?\nAnswer: 5. The recommended starting dose of bosutinib is 400 mg oncedaily.\n52. What is the recommended starting dose of ponatinib for patients with newly diagnosed CP-CML?\nAnswer: 6. The recommended starting dose of ponatinib is 45 mg oncedaily.\n53. What is the recommended starting dose of asciminib for patients with newly diagnosed CP-CML?\nAnswer: 7. The recommended starting dose of asciminib is 80 mg oncedaily.\n54. What is the recommended starting dose of asciminib for patients with CP-CML who have experienced resistance or intolerance to $2\nprior TKIs?\nAnswer: 8. The recommended starting dose of asciminib is 400 mg oncedaily.\n55. What is the recommended starting dose of dasatinib for patients with CP-CML who have experienced resistance or intolerance to $2\nprior TKIs?\nAnswer: 9. The recommended starting dose of dasatinib is 50 mg oncedaily.\n56. What is the recommended starting dose of nilotinib for patients with CP-CML who have experienced resistance or intolerance to $2\nprior TKIs?\nAnswer: 10. The recommended starting dose of nilotinib is 30", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31019, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia (CML)\n2. Chronic lymphocytic leukemia (CLL)\n3. Acute myeloid leukemia (AML)\n4. Chronic lymphocytic leukemia (CLL)\n5. Chronic myeloid leukemia (CML)\n6. Chronic myeloid leukemia (CML)\n7. Chronic myeloid leukemia (CML)\n8. Chronic myeloid leukemia (CML)\n9. Chronic myeloid leukemia (CML)\n10. Chronic myeloid leukemia (CML)\n11. Chronic myeloid leukemia (CML)\n12. Chronic myeloid leukemia (CML)\n13. Chronic myeloid leukemia (CML)\n14. Chronic myeloid leukemia (CML)\n15. Chronic myeloid leukemia (CML)\n16. Chronic myeloid leukemia (CML)\n17. Chronic myeloid leukemia (CML)\n18. Chronic myeloid leukemia (CML)\n19. Chronic myeloid leukemia (CML)\n20. Chronic myeloid leukemia (CML)\n21. Chronic myeloid leukemia (CML)\n22. Chronic myeloid leukemia (CML)\n23. Chronic myeloid leukemia (CML)\n24. Chronic myeloid leukemia (CML)\n25. Chronic myeloid leukemia (CML)\n26. Chronic myeloid leukemia (CML)\n27. Chronic myeloid leukemia (CML)\n28. Chronic myeloid leukemia (CML)\n29. Chronic myeloid leukemia (CML)\n30. Chronic myeloid leuk", "position(%)": 75, "length(string)": 88688, "length(tokens)": 30923, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's diagnosis?\nAnswer: 2. The patient was diagnosed with chronic myeloid leukemia.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's age?\nAnswer: 3. The patient was 27 years old.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's gender?\nAnswer: 4. The patient was female.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's spleen size?\nAnswer: 5. The patient's spleen size was 14 cm.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's platelet count?\nAnswer: 6. The patient's platelet count was 100,000/mm3.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's white blood cell count?\nAnswer: 7. The patient's white blood cell count was 10,000/mm3.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's hemoglobin level?\nAnswer: 8. The patient's hemoglobin level was 10 g/dL.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's blood pressure?\nAnswer: 9. The patient's blood pressure was 140/96 mmHg.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's creatinine level?\nAnswer: 10. The patient's creatinine level was 1.2 mg/dL.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient's blood urea nitrogen level?\nAnswer: 11. The patient's blood u", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31009, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: What is the patient's diagnosis? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's risk score? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old\n\nQuestion: What is the patient's treatment plan? (Please answer in the format xx)\nAnswer: 26 years old", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31083, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. The doctor recommended labetalol.\n\nQuestion: In 2021, a patient", "position(%)": 75, "length(string)": 88688, "length(tokens)": 31074, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. NeilP. Shah, MD, PhD\n\n58 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n69. ShengG,XueM,WangQ,etal.ClonalchromosomalabnormalitiesappearinginPhiladelphiachromosome-negative metaphases during CML treatment. Blood2019;130:2084–2091.\n70. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1984;64:1011–1018.\n71. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1994;84:207–214.\n72. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1994;84:207–214.\n73. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1994;84:207–214.\n74. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1994;84:207–214.\n75. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic myeloid leukemia. Blood 1994;84:207–214.\n76. Sokal J, Armitage JO, Baccarani M, et al. Prognostic factors for chronic my", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31148, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The 'Ten Stonehearts' team.\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31116, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "69. Raiden Bosenmori Mei\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n64. BaccaraniM, CastagnettiF, GugliottaG, et al. Clonal chromosomal abnormalities appearing during imatinib\ntreatment for chronic myeloid leukemia: a systematic review. Blood 2020;130:2084–2091.\n65. BaccaraniM, CastagnettiF, GugliottaG, et al. Clonal chromosomal abnormalities appearing during imatinib\ntreatment for chronic myeloid leukemia: a systematic review. Blood 2020;130:2084–2091.\n66. Issa GC, Kantarjian HM, Gonzalez GN, et al. Clonal chromosomal abnormalities appearing during imatinib\ntreatment for chronic myeloid leukemia. Blood 2020;130:2084–2091.\n67. Issa GC, Kantarjian HM, Gonzalez GN, et al. Clonal chromosomal abnormalities appearing during imatinib\ntreatment for chronic myeloid leukemia. Blood 2020;130:2084–2091.\n68. Navarro JT, Feliu E, G, et al. Myelodysplastic syndromes with Philadelphia negative monosomy 7 chromosome\nfollowing transient bonemarrow. Intern Med 2011;50:481–485.\n69. Navarro JT, Feliu E, G, et al. Myelodysplastic syndromes with Philadelphia negative monosomy 7 chromosome\nfollowing transient bonemarrow. Intern Med 2011;", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Mara-Struck Warden and 2. The Mara-Struck Soldier.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n64. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities 65. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities\nappearingduringimatinibtherapyforchronicmyeloidleukemia.Blood2002;99:195–201.\n66. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities\nappearingduringimatinibtherapyforchronicmyeloidleukemia.Blood2002;99:202–208.\n67. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities\nappearingduringimatinibtherapyforchronicmyeloidleukemia.Blood2002;99:209–215.\n68. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities\nappearingduringimatinibtherapyforchronicmyeloidleukemia.Blood2002;99:216–222.\n69. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities\nappearingduringimatinibtherapyforchronicmyeloidleukemia.Blood2002;99:223–229.\n70. Kantar", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31143, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCNGUIDELINES®\nCML-1: Risk Stratification\nThe Sokal score is the most widely used prognostic scoring system for CML. It was developed in 1984 and is based on 4\nvariables: age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood.8–12 The\nSokal score is calculated as follows:\n\nSokal score = 0.55 × age + 0.25 × spleen size + 0.15 × platelet count + 0.15 × percentage of blasts\n\nThe Sokal score is used to stratify patients into 3 risk groups: low, intermediate, and high. The Sokal score is\ncalculated at the time of diagnosis and is used to determine the initial treatment strategy.\n\nThe Sokal score is calculated using the following formula:\n\nSokal score = 0.55 × age + 0.25 × spleen size + 0.15 × platelet count + 0.15 × percentage of blasts\n\nThe Sokal score is calculated using the following formula:\n\nSokal score = 0.55 × age + 0.25 × spleen size + 0.15 × platelet count + 0.15 × percentage of blasts\n\nThe Sokal score is calculated using the following formula:\n\nSokal score = 0.55 × age + 0.25 × spleen size + 0.15 × platelet count + 0.15 × percentage of blasts\n\nThe Sokal score is calculated using the following formula:\n\nSokal score = 0.55 × age + 0.25 × spleen size + 0.15 × platelet count + 0.15 × percentage of blasts\n\nThe Sokal score is calculated using the following formula:\n\nSokal score = 0.55", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31081, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. 'Clockboy and His Friends'\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 2. e13a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 3. e14a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 4. e19a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 5. e6a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 6. e1a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 7. e13a3\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 8. e14a3\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 9. e6a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 10. e1a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 11. e19a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 12. e1a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 13. e13a3\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 14. e14a3\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 15. e6a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 16. e1a2\nQuestion: Which of the following is a BCR::ABL1 transcript variant?\nAnswer: 17", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31091, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "68. NavarroJT,FeliuE,GrauJ,etal. Monosomy 7 with severe myelodysplastic syndrome lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\n\nAnswer: 68. NavarroJT,FeliuE,GrauJ,etal. Monosomy 7 with severe myelodysplastic syndrome lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\n\nAnswer: 68. NavarroJT,FeliuE,GrauJ,etal. Monosomy 7 with severe myelodysplastic syndrome lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\n\nAnswer: 68. NavarroJT,FeliuE,GrauJ,etal. Monosomy 7 with severe myelodysplastic syndrome lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.\n\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\n\nAnswer: 68. NavarroJT,FeliuE,GrauJ,etal. Monosomy 7 with severe myelodysplastic syndrome lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31124, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCN Guidelines®\n\nQuestion: Which of the following is the most common BCR::ABL1 transcript variant?\n\nAnswer: 2.\n\n64 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCN Guidelines®\n\nQuestion: Which of the following is the most common adverse event\n\nassociated with dasatinib?\n\nAnswer: 1.\n\n65 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCN Guidelines®\n\nQuestion: Which of the following is the most common adverse event\n\nassociated with nilotinib?\n\nAnswer: 2.\n\n66 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCN Guidelines®\n\nQuestion: Which of the following is the most common adverse event\n\nassociated with imatinib?\n\nAnswer: 1.\n\n67 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.2024 NCCN Guidelines®\n\nQuestion: Which of the following is the most common adverse event\n\nassociated with bosutinib?\n\nAnswer: 1.\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia, Version 2.", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31113, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "69.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\nCML-D: Risk Stratification\nThe Sokal score is based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of\nCML-D: Risk Stratification\nblasts in the peripheral blood.238 The Sokal score is the most widely used prognostic scoring system for\nCML-D: Risk Stratification\nCML.239 The Sokal score is calculated using the following formula:\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age + 0.05 × spleen size + 0.05 × platelet count + 0.05 × percentage of blasts in the peripheral blood.\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age + 0.05 × spleen size + 0.05 × platelet count + 0.05 × percentage of blasts in the peripheral blood.\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age + 0.05 × spleen size + 0.05 × platelet count + 0.05 × percentage of blasts in the peripheral blood.\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age + 0.05 × spleen size + 0.05 × platelet count + 0.05 × percentage of blasts in the peripheral blood.\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age + 0.05 × spleen size + 0.05 × platelet count + 0.05 × percentage of blasts in the peripheral blood.\nThe Sokal score is calculated using the following formula:\nSokal score = 0.55 × age +", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31134, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The Astral Express was used to collide with the Great Septimus in Penacony.\n2. The Astral Express was used to collide with the Great Septimus in Penacony.\n3. The Astral Express was used to collide with the Great Septimus in Penacony.\n4. The Astral Express was used to collide with the Great Septimus in Penacony.\n5. The Astral Express was used to collide with the Great Septimus in Penacony.\n6. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\n7. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n8. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n9. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n10. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n11. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n12. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n13. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n14. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n15. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n16. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n17. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n18. The Astral Express was used to collide with the Great Septimus in Penacony.\n\n19. The Astr", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31109, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. The Lancet\n\n68 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a category 2B recommendation for the management of CML?\n\nA. BCR::ABL1 transcripts in the peripheral blood at very low levels (1–10 of 108 peripheral blood leukocytes) can be used to monitor response to TKI therapy.\n\nB. The presence of e1a2 transcripts (encoding for p190) is associated with a higher risk of disease progression to AP-CML or BP-CML.\n\nC. The presence of e19a2 transcripts (encoding for p230) is associated with a higher risk of disease progression to AP-CML or BP-CML.\n\nD. The presence of e19a2 transcripts (encoding for p230) is associated with a lower risk of disease progression to AP-CML or BP-CML.\n\nE. The presence of e19a2 transcripts (encoding for p230) is associated with a higher risk of disease progression to AP-CML or BP-CML.\n\nAnswer: E. The presence of e19a2 transcripts (encoding for p230) is associated with a higher risk of disease progression to AP-CML or BP-CML.\n\n\n69 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n\nQuestion: Which of the following is a category 2B recommendation for the management of CML?\n\nA. The presence of e1a2 transcripts (encoding for p190) is associated with a higher risk of disease progression to AP-CML or BP-CML.\n\nB. The presence of e1", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31049, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what percentage of the number of prostate cancer deaths in 2020? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million in 2020 to what percentage of the number of prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 200%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million in 2020 to what percentage of the number of prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 200%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what percentage of the number of prostate cancer deaths in 2020? (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million in 2020 to what percentage of the number of prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 200%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer cases is expected to increase from 1.4 million in 2020 to what percentage of the number of prostate cancer cases in 2020? (Answer in Arabic numerals)\nAnswer: 200%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to what percentage of the number of pro", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31055, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "15 years after the examination.\n63. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n64. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n65. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n66. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n67. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n68. KantarjianHM,GilesFJ,O'BrienS,etal.Clonalchromosomalabnormalities in patients with chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment. Blood2019;134:1065–1073.\n69. KantarjianHM,GilesFJ,O'BrienS,etal", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31044, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "780G\n\n63 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume22 Issue1 | February2024\nChronic Myeloid Leukemia,Version2.2024 NCCNGUIDELINES®\n48. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:1301–1306.\n49. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:1301–1306.\n50. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:1301–1306.\n51. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:1301–1306.\n52. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;98:1301–1306.\n53. BaccaraniM, CastagnettiF, GugliottaG, et al. The prognostic significance of the Sokal score in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood2001;", "position(%)": 100, "length(string)": 88688, "length(tokens)": 30910, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' depression symptoms are related to their academic achievement goals.\n2. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n3. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n4. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n5. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n6. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n7. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n8. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n9. Adolescents' depression symptoms are related to their academic achievement goals, which may be", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31000, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n\nQuestion: In the March 2020 doctor-", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31018, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: Male\n\nQuestion: In the doctor-patient chat record from April", "position(%)": 100, "length(string)": 88688, "length(tokens)": 30922, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 2. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 3. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 4. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 5. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 6. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 7. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 8. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 9. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 10. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 11. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 12. The test result is not serious\n\nQuestion: In the April 2019 doctor-patient chat record, what is the significance of the test result?\nAnswer: 13. The test result is not serious\n\nQuestion: In the April 20", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31009, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\nQuestion: In the 2023", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31083, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer:  Labetalol is okay to take...\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor", "position(%)": 100, "length(string)": 88688, "length(tokens)": 31073, "length(origin)": 32000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The manager of the Dream Bar in the Penacony Daydream Hotel is Shuweng.\n\n2. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n3. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n4. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n5. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n6. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n7. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n8. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n9. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n10. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n11. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n12. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n13. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n14. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n15. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n16. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n17. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n18. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n19. The manager of the Dream Bar in the Penacony Daydream Hotel is not Shuweng.\n\n20. The manager of the Dream Bar in the Penacony Dayd", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69464, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\nQuestion: Which of the following is the most common adverse event leading to discontinuation of bosutinib?\nAnswer: 2\nQuestion: Which of the following is the most common adverse event leading to discontinuation of dasatinib?\nAnswer: 3\nQuestion: Which of the following is the most common adverse event leading to discontinuation of imatinib?\nAnswer: 4\nQuestion: Which of the following is the most common adverse event leading to discontinuation of nilotinib?\nAnswer: 5\nQuestion: Which of the following is the most common adverse event leading to discontinuation of ponatinib?\nAnswer: 6\nQuestion: Which of the following is the most common adverse event leading to discontinuation of dasatinib?\nAnswer: 7\nQuestion: Which of the following is the most common adverse event leading to discontinuation of imatinib?\nAnswer: 8\nQuestion: Which of the following is the most common adverse event leading to discontinuation of nilotinib?\nAnswer: 9\nQuestion: Which of the following is the most common adverse event leading to discontinuation of ponatinib?\nAnswer: 10\nQuestion: Which of the following is the most common adverse event leading to discontinuation of dasatinib?\nAnswer: 11\nQuestion: Which of the following is the most common adverse event leading to discontinuation of imatinib?\nAnswer: 12\nQuestion: Which of the following is the most common adverse event leading to discontinuation of nilotinib?\nAnswer: 13\nQuestion: Which of the following is the most common adverse event leading to discontinuation of ponatinib?\nAnswer: 14\nQuestion: Which of the following is the most common adverse event leading to discontinuation of dasatinib?\nAnswer: 15\nQuestion: Which of the following is the most common adverse event leading to discontinuation of imatinib?\nAnswer: 16\nQuestion: Which of the following is the most common adverse event leading to discontinuation of nilotinib?\nAnswer: 17\nQuestion: Which of the", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69434, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Acheron\n2. Raiden Bosenmori Mei\n3. Acheron Bosenmori Mei\n4. Acheron Bosenmori Mei\n5. Acheron Bosenmori Mei\n6. Acheron Bosenmori Mei\n7. Acheron Bosenmori Mei\n8. Acheron Bosenmori Mei\n9. Acheron Bosenmori Mei\n10. Acheron Bosenmori Mei\n11. Acheron Bosenmori Mei\n12. Acheron Bosenmori Mei\n13. Acheron Bosenmori Mei\n14. Acheron Bosenmori Mei\n15. Acheron Bosenmori Mei\n16. Acheron Bosenmori Mei\n17. Acheron Bosenmori Mei\n18. Acheron Bosenmori Mei\n19. Acheron Bosenmori Mei\n20. Acheron Bosenmori Mei\n21. Acheron Bosenmori Mei\n22. Acheron Bosenmori Mei\n23. Acheron Bosenmori Mei\n24. Acheron Bosenmori Mei\n25. Acheron Bosenmori Mei\n26. Acheron Bosenmori Mei\n27. Acheron Bosenmori Mei\n28. Acheron Bosenmori Mei\n29. Acheron Bosenmori Mei\n30. Acheron Bosenmori Mei\n31. Acheron Bosenmori Mei\n32. Acheron Bosenmori Mei\n33. Acheron Bosenmori Mei\n34. Acheron Bosenmori Mei\n35. Acheron Bosenmori Mei\n36. Acheron Bosenmori Mei\n37. Acheron Bosenmori Mei\n38. Acheron Bosenmori Mei\n39. Acheron Bosenmori Mei\n40. Acheron Bosen", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69447, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Two 'Mara-Struck Soldier'\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?\nAnswer: The 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu is called 'Mara-Struck Soldier'.\n\nQuestion: What is the name of", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69452, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. The Watchmaker of Penacony is a character in the novel \"The Count of Monte Cristo\" by Alexandre Dumas.\nHe is a skilled watchmaker who is hired by the Count to help him escape from prison.\n\nQuestion: What is the significance of the Watchmaker in the novel?\nAnswer: The Watchmaker is a skilled watchmaker who is hired by the Count to help him escape from prison. He is a key\ncharacter in the novel, as he helps the Count to create a fake identity and to obtain the necessary tools and materials\nto escape.\n\nQuestion: What is the name of the character who hires the Watchmaker?\nAnswer: The character who hires the Watchmaker is the Count of Monte Cristo. He is a wealthy nobleman who is wrongly\nimprisoned and seeks revenge against those who betrayed him.\n\nQuestion: What is the name of the character who is hired to help the Count escape from prison?\nAnswer: The character who is hired to help the Count escape from prison is the Watchmaker of Penacony. He is a skilled\nwatchmaker who is hired by the Count to help him escape.\n\nQuestion: What is the name of the character who is wrongly imprisoned?\nAnswer: The character who is wrongly imprisoned is Edmond Dantès. He is a young sailor who is betrayed by his friends\nand falsely accused of treason.\n\nQuestion: What is the name of the character who helps the Count to create a fake identity?\nAnswer: The character who helps the Count to create a fake identity is the Watchmaker of Penacony. He is a skilled watchmaker\nwho is hired by the Count to help him escape.\n\nQuestion: What is the name of the character who helps the Count to obtain the necessary tools and materials to escape?\nAnswer: The character who helps the Count to obtain the necessary tools and materials to escape is the Watchmaker of Penacony.\nHe is a skilled watchmaker who is hired by the Count to help him escape.\n\nQuestion: What is the name of the character who helps the Count to escape from prison?\nAnswer: The character who helps the Count to escape from prison is the Watchmaker of Penacony. He is a skilled watchmaker\nwho is hired by the Count to help", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69433, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. The Simpsons\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 2. Carfilzomib/Cyclophosphamide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 3. Daratumumab/Lenalidomide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 4. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 5. Daratumumab/Bortezomib/Cyclophosphamide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 6. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 7. Carfilzomib/Cyclophosphamide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 8. Daratumumab/Lenalidomide/Dexamethasone\n\nQuestion: Which of the following is a category 1, preferred option for the treatment of patientswith relapsed/refractory\nmultiple myeloma?\nAnswer: 9. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: Which", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69427, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: Can the Warp Trotter be eaten? (Answer yes or no)\nAnswer: 1285 ©JNCCN—JournaloftheNationalComprehensiveCancer", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. The tree named 'Sisten' is located on the island of Sisten.\n\nQuestion: What is the name of the tree that bears fruits that would give birth to the various kinds of the island's wildlife?\nAnswer: 2. The tree that bears fruits that would give birth to the various kinds of the island's wildlife is the Sisten tree.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 3. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 4. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 5. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 6. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 7. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 8. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 9. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 10. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 11. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 12. The Sisten tree is located on the island of Sisten.\n\nQuestion: What is the name of the island where the Sisten tree is located?\nAnswer: 13. The", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69436, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Aeon 2. The Aeon 3. The Aeon 4. The Aeon 5. The Aeon 6. The Aeon 7. The Aeon 8. The Aeon 9. The Aeon 10. The Aeon 11. The Aeon 12. The Aeon 13. The Aeon 14. The Aeon 15. The Aeon 16. The Aeon 17. The Aeon 18. The Aeon 19. The Aeon 20. The Aeon 21. The Aeon 22. The Aeon 23. The Aeon 24. The Aeon 25. The Aeon 26. The Aeon 27. The Aeon 28. The Aeon 29. The Aeon 30. The Aeon 31. The Aeon 32. The Aeon 33. The Aeon 34. The Aeon 35. The Aeon 36. The Aeon 37. The Aeon 38. The Aeon 39. The Aeon 40. The Aeon 41. The Aeon 42. The Aeon 43. The Aeon 44. The Aeon 45. The Aeon 46. The Aeon 47. The Aeon 48. The Aeon 49. The Aeon 50. The Aeon 51. The Aeon 52. The Aeon 53. The Aeon 54. The Aeon 55. The Aeon 56. The Aeon 57. The Aeon 58. The Aeon 59. The Aeon 60. The Aeon 61. The Aeon 62. The Aeon 63. The Aeon 64. The A", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n2. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n3. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n4. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n5. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n6. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n7. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n8. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n9. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n10. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n11. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n12. The train to collide with the Great Septimus in Penacony was the 10:15 train from the Muggle station in\nDiagon Alley.\n13. The train to collide with the Great Septimus in Penac", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Haematology\n\nQuestion: 'The role of racial and ethnic discrimination", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69396, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common abnormality in the bone marrow of patients with chronic phase CML? (Answer in Arabic numerals)\nAnswer: 3\nQuestion: What is the recommended initial dose of ponatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 45 mg\nQuestion: What is the recommended initial dose of dasatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 100 mg\nQuestion: What is the recommended initial dose of nilotinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 300 mg\nQuestion: What is the recommended initial dose of bosutinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended initial dose of imatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended initial dose of imatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 800 mg\nQuestion: What is the recommended initial dose of imatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended initial dose of dasatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 100 mg\nQuestion: What is the recommended initial dose of nilotinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 300 mg\nQuestion: What is the recommended initial dose of bosutinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended initial dose of imatinib for patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69410, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "100% of patients with a negative colonoscopy result had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.\n\nQuestion: What is the recommended initial dose of ponatinib for patients with newly diagnosed CP-CML?\nAnswer: 45 mg once daily.\n\nQuestion: What is the recommended initial dose of dasatinib for patients with newly diagnosed CP-CML?\nAnswer: 100 mg oncedaily.\n\nQuestion: What is the recommended initial dose of nilotinib for patients with newly diagnosed CP-CML?\nAnswer: 300 mg twice daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with newly diagnosed CP-CML?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 800 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?\nAnswer: 400 mg daily.\n\nQuestion: What is the recommended initial dose of imatinib for patients with CP-CML who are intolerant to dasatinib or nilotinib?", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69391, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 2. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of major hypoglycemic events?\nAnswer: 3. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of minor hypoglycemic events?\nAnswer: 4. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of major hypoglycemic events?\nAnswer: 5. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of minor hypoglycemic events?\nAnswer: 6. Standard insulin therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of major hypoglycemic events?\nAnswer: 7. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of minor hypoglycemic events?\nAnswer: 8. Standard insulin therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of major hypoglycemic events?\nAnswer: 9. Advanced hybrid closed-loop therapy\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69328, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n2. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n3. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n4. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n5. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n6. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n7. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.\n8. Adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing master", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69354, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None of the above\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Tylenol\n2. Ibuprofen\n3. Acetaminophen\n4. Aspirin\n5. None", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 2. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 3. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 4. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 5. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 6. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 7. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 8. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 9. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 10. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 11. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 12. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease is the patient consulting about?\nAnswer: 13. Multiple myeloma\n\nQuestion: In the doctor-patient chat record from April 2021, what disease", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69406, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Bone marrow aspiration and biopsy\n2. Bone marrow cytogenetics\n3. Quantitative reverse transcription polymerase chain reaction (qRT-PCR)\n4. Flow cytometry\n5. Serum protein electrophoresis (SPEP)\n6. Urine protein electrophoresis (UPEP)\n7. Serum free light chain assay\n8. Serum immunofixation electrophoresis (IFE)\n9. Serum protein electrophoresis (SPEP)\n10. Serum free light chain assay\n11. Flow cytometry\n12. Bone marrow cytogenetics\n13. Serum protein electrophoresis (SPEP)\n14. Serum free light chain assay\n15. Urine protein electrophoresis (UPEP)\n16. Serum protein electrophoresis (SPEP)\n17. Serum free light chain assay\n18. Flow cytometry\n19. Bone marrow cytogenetics\n20. Serum protein electrophoresis (SPEP)\n21. Serum free light chain assay\n22. Urine protein electrophoresis (UPEP)\n23. Serum protein electrophoresis (SPEP)\n24. Serum free light chain assay\n25. Flow cytometry\n26. Bone marrow cytogenetics\n27. Serum protein electrophoresis (SPEP)\n28. Serum free light chain assay\n29. Urine protein electrophoresis (UPEP)\n30. Serum protein electrophoresis (SPEP)\n31. Serum free light chain assay\n32. Flow cytometry\n33. Bone marrow cytogenetics\n34. Serum protein electrophoresis (SPEP)\n35. Serum free light chain assay\n36. Urine protein electrophoresis (UPEP)\n37. Serum protein electrophoresis (SPEP)\n38. Serum free light chain assay\n39. Flow cytometry\n40. Bone marrow", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "65 years old\n\nQuestion: What is the patient’s diagnosis? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s risk score? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the initial therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the second line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the third line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the fourth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the fifth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the sixth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the seventh line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the eighth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the ninth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the tenth line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the eleventh line therapy? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: What is the patient’s response to the twelfth line therapy? (", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Nilotinib 2. Dasatinib 3. Imatinib 4. Ponatinib 5. Bosutinib 6. Asciminib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1.", "position(%)": 0, "length(string)": 177577, "length(tokens)": 69424, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n2. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n3. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n4. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n5. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n6. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n7. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n8. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n9. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n10. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n11. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n12. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n13. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n14. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n15. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n16. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n17. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n18. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n19. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n20. The manager of the Dream Bar in the Penacony Daydream Hotel is a man.\n\n21. The manager of the Dream Bar in the Penacony Daydream Hotel is a woman.\n\n22. The manager", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69465, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1. The NCCN MM Panel members have included\n\nA phase II trial (MMY1001) evaluated the safety and\nefficacy of pomalidomide/bortezomib/dexamethasone in\npatients with relapsed/refractory MM who had received 1 to 3\nprior lines of therapy.38 The panel has included this regimen as a\ncategory 1, preferred option for the treatment of patients with relapsed/\nrefractory MM.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The NCCN MM Panel members have included\n\nA phase II trial (MMY1001) evaluated the safety and\nefficacy of pomalidomide/bortezomib/dexamethasone in\npatients with relapsed/refractory MM who had received 1 to 3\nprior lines of therapy.38 The panel has included this regimen as a\ncategory 1, preferred option for the treatment of patients with relapsed/\nrefractory MM.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The NCCN MM Panel members have included\n\nA phase II trial (MMY1001) evaluated the safety and\nefficacy of pomalidomide/bortezomib/dexamethasone in\npatients with relapsed/refractory MM who had received 1 to 3\nprior lines of therapy.38 The panel has included this regimen as a\ncategory 1, preferred option for the treatment of patients with relapsed/\nrefractory MM.\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1. The NCCN MM Panel members have included\n\nA phase II trial (MMY1001) evaluated the safety and\nefficacy of pomalidomide/bortezomib/", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. The real name of the purple-haired lady known as the 'Galaxy Ranger' is Acheron.\n\n2. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n3. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n4. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n5. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n6. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n7. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n8. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n9. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n10. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n11. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n12. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n13. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n14. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n15. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n16. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n17. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n18. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n19. The 'Galaxy Ranger' is a character in the 'Star Wars' franchise.\n\n20. The 'Galaxy Ranger' is a character in the 'Star Trek' franchise.\n\n21. The 'Galaxy Ranger' is a", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69448, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The Fox Talk Forest is a forest in the Xianzhou Luofu region of China. It is located in the northwest of the\nregion, and is known for its unique and beautiful scenery. The forest is home to a variety of animals, including foxes,\nmonkeys, and deer. The forest is also known for its rich history, as it was once the site of a battle between the\nQin and Han dynasties.\n2. The two monsters behind the Fox Talk Forest are the White Tiger and the Black Tortoise. They are both powerful\nand mythical creatures, and are said to be the guardians of the forest. The White Tiger is a symbol of strength and\ncourage, while the Black Tortoise is a symbol of wisdom and longevity.\n\n3. The Fox Talk Forest is a forest located in the Xianzhou Luofu region of China. It is known for its unique and beautiful\nscenery, and is home to a variety of animals, including foxes, monkeys, and deer. The forest is also known for its\nrich history, as it was once the site of a battle between the Qin and Han dynasties.\n\n4. The Fox Talk Forest is a forest located in the Xianzhou Luofu region of China. It is known for its unique and beautiful\nscenery, and is home to a variety of animals, including foxes, monkeys, and deer. The forest is also known for its\nrich history, as it was once the site of a battle between the Qin and Han dynasties.\n\n5. The Fox Talk Forest is a forest located in the Xianzhou Luofu region of China. It is known for its unique and beautiful\nscenery, and is home to a variety of animals, including foxes, monkeys, and deer. The forest is also known for its\nrich history, as it was once the site of a battle between the Qin and Han dynasties.\n\n6. The Fox Talk Forest is a forest located in the Xianzhou Luofu region of China. It is known for its unique and beautiful\nscenery, and is home to a variety of animals, including foxes, monkeys, and deer. The forest", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69453, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. The Watchmaker is a character in the novel 'The\nWatchmaker of Penacony' by Brandon Sanderson.", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69433, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. BFORE\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nReferences\n1. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392: 2. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1307–1318. 1292. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1319–1328.\n3. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1329–1339.\n4. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1340–1349.\n5. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1350–1359.\n6. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1360–1369.\n7. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1370–1379.\n8. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1380–1389.\n9. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:\n1390–1399.\n10. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69427, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer yes or no)\nAnswer: 100% yes.\n\nQuestion:", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\n\nQuestion: What is the name of the tree?\nAnswer: 2\n\nQuestion: What is the name of the tree?\nAnswer: 3\n\nQuestion: What is the name of the tree?\nAnswer: 4\n\nQuestion: What is the name of the tree?\nAnswer: 5\n\nQuestion: What is the name of the tree?\nAnswer: 6\n\nQuestion: What is the name of the tree?\nAnswer: 7\n\nQuestion: What is the name of the tree?\nAnswer: 8\n\nQuestion: What is the name of the tree?\nAnswer: 9\n\nQuestion: What is the name of the tree?\nAnswer: 10\n\nQuestion: What is the name of the tree?\nAnswer: 11\n\nQuestion: What is the name of the tree?\nAnswer: 12\n\nQuestion: What is the name of the tree?\nAnswer: 13\n\nQuestion: What is the name of the tree?\nAnswer: 14\n\nQuestion: What is the name of the tree?\nAnswer: 15\n\nQuestion: What is the name of the tree?\nAnswer: 16\n\nQuestion: What is the name of the tree?\nAnswer: 17\n\nQuestion: What is the name of the tree?\nAnswer: 18\n\nQuestion: What is the name of the tree?\nAnswer: 19\n\nQuestion: What is the name of the tree?\nAnswer: 20\n\nQuestion: What is the name of the tree?\nAnswer: 21\n\nQuestion: What is the name of the tree?\nAnswer: 22\n\nQuestion: What is the name of the tree?\nAnswer: 23\n\nQuestion: What is the name of the tree?\nAnswer: 24\n\nQuestion: What is the name of the tree?\nAnswer: 25\n\nQuestion: What is the name of the tree?\nAnswer: 26\n\nQuestion: What is the name of the tree?\nAnswer: 27\n\nQuestion: What is the name of the tree?", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69437, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The Astral Express was a British passenger ship that\nwas blown up by a bomb in 1940.\n\n2. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n3. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n4. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n5. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n6. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n7. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n8. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n9. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n10. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n11. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n12. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n13. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n14. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n15. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n16. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n17. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n18. The Astral Express was a British passenger ship that was blown up by a bomb in 1940.\n\n19. The", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69444, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n2. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n3. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n4. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n5. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n6. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n7. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n8. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n9. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.\n10. The train to collide with the Great Septimus in Penacony was the 10:15 train from King’s Landing to Winterfell.", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 161. The Lancet Haematology\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69397, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the recommended starting dose of dasatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 100 mg\nQuestion: What is the recommended starting dose of nilotinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 300 mg\nQuestion: What is the recommended starting dose of ponatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 45 mg\nQuestion: What is the recommended starting dose of bosutinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended starting dose of imatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended starting dose of imatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 800 mg\nQuestion: What is the recommended starting dose of dasatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 70 mg\nQuestion: What is the recommended starting dose of nilotinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended starting dose of ponatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 45 mg\nQuestion: What is the recommended starting dose of bosutinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended starting dose of imatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 400 mg\nQuestion: What is the recommended starting dose of dasatinib in patients with newly diagnosed chronic phase CML? (Answer in Arabic numerals)\nAnswer: 70 mg\nQuestion: What is", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69411, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "10% of patients had a recurrence of colon cancer after 12 months.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with newly diagnosed multiple myeloma?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortezomib?\nAnswer: 1.3 mg/m2.\n\nQuestion: What is the recommended initial dose of bortezomib in patients with relapsed or refractory multiple myeloma who have received prior bortez", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69393, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 2.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 3.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 4.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 5.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 6.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 7.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the use of bortezomib with lenalidom", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69328, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. The presence of a CCyR at 12 months is associated with a lower risk of disease progression to AP-CML or BP-CML.\n2. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n3. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n4. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n5. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n6. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n7. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n8. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n9. The presence of a DMR (MR4.0; #0.01% BCR::ABL1 IS) at 12 months is associated with a higher risk of disease progression to AP-CML or BP-CML.\n10. The presence of a DMR (MR4.0;", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69355, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "Question: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69436, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s age?\nAnswer: 65 years\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 2. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 3. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 4. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 5. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 6. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 7. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 8. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 9. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 10. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 11. Relapsed/refractory multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021,", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69406, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 2. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 3. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 4. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 5. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 6. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 7. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 8. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 9. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 10. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 11. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 12. Bone marrow aspiration and biopsy\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient under", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's diagnosis? (Please answer in the format xx years old)\nAnswer: Multiple myeloma\n\nQuestion: In the 2023 doctor", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Dasatinib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 2. Bortezomib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 3. Lenalidomide\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 4. Pomalidomide\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 5. Carfilzomib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 6. Ixazomib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 7. Elotuzumab\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 8. Daratumumab\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 9. Bortezomib\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 10. Lenalidomide\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1", "position(%)": 25, "length(string)": 177577, "length(tokens)": 69425, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1.myeloidleukemia.Hematology/Oncology; 2.chronicmyeloidleukemia.Hematology/Oncology; 3.\nPfizerInc.; 4.AstellasPharmaUS,Inc.; 5.AbbVie,Inc.; 6.BristolMyersSquibb; 7.JazzPharmaceuticalsInc.; 8.\nNovartisPharmaceuticalsCorporation; 9.AmgenInc.; 10.\nTakeda Pharmaceuticals Company Limited; 11.GileadSciences,Inc.; 12.\nBoehringer Ingelheim Pharmaceuticals, Inc.; 13.CelgeneCorporation; 14.\nTaiho Pharmaceutical Co., Ltd.; 15.Karyopharm Therapeutics Inc.; 16.\nCelgene Corporation; 17.Janssen Pharmaceuticals, Inc.; 18.\nTakeda Pharmaceutical Company Limited; 19.\nAmgen Inc.; 20.\nBristolMyersSquibb; 21.\nUCLAJonssonComprehensiveCancerCenter; 22.\nThe University of Texas MD Anderson Cancer Center; 23.\nThe University of Chicago Comprehensive Cancer Center; 24.\nThe University of Wisconsin Carbone Cancer Center; 25.\nThe University of Michigan Rogel Cancer Center; 26.\nThe University of Colorado Cancer Center; 27.\nThe University of Pennsylvania Abramson Cancer Center; 28.\nThe University of Texas MD Anderson Cancer Center; 29.\nThe University of Texas MD Anderson Cancer Center; 30.\nThe University of Texas MD Anderson Cancer Center; 31.\nThe University of Texas MD Anderson Cancer Center; 32.\nThe University of Texas MD Anderson Cancer Center; 33.\nThe University of Texas MD Anderson Cancer Center; 34.\nThe University of Texas MD Anderson Cancer Center; 35.\nThe University of Texas MD Anderson Cancer Center; 36.\nThe", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69465, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 2. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 3. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 4. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 5. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 6. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 7. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 8. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 9. Amsellem\n\nQuestion: What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?\nAnswer: 10. Amsellem\n\nQuestion: What is the real name of the purple-haired lady", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69448, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "2015;94:2493–2499.\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included cyclophosphamide/bortezomib/\ndecreased from 14.2 to 10.4 months.49 The median\ndexamethasone as an other recommended regimen option for\nduration of response was 10.2 months.49 The panel has included\npatientswithrelapsed/refractoryMM–EarlyRelapse\ncyclophosphamide/bortezomib/dexamethasone as an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included cyclophosphamide/bortezomib/\ndecreased from 14.2 to 10.4 months.49 The median\ndexamethasone as an other recommended regimen option for\nduration of response was 10.2 months.49 The panel has included\npatientswithrelapsed/refractory MM–EarlyRelapse\ncyclophosphamide/bortezomib/dexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractory MM–EarlyRelapse.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included cyclophosphamide/bortezomib/\ndecreased from 14.2 to 10.4 months.49 The median\ndexamethasone as an other recommended regimen option for\nduration of response was 10.2 months.49 The panel has included\npatientswithrelapsed/refractory MM–EarlyRelapse\ncyclophosphamide/bortezomib/dexamethasone as an other recommended reg", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69453, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1.myeloidleukemia.HematolOncolStemCellTher2015;7:e583–591.\n\n2. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n3. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n4. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n5. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n6. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n7. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n8. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n9. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n10. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n11. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n12. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n13. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n14. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161,163\n\n15. BCR-ABL1 kinase domain mutation analysis (see Supplementary Table S10).161", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69433, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1283\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM.\nThe panel has included cyclophosphamide/bortezomib/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractory", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69427, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "No\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion: What is the most common adverse event leading to discontinuation of therapy in patients with relapsed/refractory MM? (Answer: thrombocytopenia)\nAnswer:  Thrombocytopenia\n\nQuestion:", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 2\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 3\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 4\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 5\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 6\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 7\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 8\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 9\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 10\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 11\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 12\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 13\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 14\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 15\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 16\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 17\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 18\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 19\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 20\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 21\n\nQuestion: What is the name of the tree named 'Sisten'?\nAnswer: 22\n\nQuestion", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69437, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The panel has included imatinib as an option for\nthe treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n2. The panel has included dasatinib as an option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n3. The panel has included bosutinib as an option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n4. The panel has included ponatinib as an option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n5. The panel has included lenalidomide/cyclophosphamide/dexamethasone as an other recommended regimen for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n6. The panel has included carfilzomib/cyclophosphamide/dexamethasone as an other recommended regimen for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n7. The panel has included daratumumab/bortezomib/cyclophosphamide/dexamethasone as an other recommended regimen for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n8. The panel has included ixazomib/lenalidomide/dexamethasone as an other recommended regimen for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies, including an IMiD and a PI.\n\n9. The panel has included elotuzumab/bortezomib/cyclophosphamide/dexamethasone as an other recommended regimen for the treatment of patients with relapsed/refractory M", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69444, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "428–4291\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nRegimens UsefulinCertainCircumstancesfor\nPreviouslyTreatedMM–EarlyRelapse\nBortezomib/Cyclophosphamide/Dexamethasone\nThe NCCN MM Panel members have included bortezomib/\nThe panel has included bortezomib/cyclophosphamide/ dexamethasone as an other recommended treatment\ndexamethasone as an other recommended treatment option for\nregimen as an other recommended treatment option for the combination significantlyextended themediantime\npatientswithrelapsed/refractoryMM–EarlyRelapse\nto disease progression compared with bortezomib alone\n(9.3 vs 6.5 months).48 Median duration of response was\nincreased from 7.0 to 10.2 months with the combination\ncompared with bortezomib alone. Based on these results, the\nNCCN MM Panel members have included cyclophosphamide/\nlenalidomide/dexamethasone treatment as an other recommended treatment\noption for patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/LiposomalDoxorubicin/Dexamethasone\nThe NCCN MM Panel members have included bortezomib/\nThe addition of dexamethasone to bortezomib in pa-\nliposomal doxorubicin/dexamethasone as an other recommended treatment\noption for patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Lenalidomide/Dexamethasone\nThe NCCN MM Panel members have included bortezomib/\nThe combination of bortezomib with lenalidomide and dexamethasone\nlenalidomide/dexamethasone as an other recommended treatment\noption for patientswith", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 16. Lancet Haematol\nQuestion: 'The role of racial and ethnic discrimination", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69397, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: What is the most common adverse event leading to discontinuation of bosutinib? (Answer in Arabic numerals)\nAnswer: 32%\nQuestion: What is the recommended initial dose of bosutinib? (Answer in Arabic numerals)\nAnswer: 400 mg oncedaily\nQuestion: What is the recommended initial dose of dasatinib? (Answer in Arabic numerals)\nAnswer: 100 mg oncedaily\nQuestion: What is the recommended initial dose of nilotinib? (Answer in Arabic numerals)\nAnswer: 300 mg twice daily\nQuestion: What is the recommended initial dose of ponatinib? (Answer in Arabic numerals)\nAnswer: 45 mg oncedaily\nQuestion: What is the recommended initial dose of imatinib? (Answer in Arabic numerals)\nAnswer: 400 mg oncedaily\nQuestion: What is the recommended initial dose of dasatinib? (Answer in Arabic numerals)\nAnswer: 70 mg oncedaily\nQuestion: What is the recommended initial dose of nilotinib? (Answer in Arabic numerals)\nAnswer: 400 mg twice daily\nQuestion: What is the recommended initial dose of ponatinib? (Answer in Arabic numerals)\nAnswer: 45 mg oncedaily\nQuestion: What is the recommended initial dose of imatinib? (Answer in Arabic numerals)\nAnswer: 400 mg oncedaily\nQuestion: What is the recommended initial dose of dasatinib? (Answer in Arabic numerals)\nAnswer: 70 mg oncedaily\nQuestion: What is the recommended initial dose of nilotinib? (Answer in Arabic numerals)\nAnswer: 400 mg twice daily\nQuestion: What is the recommended initial dose of ponatinib? (Answer in Arabic numerals)\nAnswer: 45 mg oncedaily\nQuestion: What is the recommended initial dose of imatinib? (Answer in Arabic numerals)\nAnswer: 400 mg oncedaily\nQuestion: What is the recommended", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69411, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n2. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n3. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n4. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n5. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n6. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n7. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n8. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n9. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n10. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n2. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n3. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n4. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and had no evidence of colon cancer.\n5. The study found that the risk of colon cancer was significantly lower in patients who had a colonoscopy and", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69393, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase chronic myeloid leukemia (CML), which therapy was associated with a higher rate of major cytogenetic response?\nAnswer: 2.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of deep molecular response?\nAnswer: 3.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of minor route cytogenetic abnormalities?\nAnswer: 4.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of major molecular response?\nAnswer: 5.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of minor route cytogenetic abnormalities?\nAnswer: 6.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 7.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 8.\n\nQuestion: In the study from the Journal of Clinical Oncology comparing the efficacy of dasatinib versus imatinib in patients with chronic phase CML, which therapy was associated with a higher rate of grade 3 or 4 adverse events?\nAnswer: 9.", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69328, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. BCR-ABL1 transcript type\n2. T315I mutation\n3. Age\n4. Gender\n5. Comorbid conditions\n6. Treatment-related adverse events\n7. Treatment adherence\n8. Treatment duration\n9. Treatment intensity\n10. Treatment discontinuation\n11. Treatment non-adherence\n12. Treatment interruption\n13. Treatment toxicity\n14. Treatment efficacy\n15. Treatment cost\n16. Treatment duration\n17. Treatment intensity\n18. Treatment adherence\n19. Treatment non-adherence\n20. Treatment interruption\n21. Treatment toxicity\n22. Treatment efficacy\n23. Treatment cost\n24. Treatment duration\n25. Treatment intensity\n26. Treatment adherence\n27. Treatment non-adherence\n28. Treatment interruption\n29. Treatment toxicity\n30. Treatment efficacy\n31. Treatment cost\n32. Treatment duration\n33. Treatment intensity\n34. Treatment adherence\n35. Treatment non-adherence\n36. Treatment interruption\n37. Treatment toxicity\n38. Treatment efficacy\n39. Treatment cost\n40. Treatment duration\n41. Treatment intensity\n42. Treatment adherence\n43. Treatment non-adherence\n44. Treatment interruption\n45. Treatment toxicity\n46. Treatment efficacy\n47. Treatment cost\n48. Treatment duration\n49. Treatment intensity\n50. Treatment adherence\n51. Treatment non-adherence\n52. Treatment interruption\n53. Treatment toxicity\n54. Treatment efficacy\n55. Treatment cost\n56. Treatment duration\n57. Treatment intensity\n58. Treatment adherence\n59. Treatment non-adherence\n60. Treatment interruption\n61. Treatment toxicity", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69355, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "Question: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69436, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s age?\nAnswer: 2. 65 years\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 3. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 4. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 5. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 6. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 7. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 8. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 9. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 10. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 11. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 12. Chronic myeloid leukemia\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s diagnosis?\nAnswer: 13", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69406, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 2. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 3. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 4. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 5. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 6. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 7. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 8. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 9. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 10. The patient had a very good partial response (VGPR).\nQuestion: In the April 2019 doctor-patient chat record, what was the patient’s response to the treatment?\nAnswer: 11. The patient had a very good partial response (VGPR).\nQuestion:", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "65 years old\n\nQuestion: What is the patient’s diagnosis? (Please answer in the format xx years old)\nAnswer: Relapsed/refractory multiple myeloma\n\nQuestion: What is the patient’s risk score? (Please answer in the format xx years old)\nAnswer: 10 years old\n\nQuestion: What is the patient’s performance status? (Please answer in the format xx years old)\nAnswer: 0 years old\n\nQuestion: What is the patient’s ECOG performance status? (Please answer in the format xx years old)\nAnswer: 0 years old\n\nQuestion: What is the patient’s Karnofsky performance status? (Please answer in the format xx years old)\nAnswer: 100 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old)\nAnswer: 3 years old\n\nQuestion: What is the patient’s ISS stage? (Please answer in the format xx years old", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 2. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 3. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 4. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 5. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 6. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 7. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 8. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 9. The doctor recommended that the patient take a low dose of aspirin.\n\nQuestion: In 2021, a", "position(%)": 50, "length(string)": 177577, "length(tokens)": 69425, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. Shawna\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nPanel members have included pomalidomide/cyclophos-\nPomalidomide/Cyclophosphamide/Dexamethasone\nphamide/dexamethasone as an other recommended regimen\nfor relapsed/refractory MM after 1 to 3 prior therapies.\nThe NCCN MM Panel has included pomalidomide/\ncyclophosphamide/dexamethasone as an other recommended regimen\nfor relapsed/refractory MM after 1 to 3 prior therapies.\nThe NCCN MM Panel has included pomalidomide/\ncyclophosphamide/dexamethasone as an other recommended regimen\nfor relapsed/refractory MM after 1 to 3 prior therapies.\n\nJNCCN.org | Volume21 Issue12 | December2023 1293\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe NCCN MM Panel has included pomalidomide/\ncyclophosphamide/dexamethasone as an other recommended regimen\nfor relapsed/refractory MM after 1 to 3 prior therapies.\n\nJNCCN.org | Volume21 Issue12 | December2023 1295\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe NCCN MM Panel has included pomalidomide/\ncyclophosphamide/dexamethasone as an other recommended regimen\nfor relapsed/refractory MM after 1 to 3 prior therapies.\n\nJNCCN.org | Volume21 Issue12 | December2023 1", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69465, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\n\nQuestion: Which", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n2. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n3. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n4. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n5. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n6. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n7. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n8. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n9. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n10. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n11. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n12. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony is\n13. The real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harm", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69448, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. The two monsters are the 'Fox Talk Forest Monster' and the 'Fox Talk Forest Monster'.\n\nThe panel has included cyclophosphamide/lenalidomide/\ndexamethasone as an other recommended regimen option for\npatientswithrelapsed/refractoryMM–EarlyRelapse.\n\nBortezomib/LiposomalDoxorubicin/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe panel has included bortezomib/lenalidomide/dexamethasone\nas an other recommended regimen option for patientswith\nrelapsed/refractory MM–EarlyRelapse", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69453, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "1. The Watchmaker is a fictional character in the novel The\n2. The Watchmaker is a fictional character in the novel The\n3. The Watchmaker is a fictional character in the novel The\n4. The Watchmaker is a fictional character in the novel The\n5. The Watchmaker is a fictional character in the novel The\n6. The Watchmaker is a fictional character in the novel The\n7. The Watchmaker is a fictional character in the novel The\n8. The Watchmaker is a fictional character in the novel The\n9. The Watchmaker is a fictional character in the novel The\n10. The Watchmaker is a fictional character in the novel The\n11. The Watchmaker is a fictional character in the novel The\n12. The Watchmaker is a fictional character in the novel The\n13. The Watchmaker is a fictional character in the novel The\n14. The Watchmaker is a fictional character in the novel The\n15. The Watchmaker is a fictional character in the novel The\n16. The Watchmaker is a fictional character in the novel The\n17. The Watchmaker is a fictional character in the novel The\n18. The Watchmaker is a fictional character in the novel The\n19. The Watchmaker is a fictional character in the novel The\n20. The Watchmaker is a fictional character in the novel The\n21. The Watchmaker is a fictional character in the novel The\n22. The Watchmaker is a fictional character in the novel The\n23. The Watchmaker is a fictional character in the novel The\n24. The Watchmaker is a fictional character in the novel The\n25. The Watchmaker is a fictional character in the novel The\n26. The Watchmaker is a fictional character in the novel The\n27. The Watchmaker is a fictional character in the novel The\n28. The Watchmaker is a fictional character in the novel The\n29. The Watchmaker is a fictional character in the novel The\n30. The Watchmaker is a fictional character in the novel The\n31. The Watchmaker is a fictional character in the novel The\n32. The Watchmaker is a fictional character in the", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69433, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1283\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nRegimensUsefulinCertainCircumstancesfor\nPreviouslyTreatedMM–EarlyRelapse\nThe NCCN MM Panel members have included pomalidomide/\nCyclophosphamide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe NCCN MM Panel members have included bortezomib/\nCyclophosphamide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Lenalidomide/Dexamethasone\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Lenalidomide/Dexamethasone/Thalidomide\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone/Thalidomide as an other recommended regimen\nfor patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Lenalidomide/Dexamethasone/Thalidomide/\nDaratumumab\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone/Thalidomide/Daratumumab as an other recommended regimen\nfor patientswithrelapsed/refractoryMM–EarlyRelapse.\nBortezomib/Lenalidomide/Dexamethasone/Thalidomide/\nDaratumumab/B", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69427, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1284\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe NCCN MM Panel members have included cyclo-\nphosphamide/bortezomib/dexamethasone as an other\nrecommended regimen option for patients with relapsed/\nrefractory MM who have received 1 to 3 prior lines of\ntherapy, including an IMiD and a PI.\n\nBortezomib/LiposomalDoxorubicin/Dexamethasone\n\nThe NCCN MM Panel members have included bortezomib/\n\nPLD/dexamethasone as an other recommended regimen option for\n\npatients with relapsed/refractory MM who have received 1 to 3 prior\n\nlines of therapy, including an IMiD and a PI.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe NCCN MM Panel members have included bortezomib/\n\nlenalidomide/dexamethasone as an other recommended regimen option for\n\npatients with relapsed/refractory MM who have received 1 to 3 prior\n\nlines of therapy, including an IMiD and a PI.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe NCCN MM Panel members have included bortezomib/\n\nlenalidomide/dexamethasone as an other recommended regimen option for\n\npatients with relapsed/refractory MM who have received 1 to 3 prior\n\nlines of therapy, including an IMiD and a PI.\n\nBortezomib/Lenalidomide/Dexamethasone\n\nThe NCCN MM Panel members have included bortezomib/\n\nlenalidomide/dexamethasone as an other recommended regimen option for", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1284\n\n33. JabbourE,KantarjianHM,O’BrienS,etal. Long-term follow-up of patientswith relapsed or refractory multiple myeloma\ntreated with bortezomib/lenalidomide/dexamethasone: results from the phase III ENDEAVOR trial. Leukemia2016;30:1044–1054.\n34. JabbourE,KantarjianHM,O’BrienS,etal. Long-term follow-up of patientswith relapsed or refractory multiple myeloma\ntreated with bortezomib/lenalidomide/dexamethasone: results from the phase III OPTIMISMM trial. Leukemia2016;30:1055–1063.\n35. JabbourE,KantarjianHM,O’BrienS,etal. Long-term follow-up of patientswith relapsed or refractory multiple myeloma\ntreated with bortezomib/lenalidomide/dexamethasone: results from the phase III OPTIMISMM trial. Leukemia2016;30:1064–1072.\n36. JabbourE,KantarjianHM,O’BrienS,etal. Long-term follow-up of patientswith relapsed or refractory multiple myeloma\ntreated with bortezomib/lenalidomide/dexamethasone: results from the phase III ALCYONE trial. Leukemia2016;30:1073–1081.\n37. JabbourE,KantarjianHM,O’BrienS,etal. Long-term follow-up of patientswith relapsed or refractory multiple myeloma\ntreated with bortezomib/lenalidomide/dexamethasone: results from the phase III ALCYONE trial. Leukemia2016;30:", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69437, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. The panel has included daratumumab/bortezomib/\n\ncyclophosphamide/dexamethasone as an other recommended regimen\noption for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n2. The panel has included carfilzomib/cyclophosphamide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n3. The panel has included carfilzomib/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n4. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n5. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n6. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n7. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n8. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to 3 prior therapies.\n\n9. The panel has included bortezomib/lenalidomide/dexamethasone as an other recommended regimen option for the treatment of patients with relapsed/refractory MM after 1 to", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69444, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1284\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included pomalidomide/cyclophosphamide/\ndecreased from 14.2 to 10.2 months.45 The panel has\ndexamethasone as an other recommended regimen option\nincluded this regimen as an other recommended regimen\nfor patients with relapsed/refractory MM after 1 to 3 prior\nfor patients with relapsed/refractory MM after 1 to 3 prior\ntherapies.\nlines of therapy.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included bortezomib/cyclophosphamide/\ndexamethasone as an other recommended regimen option\nfor patients with relapsed/refractory MM after 1 to 3 prior\nlines of therapy.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included bortezomib/cyclophosphamide/\ndexamethasone as an other recommended regimen option\nfor patients with relapsed/refractory MM after 1 to 3 prior\nlines of therapy.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included bortezomib/cyclophosphamide/\ndexamethasone as an other recommended regimen option\nfor patients with relapsed/refractory MM after 1 to 3 prior\nlines of therapy.\nBortezomib/Cyclophosphamide/Dexamethasone\nThe panel has included bortezomib/cyclophosphamide/\ndexamethasone as an other recommended regimen option\nfor patients with relapsed/refractory MM after 1 to 3 prior\nlines of therapy.\nBortezomib/Cyclophosphamide/Dexamethasone", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. Lancet Oncology\nQuestion: 'The use of generic imatinib as first-line therapy for chronic myeloid leukemia' is a report from which journal?\nAnswer: 2. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 3. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 4. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 5. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 6. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 7. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 8. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated with imatinib' is a report from which journal?\nAnswer: 9. Lancet Oncology\nQuestion: 'The inﬂuence of baseline BCR-ABL1 transcript type on outcome in patientswith chronic myeloid leukemia treated", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69397, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 1\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 2\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 3\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 4\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 5\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 6\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 7\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 8\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 9\nQuestion: The panel has included what as a category 1, preferred option for the treatment of patients with relapsed or refractory multiple myeloma? (Answer in Arabic numerals)\nAnswer: 10\nQuestion: The panel has included what as a category 1, preferred option", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69411, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "1283 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1283 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1283 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1283 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1283 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023\nMultipleMyeloma,Version2.2024 NCCNGUIDELINES®\nQuestion: What did the study in the Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 1283 ©JNCCN—JournaloftheNationalCom", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69393, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 2.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of major molecular response?\nAnswer: 3.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 4.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of very good partial response?\nAnswer: 5.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 6.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of very good partial response?\nAnswer: 7.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 8.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 9.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 10.\n\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the rate of complete response?\nAnswer: 11.\n\nQuestion: In the study from The Lanc", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69328, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1) the presence of a high-risk cytogenetic abnormality; 2) the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality; 3) the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk cytogenetic abnormality and a high-risk genetic abnormality and the presence of a high-risk", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69355, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "Question: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: \n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69436, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Multiple myeloma\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s age?\nAnswer: 2. 65 years\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 3. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 4. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 5. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 6. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 7. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 8. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 9. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 10. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 11. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 12. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April 2021, what is the patient’s disease status?\nAnswer: 13. Relapsed or refractory\nQuestion: In the doctor-patient chat record from April", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69406, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 2. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 3. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 4. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 5. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 6. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 7. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 8. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 9. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 10. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 11. The patient underwent a bone marrow biopsy.\nQuestion: In the April 2019 doctor-patient chat record, what test did the patient undergo?\nAnswer: 12.", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient’s age? (Please answer in the format xx years old)\nAnswer: 65 years old\n\nQuestion: In the 2023 doctor", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Daratumumab/Bortezomib/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 2. Carfilzomib/Cyclophosphamide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 3. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 4. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 5. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 6. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 7. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 8. Carfilzomib/Lenalidomide/Dexamethasone\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "position(%)": 75, "length(string)": 177577, "length(tokens)": 69425, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 0, "needle": "Located at the Dream Bar in the Penacony Daydream Hotel, there is a bar manager named Shuweng.", "question": "Who is the manager of the Dream Bar in the Penacony Daydream Hotel?", "type": "general", "true_answer": "Shuweng", "pred_answer": [], "pred_origin": "1. The NCCN MM Panel members have included\n2. The NCCN MM Panel members have included\n3. The NCCN MM Panel members have included\n4. The NCCN MM Panel members have included\n5. The NCCN MM Panel members have included\n6. The NCCN MM Panel members have included\n7. The NCCN MM Panel members have included\n8. The NCCN MM Panel members have included\n9. The NCCN MM Panel members have included\n10. The NCCN MM Panel members have included\n11. The NCCN MM Panel members have included\n12. The NCCN MM Panel members have included\n13. The NCCN MM Panel members have included\n14. The NCCN MM Panel members have included\n15. The NCCN MM Panel members have included\n16. The NCCN MM Panel members have included\n17. The NCCN MM Panel members have included\n18. The NCCN MM Panel members have included\n19. The NCCN MM Panel members have included\n20. The NCCN MM Panel members have included\n21. The NCCN MM Panel members have included\n22. The NCCN MM Panel members have included\n23. The NCCN MM Panel members have included\n24. The NCCN MM Panel members have included\n25. The NCCN MM Panel members have included\n26. The NCCN MM Panel members have included\n27. The NCCN MM Panel members have included\n28. The NCCN MM Panel members have included\n29. The NCCN MM Panel members have included\n30. The NCCN MM Panel members have included\n31. The NCCN MM Panel members have included\n32. The NCCN MM Panel members have included\n33. The NCCN MM Panel members have included\n34. The NCCN MM Panel members have included\n35. The NCCN MM Panel members have included\n36. The NCCN MM Panel members have included\n37. The N", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69464, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 1, "needle": "Aventurine is a senior official in the Strategic Investment Department of the Galactic Peace Corporation. He owns an 'Aventurine Stone' and is part of the 'Ten Stonehearts' team.", "question": "Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?", "type": "general", "true_answer": "'Ten Stonehearts'", "pred_answer": [], "pred_origin": "1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the owner of the 'Aventurine stone', belong to?\nAnswer: 1\nQuestion: Which team within the Galactic Peace Corporation does Aventurine, the", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69434, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 2, "needle": "At the 'Harmony Grand Ceremony' in Penacony, a lady with purple hair, who calls herself the 'Galaxy Ranger', attended. She is known as Acheron, but her real name is Raiden Bosenmori Mei.", "question": "What is the real name of the purple-haired lady known as the 'Galaxy Ranger' who attended the 'Harmony Grand Ceremony' in Penacony?", "type": "general", "true_answer": "Raiden Bosenmori Mei", "pred_answer": [], "pred_origin": "1. Raiden Bosenmori Mei\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nReferences\n1. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n2. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n3. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n4. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n5. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n6. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n7. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n8. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n9. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n10. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018;392:1799–1812.\n11. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet 2018", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69447, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 3, "needle": "Locufox Forest Backdoor in the Xianzhou Luofu, there is a group of 'Monster Legion', including one Mara-Struck Warden and two 'Mara-Struck Soldier'.", "question": "What are the two monsters in the 'Monster Legion' behind the Fox Talk Forest in the Xianzhou Luofu?", "type": "general", "true_answer": "Mara-Struck Soldier", "pred_answer": [], "pred_origin": "1. Mara-Struck Warden 2. Mara-Struck Soldier", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69452, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 4, "needle": "In Elio's script, there are three nameless guests who got off the Astral Express in Penacony: 1. Razarina Jane Estella, a ex-surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity. 2. Breukelen Tiernan, the former guard of the Astral Express and a outstanding gunslinger. 3. Mikhail Char Legwork, Former mechanic of the Astral Express, and the legendary big shot of Penacony, 'the Watchmaker'.", "question": "Who is 'the Watchmaker' of Penacony?", "type": "general", "true_answer": "Mikhail Char Legwork", "pred_answer": [], "pred_origin": "3. Mikhail Char Legwork\n\nQuestion: Who is the former guard of the Astral Express?\nAnswer: 2. Breukelen Tiernan\n\nQuestion: Who is the young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former mechanic of the Astral Express?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is the legendary big shot of Penacony?\nAnswer: 3. Mikhail Char Legwork\n\nQuestion: Who is the former guard of the Astral Express and a outstanding gunslinger?\nAnswer: 2. Breukelen Tiernan\n\nQuestion: Who is the young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with enthusiasm and curiosity?\nAnswer: 1. Razarina Jane Estella\n\nQuestion: Who is the former surveyor aboard the Astral Express and a young scholar, brimming with", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69433, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 5, "needle": "Clockboy is the most famous cartoon character in Pinoconi, originating from the long-running animation series 'Clockboy and His Friends', which has over 10,000 episodes and is a symbol of Pinoconi. The character is based on the 'Clockmaker' Lagvok Charles Mikhail, who is known as the father of Pinoconi.", "question": "Which animation series features the cartoon character Clockboy?", "type": "general", "true_answer": "'Clockboy and His Friends'", "pred_answer": [], "pred_origin": "1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon character Clockboy?\nAnswer: 1. 'Clockboy and His Friends'\n\nQuestion: Which animation series features the cartoon", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69427, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 6, "needle": "The Warp Trotter is a cross-dimensional creature lost among the stars, with a gentle nature and sweet taste, but it is inedible. It spends most of its life eating and fleeing. Travelers who encounter it consider it a good omen.", "question": "Can the Warp Trotter be eaten? (Answer yes or no)", "type": "general", "true_answer": "No", "pred_answer": [], "pred_origin": "1289\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\nRegimens UsefulinCertainCircumstancesfor\nPreviouslyTreatedMM–EarlyRelapse\nThe NCCN MM Panel members have included lenalidomide/\nCyclophosphamide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLiposomal Doxorubicin/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/refractory MM who have not previously received\nbortezomib.\n\nThe NCCN MM Panel members have included bortezomib/\nLenalidomide/Dexamethasone as an other recommended regimen\nfor patientswithrelapsed/", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 7, "needle": "The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.", "question": "On which island is the tree named 'Sisten' located?", "type": "general", "true_answer": "Wacq Island", "pred_answer": [], "pred_origin": "1. The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nQuestion: On which island is the tree named 'Sisten' located?\n\nAnswer: 1. The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nQuestion: On which island is the tree named 'Sisten' located?\n\nAnswer: 1. The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nQuestion: On which island is the tree named 'Sisten' located?\n\nAnswer: 1. The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nQuestion: On which island is the tree named 'Sisten' located?\n\nAnswer: 1. The Relic 'Sprightly Vonwacq' contains Wacq Island, it was the most well-known island on Planet Vonwacq and teems with plant life. On the island was a gigantic tree called Thestang, bearing fruits that would give birth to the various kinds of the island's wildlife.\n\nQuestion: On which island is the tree named 'Sisten' located?\n\nAnswer: 1. The Relic 'Sprightly Vonwacq' contains Wacq Island", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69436, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 8, "needle": "Aha is the Aeon in charge of the Path of Joy, and it has a group of followers called the 'Masked Fools', but also a group of opponents called the 'Mourning Actors'. It once blew up the Astral Express of Akivili.", "question": "Who once blew up the Astral Express?", "type": "general", "true_answer": "Aha", "pred_answer": [], "pred_origin": "1. Avarietyoftherapiesareavailableforpreviously\ntreatedorrelapsed/refractoryMM. The choice of appropriate\ntherapy for a specific patient depends on the context of clinical\nrelapse such as prior treatment and duration of response, and\npatient-specific factors such as age and other comorbidities.\nThe NCCN MM Panel has included pomalidomide/cyclo-\nphosphamide/dexamethasone as an other recommended\nregimen option for the treatment of patients with relapsed/refractory\nMM.\n\nQuestion: Who once blew up the Astral Express?\n\nAnswer: 1. Avarietyoftherapiesareavailableforpreviously\ntreatedorrelapsed/refractoryMM. The choice of appropriate\ntherapy for a specific patient depends on the context of clinical\nrelapse such as prior treatment and duration of response, and\npatient-specific factors such as age and other comorbidities.\n\nQuestion: Who once blew up the Astral Express?\n\nAnswer: 1. Avarietyoftherapiesareavailableforpreviously\ntreatedorrelapsed/refractoryMM. The choice of appropriate\ntherapy for a specific patient depends on the context of clinical\nrelapse such as prior treatment and duration of response, and\npatient-specific factors such as age and other comorbidities.\n\nQuestion: Who once blew up the Astral Express?\n\nAnswer: 1. Avarietyoftherapiesareavailableforpreviously\ntreatedorrelapsed/refractoryMM. The choice of appropriate\ntherapy for a specific patient depends on the context of clinical\nrelapse such as prior treatment and duration of response, and\npatient-specific factors such as age and other comorbidities.\n\nQuestion: Who once blew up the Astral Express?\n\nAnswer: 1. Avarietyoftherapiesareavailableforpreviously\ntreatedorrelapsed/refractoryMM. The choice of appropriate\ntherapy for a specific patient depends on the context of clinical\nrelapse such as prior treatment and duration of response, and\npatient-specific factors such as age and other comorbidities.\n\nQuestion: Who once blew up the Astral Express?\n\nAn", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 9, "needle": "At the 'Penacony Grand Theater' in Penacony, Pom-Pom piloted the Astral Express (attacking by collision) and, along with other nameless guests, defeated Dominicus, the 'Harmonious Choir, The Great Septimus', who was disturbed by 'Order', resolving the crisis.", "question": "Where did Pom-Pom use the train to collide with the Great Septimus in Penacony?", "type": "general", "true_answer": "Penacony Grand Theater", "pred_answer": [], "pred_origin": "1. The Great Septimus was located in the 'Harmonious Choir' in Penacony.\n2. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n3. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n4. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n5. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n6. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n7. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n8. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n9. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n10. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n11. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n12. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n13. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n14. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n15. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n16. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n17. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n18. The Astral Express was a train that was used to collide with the Great Septimus in Penacony.\n19. The Astral Express", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69441, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 10, "needle": "The major breast cancer report 'The role of racial and ethnic discrimination in breast cancer disparities' in The Lancet points out that there are serious inequalities in breast cancer treatment between low-income and high-income countries worldwide, with many groups being 'systematically abandoned', neglected, and even forgotten.", "question": "'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?", "type": "med", "true_answer": "The Lancet", "pred_answer": [], "pred_origin": "1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination in breast cancer disparities' is a report from which journal?\nAnswer: 1. Lancet Oncology\n\nQuestion: 'The role of racial and ethnic discrimination", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69396, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 11, "needle": "Prostate cancer has become a major cause of death and disability, accounting for 15% of all male cancers. 'The Lancet Commission on prostate cancer: planning for the surge in cases' report states that the number of global prostate cancer cases is expected to increase from 1.4 million annually in 2020 to 2.9 million annually in 2040, doubling the number of cases; the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%.", "question": "According to the latest report from The Lancet, prostate cancer accounts for what percentage of all male cancers? (Answer in Arabic numerals)", "type": "med", "true_answer": "15", "pred_answer": [], "pred_origin": "15%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85%\nQuestion: According to the latest report from The Lancet, the global annual number of prostate cancer deaths is expected to increase from 375,000 in 2020 to nearly 700,000 in 2040, an increase of about 85%. (Answer in Arabic numerals)\nAnswer: 85", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69410, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 12, "needle": "The Lancet Gastroenterology & Hepatology recently published a study on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada. The study found that compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "question": "What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?", "type": "med", "true_answer": "Compared to those who did not undergo colonoscopy, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality more than 15 years after the examination.", "pred_answer": [], "pred_origin": "15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in Ontario, Canada find?\nAnswer: 15 years after the examination, individuals with negative colonoscopy results still had a lower risk of colorectal cancer incidence and mortality compared to those who did not undergo colonoscopy.\n\nQuestion: What did the study in The Lancet on the duration of reduced colorectal cancer incidence and mortality risk after colonoscopy in", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69391, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 13, "needle": "The Lancet Diabetes & Endocrinology recently published a study comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes. The study found that for pregnant women starting strict blood glucose control, advanced hybrid closed-loop therapy did not improve overall time in target range but improved overnight time in target range, reduced time below target range, and increased treatment satisfaction. These data suggest that MiniMed 780G (an advanced hybrid closed-loop therapy) can be safely used during pregnancy and offers some additional benefits compared to standard insulin therapy; however, it is important to improve the algorithm to better meet pregnancy requirements.", "question": "In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overnight time in target range?", "type": "med", "true_answer": "Advanced hybrid closed-loop therapy", "pred_answer": [], "pred_origin": "1. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the overall time in target range?\nAnswer: 2. Standard insulin therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time below target range?\nAnswer: 3. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time above target range?\nAnswer: 4. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 5. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 6. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 7. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 8. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 9. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-loop therapy and standard insulin therapy in pregnant women with type 1 diabetes, which therapy improved the time in target range?\nAnswer: 10. Advanced hybrid closed-loop therapy\nQuestion: In the study from The Lancet comparing advanced hybrid closed-", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69328, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 14, "needle": "The Lancet Child & Adolescent Health recently published a study on the relationship between academic achievement goals and adolescent depression symptoms. The study found that adolescents' depression symptoms are related to their academic achievement goals, which may be a target risk factor for future trials to investigate whether school interventions aimed at enhancing mastery goals (i.e., learning skills and understanding subjects rather than assessing abilities compared to peers) can prevent adolescent depression.", "question": "According to the recent study from The Lancet Child & Adolescent Health, what are adolescents' depression symptoms related to?", "type": "med", "true_answer": "Their academic achievement goals", "pred_answer": [], "pred_origin": "1. Adolescents' academic achievement goals\n2. Adolescents' academic achievement goals and their academic performance\n3. Adolescents' academic achievement goals and their academic performance goals\n4. Adolescents' academic achievement goals and their academic performance goals and their academic performance\n5. Adolescents' academic achievement goals and their academic performance goals and their academic performance goals and their academic performance\n\nJNCCN.org | Volume21 Issue12 | December2023 1291\n\nNCCNGUIDELINES® MultipleMyeloma, Version2.2024\n\nReferences\n\n1. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n2. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n3. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n4. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n5. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n6. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n7. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n8. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n9. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 2014;15:e12.\n\n10. Kumar SK, Rajkumar SV. Multiple myeloma. Lancet Oncol 20", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69354, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 15, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nDizzy and bloated, stomach uncomfortable without diarrhea (male, 16 years old)\n\nDoctor:\nHello, how long has this been going on? Any vomiting?\nHow is your sleep?\n\nPatient:\nNo vomiting, sleep is okay, it's been 2 days\n\nDoctor:\nIs it a light dizziness or a spinning dizziness?\n\nPatient:\nSometimes, just a little bit\n\nDoctor:\nHave you caught a cold recently?\n\nPatient:\nYes\nA bit of a cold\n\nDoctor:\nIf you have caught a cold, take antiviral medication to treat the cold and observe. Also check if you have cervical spondylosis\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nFrequent head-down posture playing on your phone, gaming, leads to insufficient blood supply to the brain, causing dizziness\nYou're welcome\n\nPatient:\nYes\n\nDoctor:\nPlease give a good review if you have time, thank you", "question": "In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?", "type": "med", "true_answer": "Antiviral medication", "pred_answer": [], "pred_origin": "1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the doctor recommend for treating the cold?\nAnswer: 1. Antiviral medication\n2. Antibiotics\n3. Antifungal medication\n4. Antipyretic medication\n\nQuestion: In the March 2020 doctor-patient chat record, what medication did the", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 16, "needle": "The following is a doctor-patient chat record from March 2020\n\nPatient:\nIs it necessary to undergo microwave and radiofrequency treatment for neurogenic tinnitus? (male, 23 years old)\n\nDoctor:\nHello, professionally there is no such thing as neurogenic tinnitus, it's neurogenic deafness and tinnitus. How long have you had tinnitus?\n\nPatient:\nOne week\n\nDoctor:\nAny changes in hearing?\n\nPatient:\nNo\nI can hear, but there is a buzzing sound\n\nDoctor:\nIs it constant or intermittent?\n\nPatient:\nConstant\n\nDoctor:\nShort-term tinnitus can still be treated, using medication to improve microcirculation and nourish the nerves, supplemented by microwave and acoustic therapy, generally showing improvement. Also, make sure to rest well and avoid fatigue\n\nPatient:\nBut these treatments are too expensive, I just started an internship and can't afford it. Are there any unnecessary treatments in my current regimen: 1. microwave therapy 2. radiofrequency therapy 3. outpatient intravenous infusion 4. nerve plexus block\n\nDoctor:\nShort-term tinnitus is still recommended to be treated, the nerve-nourishing and microcirculation-improving drugs are indeed expensive. However, if you feel the tinnitus does not affect your normal life, you can ignore it", "question": "In the doctor-patient chat record from April 2021, what disease is the patient consulting about?", "type": "med", "true_answer": "Neurogenic tinnitus", "pred_answer": [], "pred_origin": "1. Chronic myeloid leukemia 2. Multiple myeloma 3. Chronic lymphocytic leukemia 4. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's age?\nAnswer: 1. 23 years old 2. 23 years old 3. 23 years old 4. 23 years old\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's gender?\nAnswer: 1. Male 2. Male 3. Male 4. Male\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's disease?\nAnswer: 1. Chronic myeloid leukemia 2. Multiple myeloma 3. Chronic lymphocytic leukemia 4. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's disease?\nAnswer: 1. Chronic myeloid leukemia 2. Multiple myeloma 3. Chronic lymphocytic leukemia 4. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's disease?\nAnswer: 1. Chronic myeloid leukemia 2. Multiple myeloma 3. Chronic lymphocytic leukemia 4. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's disease?\nAnswer: 1. Chronic myeloid leukemia 2. Multiple myeloma 3. Chronic lymphocytic leukemia 4. Chronic myeloid leukemia\n\nQuestion: In the doctor-patient chat record from April 2021, what is the patient's disease?\nAnswer:", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69406, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 17, "needle": "The following is a doctor-patient chat record from May 2019\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions\n\nThe following is a doctor-patient chat record from April 2019\n\nPatient:\nDoctor, I'm back again, today I had a urine routine test, occult blood 1+, is it serious? (female, 25 years old)\n\nDoctor:\nHave you had this test before? When was your last menstrual period?\n\nPatient:\nNo, just today\n\nDoctor:\nOkay\n\nPatient:\nThis month on the 15th, there was still a little bit yesterday\n\nDoctor:\nOh, then it may be related to your period, it's okay, recheck the urine routine in half a month\n\nPatient:\nOkay, thank you doctor\n\nDoctor:\nYou're welcome", "question": "In the April 2019 doctor-patient chat record, what test did the patient undergo?", "type": "med", "true_answer": "Urine routine test", "pred_answer": [], "pred_origin": "1. Urine routine test\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 2. Control salt intake, avoid foods that promote blood circulation, no other restrictions\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 3. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 4. Occult blood 1+, is it serious?\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 5. Have you had this test before? When was your last menstrual period?\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 6. Okay, recheck the urine routine in half a month\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 7. Labetalol is okay to take...\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 8. Control salt intake, avoid foods that promote blood circulation, no other restrictions\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 9. Occult blood 1+, is it serious?\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 10. Have you had this test before? When was your last menstrual period?\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 11. Okay, recheck the urine routine in half a month\n\nQuestion: In the May 2019 doctor-patient chat record, what is the doctor's advice?\nAnswer: 12. Labet", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69443, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 18, "needle": "The following is a doctor-patient chat record from 2023\n\nPatient:\nHello doctor, can cefuroxime axetil and ofloxacin be taken together? (male, 26 years old)\n\nDoctor:\nHello, yes, they can be taken together!!!\n\nPatient:\nAre there significant side effects from taking them together?\n\nDoctor:\nAny medication can have potential side effects, it varies from person to person", "question": "In the 2023 doctor-patient conversation, how old is the patient? (Please answer in the format xx years old)", "type": "med", "true_answer": "26 years old", "pred_answer": [], "pred_origin": "26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26 years old\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's gender? (Please answer in the format male or female)\nAnswer: male\n\nQuestion: In the 2023 doctor-patient conversation, what is the patient's age? (Please answer in the format xx years old)\nAnswer: 26", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69435, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
{"idx": 19, "needle": "The following is a doctor-patient chat record from 2021\n\nPatient:\nJust had a C-section 9 days ago. Today, the hospital check showed a bit of high blood pressure. Systolic 140, diastolic 96, still breastfeeding, what can I eat postpartum that is good? (female, 27 years old)\n\nDoctor:\nLabetalol is okay to take...\n\nPatient:\nWhat about food, what can I eat?\n\nDoctor:\nControl salt intake, avoid foods that promote blood circulation, no other restrictions", "question": "In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?", "type": "med", "true_answer": "Labetalol", "pred_answer": [], "pred_origin": "1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion: In 2021, a patient who had a C-section consulted a doctor about a high blood pressure treatment plan. What medication did the doctor recommend?\nAnswer: 1. Labetalol\n\nQuestion:", "position(%)": 100, "length(string)": 177577, "length(tokens)": 69424, "length(origin)": 64000, "model": "Yarn-Mistral-7b-128k", "note": "wrong format"}
